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Aim of the thesis 
	
A major need in the genome editing community is the generation of an error-free 
toolbox to allow its in vivo application for therapeutic purposes. The aim of this thesis 
is the development and the validation of innovative technologies to reduce SpCas9 off-
target activity. We addressed critical aspects related to Cas9 specificity as well as 
important issues connected to the accumulation of unwanted cleavages after long 
term expression of the nuclease into cells.  
The first goal of the present study is the identification of high-fidelity SpCas9 variants 
with significantly reduced off-target activity. To this aim we set-up a yeast-based in vivo 
screening platform to allow the unbiased isolation amino acid substitutions increasing 
SpCas9 targeting specificity. An in depth characterization of the identified variants in 
terms of specificity, as well as on-target activity, was performed. Further analyses will 
be required to complete the structural and biochemical characterization of the selected 
hits. 
To address the long-term adverse effects related to Cas9 permanence into cells, we 
decided to engineer a self-limiting synthetic circuit deliverable through an all-in-one 
lentiviral vector to switch-off Cas9 expression in transduced cells. This system is 
designed to generate a peak-like pulse of nuclease activity sufficient to modify the locus 
of interest, while limiting time- and dose-depended Cas9 detrimental effects. 
Further optimizations of the platforms here described could be envisioned, such as the 
isolation of alternative high-specificity variants, the application of the in vivo screening 
assay to other RNA guided nucleases or additional implementations of the self-limiting 
circuit involving other vector systems. The work hereby presented aims at validating 
these new technologies as valuable tools to prevent Cas9 unwanted effects and 
anticipates their employment in everyday research protocols and in in vivo 
experimental disease models, as well as their application as prospective therapeutic 
agents.  
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Abstract 
 
CRISPR nucleases are efficient tools to edit cellular genomes in a variety of organisms. 
However, the in vivo application of this technology is still severely limited by unwanted 
genomic cleavages, that are further increased by long-term expression of the nuclease 
and can lead to unpredictable results.  
To address this limitation, we developed a yeast-based assay which allows to 
simultaneously evaluate the on- and off-target activity towards two engineered 
genomic targets in order to select optimized Streptococcus pyogenes Cas9 (SpCas9) 
variants. The screening of SpCas9 variants obtained by random mutagenesis of the 
Rec1-II domain allowed the identification of hits with increased on/off ratios. Through 
the combination of the identified mutations within a single variant we isolated the best 
performing nuclease, that we named evoCas9 (evolved Cas9). Side by side analyses 
with recently reported rationally designed variants demonstrated a significant 
improvement in fidelity of our evoCas9.  
In addition, to control Cas9 persistence into cells over time, we developed a Self-
Limiting Cas9 circuitry for Enhanced Safety (SLiCES) which consists of an expression 
unit for SpCas9, a self-targeting sgRNA and a second sgRNA targeting a chosen genomic 
locus. This self-limiting circuit, by controlling Cas9 levels, results in increased genome 
editing specificity. For its in vivo utilization, we integrated SLiCES into a lentiviral delivery 
system (lentiSLiCES) via circuit inhibition to achieve viral particle production. Following 
its delivery into target cells, the lentiSLiCES circuit is switched on to edit the intended 
genomic locus while simultaneously promoting its own neutralization through SpCas9 
inactivation.  
The two strategies here developed represent complementary approaches to address 
a major issue in the genome editing field. On one hand, by preserving target cells from 
residual nuclease activity, our hit and go SLiCES system increases the safety margins for 
genome engineering. On the other, if compared to published structure-guided protein 
engineering approaches, our in vivo screening increases the likelihood to identify the 
best combination of amino acid substitutions for the generation of novel, error-free 
SpCas9 and could represent a valid strategy to enhance the specificity of other RNA-
guided nucleases. 
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Introduction 
	
The modification of genomes 
 
The alternation of the genome of useful plants and animals, in the form of 
domestication and selective breeding, is an activity that humans have been performing 
since early prehistory1, well before the discovery that DNA is the carrier of genetic 
information and the development of modern molecular biology techniques (Fig. 1). 
Charles Darwin devoted the entire first chapter of his “On the Origin of Species” to this 
topic and used the observations made on artificial selection to give shape to his 
evolutionary theory. Thus, the possibility to modify the genetic characteristics of farm 
animals and crops, with the consequent alteration of their phenotype, was a need that 
accompanied humankind from its dawn and shaped dramatically its history.  
It was not until mid-1800 onwards that the idea of inheritable characters was suggested 
by Gregor Mendel, giving birth to classical genetics, and only almost a century later 
DNA was identified as the repository of genetic information2. In the following years, the 
development of the bases of modern molecular biology, that allowed the in vitro 
manipulation of DNA molecules, led to the first experiments with the specific aim of 
altering the genetic makeup of a lab-grown bacteria3. Only few years later, Rudolf 
Jaenisch developed the first transgenic mouse4 pushing even further the boundaries 
of artificial genomic modification. The profound change in the ways in which 
researchers could act on and interact with biological systems was deeply perceived by 
Figure 1. Domestication of wheat. From 
left to right: wild wheat and the artificially 
selected variants einkorn wheat, emmer 
wheat and common bread wheat. The 
increased productivity of each ear is 
immediately apparent. Retrieved from 
Slideshare.net. 
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the scientific community that felt the need to call for an international meeting with the 
goal of developing a common regulatory framework on genetic engineering, the 
Council of Asilomar (1975). The further development of the knowledge on DNA, the 
possibility to read and decipher the information it contains by ever-evolving 
sequencing methods and the advent of technological advances that significantly 
reduced the costs of biotechnological applications led to a massive expansion of the 
use of genetic engineering, even outside research labs. The introduction of genetic 
engineering into the industry allowed the production of several genetically modified 
crops (famous examples are the Flavr Savr tomato and several varieties of rice, soy, 
cotton, maize, canola) as well as numerous recombinant proteins with a relevant 
therapeutic impact, such as insulin or the growth hormone, which were previously very 
difficult or impossible to recover from natural sources. 
Recently, the creation of a mycobacterium cell with a completely in vitro synthesized 
genome5 and then of an upgraded version of the same cell with a minimal genome 
containing only a set of essential genes6 is an indication of how far the modification of 
genomes could be pushed: building a new genome from scratch, even though the 
possibility to start form an engineered blueprint is not a reality yet. While the ability to 
assemble entire genomes is limited to relatively simple circular prokaryotic DNA 
molecules, the recent discovery of programmable endonucleases allowed the 
extensive modification of more complex plant and mammalian genomes and 
represents the state-of-the-art in terms of genomic engineering in complex organisms.  
In addition, the ease of use of programmable endonucleases and their low operative 
costs transformed genome editing into a mass-phenomenon. This, together with the 
introduction on the market of genetically modified organisms (GMOs), generated a 
heated debate in the public opinion, that in general looks with suspicion at such 
artificial manipulations, although sometimes the final result is very similar to what 
could have been obtained by traditional breeding techniques, such as in the case of 
crops able to grow in harsh environments7. 
The different perception that nowadays the non-specialized public has of genetic 
engineering underlines the fundamental differences between these new technologies 
and the more traditional ones. The most evident is the speed at which the desired 
phenotype can be obtained, as targeted genomic modifications are characterized by 
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an almost immediate effect if compared to the generations of crossings needed to 
isolate a pure line with the desired characters. Secondly, it is now clear that to modify 
the phenotype we need to alter the genome of the individual, while in the past only the 
final effects on the phenotype were perceived. Third, researchers are now able to 
directly alter the genomic DNA of many organisms rather than indirectly putting a 
selective pressure on certain characters and leave the rest of the work to evolution. 
Connected to the last aspect, the idea of swapping pieces of DNA between different 
species and even between different kingdoms is an unprecedented possibility and is 
considered by part of the public opinion as irresponsible and unnatural. 
Altogether, although the modification of genomes is an activity that humans have been 
carrying out since millennia, the discoveries made in the last century opened a 
completely new scenario with remarkable perspectives and almost endless 
possibilities, very often connected with important ethical issues.       
   
Gene therapy, gene targeting and genome engineering 
 
The discovery that the main characteristics of all biological systems are determined by 
their genetic makeup, together with the possibility to modify this genetic material, had 
an immediate impact on biomedical research, as well as on the therapeutic approach 
to several diseases. The concept that exogenous “good” DNA could be introduced in 
diseased cells to restore their normal functions (“genes as drugs”) gave birth to gene 
therapy, which aim is to cure the disease at its genetic roots, without the need of 
further medical interventions8. The main challenges in gene therapy are to deliver 
correctly the exogenous DNA to target cells, overcoming cellular and tissue barriers, 
and to obtain the desired expression pattern of the therapeutic molecule in an 
appropriate number of cells that must persist in the patient, without being cleared by 
the immune system, in order to eventually transmit the modification to daughter cells9. 
In the past decades several methods have been developed to efficiently deliver 
therapeutic DNA to target cells, both in vivo and ex vivo. On one hand, researcher have 
devised physical and chemical approaches to introduce transgenes into cells10. These 
methods usually suffer from low efficiency and are applicable only in certain contexts. 
Alternatively, the use of viral vectors has found widespread use thanks to their innate 
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efficiency in penetrating different cell types, even though safety concerns are more 
pressing since this kind of delivery tools are often based on parental pathogenic 
viruses11. Several type of viruses have been modified and tested as gene therapy 
vectors and some of them have been used in clinical trials to treat a wide range of 
inherited diseases, cancers and chronic infections, albeit with mixed efficacy9,12,13. For 
example lentiviruses, g-retroviruses and adeno-associated viruses (AAV) have all been 
tested in patients9. A few have received the approval by regulatory bodies for 
commercialization (such as Glybera14,15 and Strimvelis16,17). Many gene therapy 
applications require stable expression of the transgene and for this reason the 
integration of the transferred DNA is generally required. In this process, known as gene 
insertion and efficiently mediated by retroviral vectors, the exogenous transgenic 
nucleic acid does not substitute the non-functional endogenous copy but is simply 
added to the patient’s genome in order to provide the missing molecular function or 
counteract a malfunctioning gene product. However, the present knowledge of vector 
biology does not allow a precise engineering of their integration preferences and for 
this reason the semi-random pattern of insertion into the patient’s genome can 
potentially cause insertional mutagenesis, leading in the worst case to the selection of 
malignant clones in the population of transduced cells11,18. In the past, this has 
produced dramatic side effects in a clinical trial for the treatment of X-SCID19, where 
vector-induced activation of the LMO-2 proto-oncogene caused leukaemia in some of 
the patients20,21. Technical improvements in vector design allowed the generation of 
safer next generation gene therapy tools that however still suffered from limitations 
such as the impossibility to deliver and integrate big transgenes or the inability to cure 
conditions for which the diseased gene product exerts a dominant effect which cannot 
be counteracted by gene insertion strategies. In both cases a targeted correction of the 
mutated endogenous locus would represent a valid therapeutic approach. In 
conclusion, even though viral vectors are first-choice tools for gene therapy protocols, 
they still lack the delivery precision that is needed by advanced genomic surgery 
approaches. 
The necessity to alter specific genomic regions, either for research purposes or for 
therapeutic protocols, led to the development of gene targeting that was pioneered by 
Mario Capecchi, Martin Evans and Oliver Smithies who were awarded the 2007 Nobel 
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Prize for Physiology and Medicine "for their discoveries of principles for introducing 
specific gene modifications in mice by the use of embryonic stem cells". Their merit 
was to adapt to mammalian cells observations on homologous gene targeting made 
previously in yeast22,23, generating a technology that today still remains the gold 
standard to produce transgenic mice24. Gene targeting relies on the possibility to select 
specific events of homologous recombination between a heterologous DNA molecule 
containing the desired modification and the genomic sequence of interest (Fig. 2)25-28. 
This approach was revolutionary if compared to previous technologies where random 
mutations were introduced into the genome and the desired modification was then 
isolated a posteriori from a specific phenotype. The latter methodology relies on one 
hand on the previous knowledge of the phenotypic change to be expected from the 
desired alteration, while on the other requires extensive experimental work for mutant 
isolation and phenotype validation, without the assurance to recover the desired 
genomic modification. 
 
Fundamental to the advancement of the genome modification field was a better 
understanding of how the cell copes with the presence of exogenous DNA molecules 
that share some similarities with endogenous sequences. The discovery that cells have 
an intrinsic ability to target exogenous DNA to chromosomal sites suggested that the 
cellular machinery responsible for such processes could be harnessed to obtain 
Figure 2. Gene targeting by positive-
negative selection. A targeting vector 
containing appropriate homology 
arms, the neor and the HSV thymidine 
kinase selective markers is introduced 
into cells. After successful 
recombination with the Gene X locus, 
cells acquire G418 resistance while 
losing the HSV-tk gene.  Random 
integration events that lead to the 
incorporation of the whole targeting 
vector into the genome can be counter 
selected exploiting the HSV-tk. FIAU: 
fialuridine. Adapted from Capecchi, 
Nat. Rev. Genet., 2005. 
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targeted modifications of the genome22,27. Moreover, several studies analysed the 
parameters that influence the recombination reaction, such as the extent of the 
homology between the exogenous DNA and the target sequence29,30, the type of 
modifications that are more likely to be introduced into the genome31 or the influence 
of the cell cycle on the efficiency of the process32,33, thus allowing the design of 
strategies to optimize gene targeting experiments. Even though cells are capable of 
incorporating exogenous DNA by homologous recombination, the parallel process 
involving incorporation by non-homologous end joining (NHEJ)33, which results in a 
random integration pattern into chromosomes, is actually preferred31,34. For this 
reason, it is necessary to select cells where this relative rare events took place by using 
a drug-resistance gene that is inserted in the locus of interest together with the desired 
DNA sequence. Generally, a second selectable marker is positioned outside the 
homology regions in order to negatively select cells in which the integration of the 
targeting construct is mediated by non-homologous end joining, considering that those 
portions of the construct will be lost due to crossing over in case homologous 
recombination occurs (Fig. 2)25,26. Several variants of the gene targeting technique have 
been developed over time with the main aim of optimizing the selection procedure to 
enrich for correctly edited cells; some examples are the “in-out” approach35 or the tag-
and-exchange strategy36. The introduction of the Cre/loxP recombinase systems, on 
the other hand, allowed an easier removal of the selectable markers from the edited 
locus when needed and, more importantly, granted the possibility of generating 
conditional knockouts by controlling the expression of the Cre recombinase using 
inducible or tissue specific promoters or by transfecting or transducing the 
recombinase locally37.  
Despite the progresses made in designing new protocols, gene targeting still suffered 
from a fundamental limitation that is deeply connected with the principle on which the 
technique is based: the low frequency at which homologous recombination events take 
place in the cell. It has been calculated that in higher eukaryotic cells such events have 
a frequency from 1 in 106 to 1 in 107, which renders gene targeting a non-viable option 
for in vivo applications, where selection of edited cells is seldom possible38. The 
discovery that double strand breaks (DSB) in proximity to the target locus are able to 
increase the frequency of homologous recombination by several orders of 
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magnitude39-41, allowed the generation of edited cells with much less effort, if 
compared to classical gene targeting experiments. This could be considered a 
milestone towards the possibility to edit the cellular genome in vivo, paving the way for 
innovative therapeutic approaches. As demonstrated by these early studies, where the 
rare cutting yeast mitochondrial endonuclease I-SceI has been used to generate the 
DSB at the desired location39-41, the ability to induce DSB at will in a specific genomic 
location becomes of primary importance. Indeed, the use of endonucleases together 
with targeting constructs containing specific homology arms allowed the transfer of 
single-base-pair changes with high efficiency to a mutated chromosomal sequence 
(Fig. 3)42. This has clear implications for the correction of disease-causing mutations, 
as demonstrated by many studies43. In addition, recent works have analysed the 
characteristic of the donor template, which has been traditionally identified as plasmid 
DNA with extensive homology with the target locus, suggesting that much shorter 
single-stranded oligonucleotides44-46 or carefully designed donor molecules47 could be 
more efficient in mediating homologous recombination. In addition, for in vivo 
applications where the delivery of donor molecules could be more difficult and for cells 
that are simply harder to transfect, the use of integration-defective lentiviral vectors 
(IDLVs) or AAV vectors as donor substrates has been proposed48-53.  
 
The recent discovery of programmable nucleases, which will be the topic of the next 
chapters, for the first time enabled the introduction of DSBs into specific genomic sites, 
boosting the efficiency of the addition of exogenous sequences at desired loci into the 
Figure 3. DSB-induced genome 
modification. Nuclease-induced 
DSBs can be repaired by the cell 
either by NHEJ, introducing 
variable length indels into the 
target locus, or by homology 
directed repair, using an 
exogenous donor template, 
generating specific modifications 
to the locus of interest. Adapted 
from Sanders&Joung, Nat. 
Biotechnol., 2014. 
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human genome, using ad hoc designed donor molecules54. This allowed the insertion 
of therapeutic sequences into genomic “safe harbours”, in order to avoid the collateral 
effects observed in the past with randomly integrating vectors, such as insertional 
mutagenesis18,20, dysregulation of endogenous gene expression and positional effects 
on transgene expression55. Unfortunately, the identification of genomic safe harbours 
is a complex procedure that requires a profound knowledge of the target locus, which 
is seldom available. Alternatively, the replacement of genes containing disease-causing 
mutations by the targeted insertion of a wild-type counterpart can be promoted by 
exploiting the same basic principles: the clear advantage here is the possibility to 
maintain the endogenous regulatory elements and the exact location into the 
genome56, even though the insertion of large coding sequences could be difficult due 
to a decrease in homology-directed repair efficiency. 
As mentioned previously, mammalian cells generally tend to repair DSB using non 
homologous end joining (NHEJ), a process where two DNA ends are directly joined 
without the need of a guiding template57. This repair pathway is intrinsically error-
prone as the DNA ends that take part in the joining reaction are often modified by the 
removal or addition of a variable number of bases before the ligation. An alternative 
pathway, called microhomology-mediated end joining (MMEJ), uses short homology 
regions flanking the DSB to favour the annealing of the two DNA ends before repair, 
generally producing the deletion of a variable stretch of bases58. Similarly to targeted 
integration approaches, the use of programmable nucleases allowed the exploitation 
of these molecular events to produce gene knockouts with high efficiency, as the indels 
that would likely result as a byproduct of the repair reaction will lead to frameshift 
mutations and to premature termination of protein translation if existing out-of-frame 
stop codon are brought in frame (Fig. 3)58,59. It is also possible to couple two DSB to 
delete the genomic sequence included between the two target sites, removing regions 
up to some megabases in size60-63. This strategy is particularly useful when entire 
intronic or esonic portions of genes have to be excised64,65 or when it is necessary to 
target regulatory elements. The generation of knockouts is extremely useful in 
research applications, as it allows the dissection of complex biological functions, and 
in many instances it is superior to RNA-based knockdown approaches, where the 
downregulation of gene expression is never complete. The knockout technology has 
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also interesting therapeutic applications such as the removal of gene products with 
toxic gain of function dominant mutations, like the ones linked with trinucleotide 
repeats expansion66. Notably, one of the first clinical trials using gene editing 
techniques has the goal of assessing if the knockdown the CCR5 gene in immune cells 
makes them resistant to HIV-1 infection67-69. In fact, CCR5 is one of HIV-1 co-receptors 
and is not essential for the normal function of T cells, as demonstrated by the 
occurrence of individuals with an inactivating deletion into the gene that are naturally 
resistant to HIV-1 infection70.    
Altogether, the possibility to modify the genome with relative ease and the recent 
discovery of several different classes of programmable nucleases that allow the 
targeting of virtually any genomic locus, gave birth to a whole new field of genome 
biology: genome engineering.  
 
Targeted nucleases 
	
As outlined in the previous chapter, fundamental for the development of genome 
editing approaches is the availability of targeted endonucleases to produce DSB at 
specific locations in the genome in order to stimulate the activation of the endogenous 
repair machinery either for NHEJ-mediated knockouts or homologous recombination 
dependent gene editing. To date, four main classes of targeted nucleases have been 
widely used: meganucleases, zinc finger nucleases (ZFNs), Transcription Activator-Like 
Effector (TALE) nucleases (TALENs) and the more recently discovered Clustered 
Regularly Interspaced Short Palindromic Repeats (CRISPR)/ CRISPR associated (Cas) 
nucleases, also called RNA guided nucleases (RGNs). 
  
Meganucleases. This family of dimeric nucleases was the first to be discovered and 
has been used for gene targeting experiments for the past 20 years. They usually 
recognize extended DNA sequences (14-44 bp) that are very rare in genomes71. Given 
the length of their recognition site, and contrary to bacterial restriction enzymes, 
meganucleases can tolerate few mismatches in their target sequence even though the 
cleavage efficiency tends to decrease72. Meganucleases are generally coded within 
introns or inteins, although freestanding members also are present73. To the present 
Introduction - Targeted nucleases 
	 12 
knowledge their sole purpose is to promote the mobility within the genome of the DNA 
sequences from which they are coded, so they could be classified as selfish genetic 
elements72, even though recent studies indicate that the complex nature of the 
interconnection of the nuclease with the host may suggest a mutualistic relationship74. 
The mechanism used to colonize cognate alleles lacking the endonuclease coding 
sequence involves the generation of a DSB or a DNA nick in a genomic locus 
homologous to the parent site (from here the alternative name of homing 
endonucleases, HE), followed by repair by homologous recombination and gene 
conversion that disrupts the target site to avoid further invasion75. Five main families 
of HE have been identified according to sequence and structure: GIY-YIG, HNH, His-Cys 
box, PD-(D/E)XK and LAGLIDADG, which has been found in all the main taxonomic 
groups and is the most well studied family72. Thanks to the length of the recognition 
sequence of most HE, differently to type II bacterial restriction endonucleases, they can 
be exploited for many molecular biology applications where rare or single cuts are 
needed (for examples of recognition sites see Fig. 4). Nowadays most applications are 
based on a restricted number of well-studied natural nucleases76 and even though the 
number of HE still to be discovered and characterized remains prospectively high72, the 
targetable sequences are still too few to allow enough targeting diversity in complex 
eukaryotic genomes. To overcome this issue, the modification of the natural 
recognition sites of the I-SceI and I-CreI nucleases was obtained by altering specific 
amino acids making contacts with the target DNA77-81. Another strategy is based on the 
combination of different DNA binding subdomains obtained from different HE in order 
to generate chimeras with an hybrid specificity inherited from each of the two parental 
nucleases82,83. In addition, the targeting range of chimeric nucleases can be further 
tuned using mutagenesis on each of the different subdomain (Fig. 4)84. Other 
approaches involving high-throughput generation of HE variants to explore a larger 
space of target sites have been devised84,85. Given the extensive mechanistic and 
structural knowledge of the active site of some of these enzymes, it has been 
demonstrated that their cleavage activity can be modulated in order to obtain nicks in 
the target DNA instead of double strand breaks86,87. Homing endonucleases have been 
extensively used in vivo in several model organisms88-93 to induce genomic DSB even 
though the more frequent targets were integrated reporters containing the natural site 
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recognized by the nuclease. There are few reported cases in which engineered 
nucleases have been used to introduce DSB in non-natural sequences containing 
disease-causing mutations to promote gene targeting and correct the defect; two 
examples are mutations in the XPC gene connected with xeroderma pigmentosum94 
and a mutation in the RAG1 gene causing SCID (Severe Combined 
ImmunoDeficiency)95. 
 
 
 
Zinc finger nucleases (ZFN). The necessity to obtain nucleases with suitable 
properties for the application in genome editing, such as the ability to specifically 
recognize unique genomic sequences and the amenability for retargeting towards 
different loci96, led to the development of zinc finger nucleases. These have been 
obtained by linking a DNA binding domain commonly found in several eukaryotic 
transcription factors, called zinc finger proteins, to the nuclease domain of the FokI 
restriction enzyme97. The nuclease portion of ZFNs is composed by the FokI catalytic 
Figure 4. Engineering of homing endonucleases. New nuclease specificities can be obtained by engineering more 
or less extensively the meganuclease structure (upper panels). Alternatively, redesigned chimeric variants with hybrid 
target specificities can be obtained by combining the recognition domains of different natural occurring enzymes 
(lower panel). The mutations introduced in the structures are indicated in different colours. Adapted from Prieto et 
al., Crit. Rev. Biochem. Mol. Biol., 2012. 
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domain and needs to dimerize in order to generate a DSB at a specific target site (Fig. 
5)98. This feature, combined with the weak interaction between the two monomers, is 
crucial to ensure the specificity of ZFNs as only two adjacent zinc finger DNA binding 
domains will be able to recruit their FokI moieties close enough to favour dimerization 
and cleavage. Further engineering of the FokI domain allowed the generation of ZFNs 
that work as obligate heterodimers99,100, thus avoiding the possible targeting of 
alternate sites by homodimers. Additionally, the modulation of the length of the linker 
peptide that separates the DNA binding domain and the catalytic portion of the 
nuclease allowed the modification of the spacing requirements between the two hemi-
sites necessary for the cleavage of the target locus101, further increasing the flexibility 
of the system. The DNA binding domain of zinc finger nucleases is composed by a 
tandem array of Cys2-His2 motifs (fingers)102, each of them binding specifically to 3 bp 
(Fig. 5), with early nucleases being composed of three different fingers with the ability 
to recognize a 9 bp sequence. Since zinc fingers work as dimers the whole target 
sequence measures 18 bp, similarly to meganucleases. Later studies employed 
nucleases with up to six fingers per monomer, further improving the specificity of the 
approach96. However, it must be underlined that longer recognition sequences not 
always necessarily produce an enhanced binding specificity as the tolerance for 
mismatches could also be increased. Structural analyses have revealed that individual 
fingers are able to bind DNA independently to neighbouring motifs103, giving the 
possibility to generate zinc finger nucleases with custom specificity using modular 
assembly approaches104. Using this strategy, new specificities are generated by the 
sequential assembly of different fingers previously isolated for their ability to bind to a 
specific DNA triplet105,106. This method, however, oversimplifies the interaction 
dynamics inside the DNA binding module as it does not take into account that the 
contacts between different fingers or the interactions established by each finger with 
the target DNA outside its proximal triplet could have an effect on the zinc finger 
behaviour as a whole107-109. This prompted researches to find new ways to assemble 
ZFNs that explicitly take into account context-depend effects inside zinc fingers arrays: 
some examples are the oligomerized pool engineering (OPEN) system and its 
variants110,111, where ZFNs are selected in bacteria by a two-step process, first singularly 
and then as an assembled array, or context-depend assembly (CoDA)112. Both 
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methods, however, have some limitations in the range of sequences they can target. 
Another approach uses the modular assembly of two-fingers modules previously 
isolated for their ability to bind to a specific 6 bp sequence113. In this way, the number 
of untested module-module contacts are reduced to a minimum while maintaining the 
ease and speed of the modular approach, even though the initial screen to identify the 
specificity of double-finger modules is labour intensive.  
 
 
Zinc finger nucleases are among the first engineered endonucleases used in genome 
editing experiments, which involved the generation of knockout fruit flies114. Gene 
disruption experiments have then been performed in all main model organisms, with 
the consequent generation of transgenic lines111,115-117, as well as in a plethora of other 
plants and animals118. The technology has been extended to mammalian cell lines119, 
implementing the possibility to generate simultaneously multiple knockouts120 or large 
deletions60. In addition, by exploiting the recombinogenic nature of ZFN-induced DSBs, 
it was possible to increase the efficiency of gene editing42 or gene addition54 in different 
mammalian cellular models. As stated before, the possibility to dramatically enhance 
homology directed repair in cells through the introduction of targeted genomic lesions 
represents probably the major achievement in the genome engineering field and a 
turning point with previous editing approaches. The same technologies have been also 
employed to target specific loci in human stem cells121-123, which are increasingly used 
as surrogate models for human tissues in basic research as well as in therapeutic and 
Figure 5. Zinc-finger nucleases. (a) Schematic representation of a zinc-finger nuclease dimer bound to its target 
DNA. Each monomer contains a FokI nuclease domain that upon dimerization cleaves the target sequence. A short 
spacer sequence (5-6 bp) separates the two recognition sites. (b) Zinc finger proteins are modularly assembled from 
finger monomers (in general 3-6 fingers arrays are used) each recognizing a 3 bp sequence. Adapted from Urnov et 
al., Nat. Rev. Genet., 2010. 
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drug discovery applications. The possibility to tailor custom ZFNs to target endogenous 
genomic loci with precision is very attractive for several clinical applications, from the 
correction of monogenic diseases to the employment for cancer therapy or against 
infectious pathogens124. Different studies have shown the possibility to edit and correct 
disease-causing mutations involved in sickle cell anemia125, a1-antitrypsin disease126 
and in the alpha-synuclein gene associated with Parkinson’s127 in human induced 
pluripotent stem cells. In particular, ZFN-mediated gene disruption underwent a 
clinical trial for the treatment of glioblastoma through gene editing mediated 
disruption of the glucocorticoid receptor gene in T cells used for cancer 
immunotherapy (clinical trial number NCT01082926).  Other clinical trials to treat HIV-
1 infections by knocking-down the main viral co-receptor67,68,128, the chemokine binding 
protein CCR5, have been completed (clinical trials number NCT00842634 and 
NCT01044654). CCR5 has been shown to be essential for viral propagation in the host 
but is dispensable for a correct development of immune cells, since ~1% of individuals 
is homozygous for a deletion of 32 bp in the CCR5 gene (D32 mutation)70. The treatment 
can be applied ex vivo both to T cells68 and CD34+ hematopoietic stem cells69, that can 
be re-infused into the patient to give rise to an HIV-resistant immune system. Proof of 
principle of the concept has been indirectly obtained by CCR5D32 homozygous bone 
marrow transplantation into an HIV-positive leukemic patient led to the disappearance 
of the virus from the blood stream129. Overall, if compared to homing endonucleases, 
the flexibility of design of ZFNs allows the specific targeting of a wide range of genomic 
loci and makes them a good candidate for therapeutic applications, as demonstrated 
by their use in several clinical trials, as well as a major improvement in basic research. 
However, there are still some drawbacks in this technology: the complexity connected 
to the design and the assembly of the zinc finger protein module required to bind the 
target DNA as well as the lack of absolute specificity, that causes the introduction on 
unwanted cleavages into the target genome130, are issues that can limit the broad 
applicability of ZFNs. 
 
Transcription activator-like effector (TALE) nucleases (TALENs). To address the 
limitations connected to the ZFNs technology, a new class of guided nucleases was 
recently presented and rapidly developed: the TALENs. The basic design of TALENs is 
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similar to the one of ZFNs, where a DNA binding domain that recognizes a specific 
sequence is fused to an unspecific endonuclease domain obtained from the FokI 
enzyme (Fig. 6). As with ZFNs, also for TALENs it is possible to introduce mutations in 
the nuclease domain in order to avoid homodimerization and reduce possible off-
target cleavages and consequent toxicity131. The DNA binding domain is composed of 
highly conserved repeats isolated from Transcription Activator-Like Effector (TALE) 
proteins secreted in host plant cells through a type III secretion system by the 
bacterium Xanthomonas to alter gene transcription and favour infection132. TALEs bind 
DNA through a highly conserved array of short (ca. 30 amino acids, except the last 
repeat that is usually shorter) motifs flanked by additional domains at both ends, with 
each repeat recognizing a single nucleotide. Complete modularity differentiates this 
system from zinc fingers binding domains, in which context-dependent effects must be 
taken in consideration, making TALE design extremely easy and straightforward. In 
addition, virtually any desired sequence starting with a thymidine residue can be 
targeted133, even though this requirement is not strict134,135. In general, each TALEN is 
engineered to bind a 15-30 bp target site, conferring the ability to recognize a final 30-
60 bp sequence to the cleavage-competent dimer. Several groups over time have 
optimized in different ways the TALE scaffold to eliminate non-essential portions of the 
protein from the two constant N- and C-terminal domains, consequently modifying the 
length of the spacer DNA that must separate the TALEN couple to ensure efficient 
cleavage134-139. Subsequent structural studies revealed an essential role in DNA binding, 
but without any contribution to specificity, for the region of the N-terminal domain 
immediately preceding the repeats. For this reason the domain must be retained in 
TALEN constructs140. In addition, mutations have been inserted in the N- and C-terminal 
domains of TALENs to improve the efficiency of genome editing44. As stated before, 
DNA recognition specificity is determined by the ability of each TALE repeat to bind to 
a specific nucleobase using two variable amino acids in position 12-13 of the repeat141. 
The experimental evidence that the length of recognition site correlates with the 
number of repeats contained in the TALE protein coupled with bioinformatics analysis 
of naturally occurring binding sites, allowed the determination of the code that governs 
the interaction133,141. Crystal structures have revealed that TALE binds DNA as a right-
handed superhelix, with each repeat forming a two-helix bundle containing a variable 
Introduction - Targeted nucleases 
	 18 
loop that inserts in the major groove of the target DNA (Fig. 6). Residue 12 (histidine or 
asparagine) does not contact DNA directly but stabilizes the loop by hydrogen-bonding 
with the alanine in position 8. On the other hand, residue 13 makes contact with the 
corresponding base of the sense strand of target DNA142,143. The majority of studies 
published so far employs just four different domains containing the hypervariable 
residues NN, NI, HD and NG to recognize guanine, adenine, cytosine and thymidine, 
respectively118. However, the NN di-residue is able to interact also with adenine, leading 
to unwanted binding to similar sequences. Other di-residues (NH and NK) have been 
identified for their ability to uniquely interact with guanine residues, restoring binding 
specificity. Nevertheless, the employment of the NK di-residue is responsible for a drop 
in TALENs cleavage efficiency that cannot always be tolerated135,144,145. In addition, 
following the observation that in some instances methylated DNA was not cleaved by 
TALENs146, different groups have shown that the NG di-residue or a truncated loop 
missing the amino acid in position 13 can bind to 5-methyl-cytosine, commonly found 
in CpG islands of mammalian genomes147,148.  
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The assembly of TALE repeats can be a challenging process and different methods have 
been proposed to minimize the effort: the restriction enzyme and ligation (REAL) 
method and its variants149-151 are the more classical ones and involve the hierarchical 
assembly of increasingly complex arrays of TALE repeats by standard cloning 
techniques. A direct improvement of the latter approach is Golden Gate assembly, that 
is now widely employed in the field and makes use of type IIS restriction endonucleases 
that cut outside their recognition sequence and can generate any desired 5’-overhang 
sequence136,152-158. By flanking each TALE domain with two type IIS restriction sites and 
by carefully designing the overhangs it is possible to assemble a TALE array (6-10 
repeats) in a single ligation reaction. Higher order repeats fused with the constant 
portions of the TALEN can then be obtained by adopting the same strategy on 
previously built smaller arrays. Another approach uses ligation independent cloning 
(LIC) that is based on the very specific annealing of fragments long overhangs during 
transformation without the need of a ligation step or selection of single colonies on 
agar plates159. In addition, all these processes could be sped up considerably by using 
pre-assembled libraries of multimers of TALE repeats. Other high-throughput 
approaches mainly based on solid-phase ligation strategies have been devised for 
industrial scale synthesis160-162.  
TALENs application to both basic and biomedical research builds on the previous 
widespread use of ZFNs for similar scopes, improving on the simplicity and reliability 
of the tool. In particular, different groups have shown that TALEN demonstrate higher 
specificity and less toxicity into cellular and animal applications, if compared to zinc 
finger nucleases46,131,138. The application of the TALEN technology to laboratory animals 
led to the development of several knockout lines that could be used to model human 
diseases118. Similarly, genome editing experiments have been carried out in cell culture 
mainly by inducing knockouts by NHEJ-mediated repair134,135,138,152,156,161 but also 
exploiting HDR and double-stranded DNA templates to introduce specific changes into 
Figure 6 (on previous page). TALE nucleases. Schematic representation of a TALEN dimer bound to its target 
DNA. The FokI nuclease domain dimerizes to cut the target sequence. Each TALE monomer is composed of a 33-35 
amino acid repeat that recognizes a single base and is assembled modularly to generate the final DNA binding 
domain, that interacts with a 15-30 bp target site. Base recognition employs a Repeat Variable Diresidue (RVD, in 
red) that contacts the target DNA major groove. The N-terminal repeats (0 and -1) contact an invariable 5’-thymidine. 
Adapted from Kim&Kim, Nat. Rev. Genet., 2014. 
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the genome of clinically relevant cell types such as human pluripotent stem cells135,163. 
Aside from generating DSB at target sites other applications have been designed for 
TALE proteins by fusion with domains different from the FokI nuclease. TALE-based 
transcriptional activators have been tested in plants144,154,158,164-166 and human cells146 
to modulate gene expression, obtaining at best a 2-30 fold increase in gene or protein 
expression, with the vast majority of TALE-based transcription factors showing only low 
levels of activity. On the opposite, by fusing TALE repeats to transcriptional repressors 
it was possible to downregulate gene expression in a sequence-specific manner in 
different model organisms145,165,167,168. A recent study employed TALE proteins to 
transiently direct the binding of a set of three different epigenetic modifiers to specific 
genomic sites in order to obtain stable and inheritable silencing169. Another fusion 
partner that has been tested in combination with TALEs is the catalytic domain of the 
DNA invertase Gin to obtain a targeted recombinase (TALER)170. In principle, other 
fusion proteins can be generated to act on the cellular genome in a sequence specific 
fashion. Overall, TALE proteins improve the technology launched with zinc finger 
nucleases by increasing the specificity of DNA recognition and lowering the effort in 
designing each locus-specific binder.   
 
The CRISPR/Cas system 
	
A new class of programmable nucleases emerged in the last years, the Clustered 
Regularly Interspaced Palindromic Repeats (CRISPR)/ CRISPR associated (Cas) system, 
also known as RNA guided nucleases (RGNs), finding quickly broad application in 
genome engineering approaches and often superseding previous classes of editing 
nucleases. Its extreme technical simplicity and low cost made RGNs very popular 
between non-specialist scientists, transforming CRISPR-mediated genome editing into 
a mass-phenomenon. 
The origins of RGNs sit into a completely separate scientific field, born when 
researchers begun investigating the functions of CRISPRs in bacterial genomes, almost 
20 years after their discovery in E. coli171. CRISPR-Cas loci are present in all Archea and 
in almost half bacterial genomes, are constituted of a characteristic pattern of repeated 
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stretches of DNA alternated by spacer sequences and are usually located near cas 
genes (Fig. 7)172.  
  
 
Different studies determined that the spacer sequences found in CRISPR loci were 
identical to sequences present in the genome of bacteriophages and other mobile 
genetic elements173-175 to which the bacterium was resistant. This, combined with the 
observation that cas genes code for proteins with putative helicase and nuclease 
activities173,176, led to the identification of the CRISPR system as a form of nucleic acid-
based bacterial adaptive immunity177. Experimental evidences indicated that this sort 
of adaptive immune system is based on ribonucleoprotein complexes (crRNP) 
composed of Cas proteins that cleave invading nucleic acids guided by RNAs 
transcribed from the spacer sequences found in bacterial genomes (crRNAs), exploiting 
base-pairing with the exogenous nucleic acid (Fig. 7)178,179. The CRISPR/Cas loci are 
highly diverse due to the rapid evolution induced by the arms race with invading 
pathogens and, according to the present knowledge, are classified in two classes in 
accordance to the number of Cas proteins present in the complex that degrades 
invading nucleic acids with a further division in six types with many different 
subtypes180. Each main CRISPR type is characterized by a peculiar Cas protein: type I 
systems contain Cas3, type II systems signature protein is Cas9, all type III systems are 
Figure 7. The bacterial 
CRISPR system. Bacterial 
adaptive immunity is 
mediated by CRISPR RNAs in 
complex with cas proteins. 
Following invasion by a 
foreign nucleic acid, new 
spacers are acquired and 
integrated into the CRISPR 
locus for later expression, 
processing and incorporation 
into crRNP for the 
interference stage. Adapted 
from van der Oost et al., Nat. 
Rev. Micro., 2014. 
Introduction - The CRISPR/Cas system 
	 22 
associated with Cas10, type V systems are characterized by Cpf1 and type VI systems 
are identified by the C2c2 protein. Consequently, each CRISPR type is also 
characterized by a particular crRNP: the Cascade (CRISPR-associated complex for 
antiviral defence) for type I-A to I-F, type II systems use Cas9 complexes, while type III-
A and type III-B are identified by Csm and Crm crRNPs, respectively181. Despite the 
apparent complexity, Cas proteins can be divided in four main functional groups: 
nucleases and recombinases, involved in spacer acquisition; ribonucleases involved in 
guide RNA processing; proteins that together with guide RNAs form crRNPs; nucleases 
that cut target DNAs or RNAs. The first step in CRISPR/Cas mediated immunity involves 
the acquisition of new spacer sequences to be integrated into the host chromosome 
(Fig. 7). This process is spatially ordered and new spacers are always added upstream 
of the CRISPR locus173,177 after sampling by the conserved Cas1 and Cas2 proteins182 
and processing to a specific spacer size183. Some studies suggested that other Cas 
proteins, as well as some housekeeping proteins involved in DNA repair and 
recombination, are involved in spacer acquisition177,184-186. The distinction between self 
and non-self in type I and II systems is obtained through short stretches of nucleotides 
collectively called protospacer adjacent motif (PAM) that are absent from the CRISPR 
spacer located into the bacterial genome but are present in the foreign nucleic 
acid187,188. Several studies demonstrated that the presence of a PAM is essential for 
CRISPR/Cas mediated restriction189-194 as well as for the incorporation of new 
spacers187. Type III systems use a PAM-independent self/non-self discrimination 
mechanism based on the pairing of the crRNA with specific sequences in the 
genome195. CRISPR-arrays are transcribed as long RNA precursors (pre-crRNA) that are 
processed to generate mature crRNAs. In both type I and type III systems Cas6 is 
generally involved in this maturation step, generating a hairpin structure at the 3’-end 
of the RNA196. In type I-E and type I-F systems Cas6 remains associated with the mature 
crRNA and becomes part of the crRNP after crRNA incorporation197. In addition, the 3’-
end of crRNAs is further trimmed after incorporation into crRNP198. In type V systems, 
the maturation of crRNAs requires only the Cpf1199 protein.  
crRNPs differ in protein composition between different CRISPR types, even though 
effector complexes from type I and type III systems share several structural similarities 
(Fig. 8)200-202. The prototype type I Cascade complex, belonging to type I-E systems, is 
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composed of a core of Cas5-Cas6-Cas7 proteins organized around the crRNA, with the 
addition of two other subunits (Cse1 and Cse2) with uneven stoichiometry178,203. Other 
type I subtypes differ in the identity of the Cas protein involved in crRNP assembly even 
though the overall structure of the complex remains very similar, with a characteristic 
helical backbone204,205. Similarly, type III complexes are composed of a different set of 
homologous Cas proteins, but nevertheless share several common structural features 
with type I RNPs200,202.  
 
 
 
Target recognition and restriction proceed in a stepwise manner and begin with PAM 
recognition in the invading nucleic acid followed by DNA duplex melting and pairing 
between the crRNA and the target sequence, starting from a seed sequence (7-8 
nucleotides) proximal to the PAM192,206,207. This induces a conformational change in the 
crRNP, activating its endonuclease function (either directly or via an additional subunit) 
and promoting target cleavage202,203,208. In type I systems, the Cse1 subunit of the 
Cascade complex scans the DNA for PAM recognition193,203,206, crRNA-DNA pairing is 
aided by the Cse2 subunit208 and a conformational change in the complex recruits the 
helicase-nuclease Cas3 that mediates complete degradation of the target DNA194. The 
mechanistic details of type III-A systems are still to be elucidated completely, however, 
Figure 8. CRISPR effector complexes. Schematic representation of the subunit composition of the main three 
CRISPR-Cas types. Similar colours indicate homology between the different components of each complex. crRNA is 
represented in each complex, Cas9 is depicted bound to a synthetic single guide RNA. Numbers indicate the name 
of the subunit in the context of each particular CRISPR type. Cas3’ and Cas3’’, the dashed red subunit in the Cse 
complex and the grey subunit in the Csm complex are not well characterized. Adapted from van der Oost et al., 
Nat. Rev. Micro., 2014. 
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it is known that Csm complexes are able to recognize foreign DNA in a PAM-
independent manner195 and that target degradation is mediated by a helicase-nuclease 
recruited after binding, possibly Csm6209. Type III-B systems are peculiar in their ability 
to target RNA instead of DNA210. Crm complexes are in fact able to cleave target RNAs 
multiple times following a regularly spaced pattern200. 
 
CRISPR type II systems: the Cas9 endonuclease 
	
Different studies in Streptococcus thermophilus have shown that Cas9 is responsible for 
the defence against invading nucleic acids through the introduction of DSB into 
plasmids and phages177,211-213. The CRISPR type II locus, that so far has been found only 
in bacteria, is characterized by the presence of an atypical family of small non coding 
trans-activating RNAs (tracrRNAs). TracrRNAs share a 24-nucleotide complementarity 
with the repeat region of crRNAs precursors and are responsible for directing the 
activity of the host protein RNAse III, that in presence of Cas9 promotes the maturation 
of pre-crRNA into mature crRNA in which the spacer sequence is trimmed to a final 
length of 20 nucleotides. In the process tracrRNAs are also cleaved to their mature 
form of 75 nucleotides211.  
Both mature crRNA and tracrRNA are essential to direct Cas9 cleavage towards a DNA 
molecule that contains a target complementary to the crRNA followed by an 
appropriate PAM sequence which is species-specific189. The essentiality of the PAM 
sequence was demonstrated by interaction studies that revealed that Cas9 
preferentially binds to PAM-containing DNA sequences while forming only transient 
interactions with other sequences214,215. After PAM binding, Cas9 interrogates the 
flanking DNA for complementarity with the crRNA to initiate R-loop formation at the 3’-
end of the guide RNA with sequential unwinding of the target DNA through a 
Browninan ratchet motion model (Fig. 9). Thus, R-loop association rates are influenced 
by the presence/absence of a PAM, while R-loop stability depends on the pairing 
between guide RNA and target DNA214. It has been shown that perfect matching of a 
12 nucleotide PAM-proximal seed region is important for proper target recognition and 
cleavage, while more PAM-distal positions can tolerate mismatches189,190,215. Cas9 
contains a HNH- and a RuvC-nuclease domain that are responsible for the cleavage of 
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the target DNA strand complementary and non-complementary to the crRNA, 
respectively (Fig. 10)189,190. Cleavage products are characterized by blunt ends 
produced  3 nucleotides upstream of the PAM sequence213.  
 
 
 
Cas9 proteins form a large family across the bacterial kingdom with members 
characterized by little sequence similarity and spanning different sizes, even though 
two main populations centred around 1100 and 1350 amino acids can be identified. 
Three principal sub-families have been proposed based on the architecture and the 
organization of each CRISPR locus: type II-A and type II-C, that comprise most of Cas9 
proteins, plus type II-B216. Structural analyses of prototype members of sub-families II-
A and II-C, Cas9 from Streptococcus pyogenes, Staphilococcus aureus and Actinomyces 
naeslundii, revealed some common structural features and the general domain 
organization of this protein family217-219. Before binding to their target both proteins 
fold in a bi-lobed structure in which is possible to discriminate a nuclease lobe, that 
contains the conserved catalytic structural core, and an alpha-helical lobe that, 
together with the carboxy-terminal domain, are more diverse between different 
members of this family and are probably involved in the recognition of molecular 
partners peculiar to each Cas9 protein, such as guide RNAs and PAMs220. The transition 
from the apo state to the guide RNA-bound state corresponds to a significant structural 
rearrangement, involving in particular the alpha-helical lobe, with the formation of a 
central channel between the two lobes to home the target DNA-guide RNA duplex (Fig. 
10)217,218.  
 
Figure 9. Cas9 target recognition and cleavage. Schematic representation of Cas9 mode of action: Cas9 in 
complex with both crRNA and tracrRNA scans the DNA for PAM sequences. PAM recognition is followed by seed 
pairing that upon perfect match is extended to the rest of the spacer sequence triggering conformational changes 
and R-loop formation. The two target DNA strand are then cleaved by distinct Cas9 nuclease domains. Adapted 
from van der Oost et al., Nat. Rev. Micro., 2014. 
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Cas9 interacts with the RNA-DNA heteroduplex independently of its sequence, 
recognizing the geometry of the complex rather than its base composition. On the 
other hand, the interaction with the guide RNA is sequence specific, explaining the 
strict preferences in crRNA/tracrRNA loading of each Cas9 orthologue. In addition, a 
conserved arginine-rich helix present in the N-terminal portion of the protein is 
essential for both RNA and DNA recognition and act as a hinge, connecting the two 
Cas9 lobes. The structural basis of PAM requirement and recognition has been 
elucidated221, demonstrating that Cas9 makes specific contacts with the GG 
dinucleotide of the non-target DNA strand (residues R1333 and R1335 of S. pyogenes 
Cas9), without forming any interactions with the cognate bases on the target strand. A 
general model for Cas9 target recognition and cleavage has been proposed: in the 
absence of its RNA component Cas9 assumes an auto-inhibited conformation that is 
switched to an active conformation upon guide RNA binding; after this step Cas9 can 
interrogate putative target DNAs for PAM sequences. Upon PAM binding and R-loop 
formation, progressive RNA-DNA heteroduplex pairing unwinds the target DNA from 
the PAM-proximal end and generates an amenable substrate for Cas9-mediated 
Figure 10. Cas9 structure. (a) Schematic representation of Cas9 domain organization. (b) Surface representation 
of Cas9 in complex with a single guide RNA and target DNA. A bilobed structural organization can be appreciated, 
with the alpha helical lobe and the nucleases lobe that fold to generate a central cavity to host the sgRNA:DNA 
heteroduplex. Colours in (a) correspond to surface colourings in (b). BH: bridge helix. Adapted from Nishimasu et 
al., Cell, 2014. 
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cleavage220. This general model, however, is still unable to explain the exact mechanism 
that leads to the cleavage of each target DNA strand, since structural studies generally 
employed Cas9 mutants in which at least one of the two catalytic sites is inactivated. 
Additionally, it is not clear how target DNA unwinding proceeds or if it is connected to 
the conformational changes induced by PAM binding. Recently, new insights on Cas9 
cleavage mechanism have been obtained222, showing that the conformational state of 
the HNH nuclease domain determines the extent to which Cas9 endonucleolytic 
activity is engaged, identifying an allosteric communication between the HNH and the 
RuvC domains to allow a concerted cleavage reaction.  
 
Biotechnological applications of CRISPR nucleases 
	
Among different RGNs, the type II system is particularly interesting for its dependence 
on a single multi-domain and multi-functional Cas protein (Cas9) and two short RNAs 
for its effector roles. In 2012 two different groups analysed the cleavage requirements 
of Cas9 from Streptococcus pyogenes189 (SpCas9) and Streptococcus thermophilus190 
(St3Cas9) and demonstrated the possibility to redirect their target specificity by 
modifying the crRNA. Immediately after, the application of S. pyogenes Cas9 to edit the 
genome of eukaryotic cell lines has been reported by different groups that introduced 
indel mutations in different loci by exploiting NHEJ-mediated repair of Cas9-induced 
DSBs223-225. In one instance, a significant increase in the frequency of homologous 
recombination at the targeted site has been reported224. These results opened a brand 
new era in the field of programmable nucleases and, more broadly, in genome 
engineering. If compared to previous tools, such as ZFNs or TALENs, RGNs are 
characterized by a similar efficiency in targeting specific loci, combined with a much 
more straightforward design process for retargeting226. The generation of a chimeric 
molecule, the single-guide RNA (sgRNA), from the fusion between the crRNA and the 
tracrRNA through a four base pair loop189 allowed to further simplify the experimental 
design, facilitating the delivery of all the RGN components (Fig. 11). In addition, the fact 
that Cas9 is not directly coupled with its sgRNA allows easy multiplexing experiments 
in which different guide RNAs are delivered in the cell at the same time to obtain 
mutations in different genomic loci227-229 or deletions and inversions61. This is a unique 
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advantage of the RGN platform relative to previous programmable nucleases 
technologies.  
 
 
 
In the last years, Cas9-mediated genome editing has been efficiently applied to many 
different human and non-human cells and embryonic stem cells 230-232. Relevant 
applications are, for example, the generation of cancer models bearing genomic 
modifications similar to the ones found in patients’ samples233-236 or proof-of-principle 
studies demonstrating the correction of genetic mutations responsible for inheritable 
diseases43,237,238. The application of the Cas9 toolkit for the generation of animal models 
proceeded at a rapid pace and several transgenic species have now been obtained 
including, in addition to mice, worms, flies, fish, rats, rabbits, goats, sheep, dogs, pigs, 
and monkeys231,239. This demonstrates the possibility of a further expansion of the pool 
of species amenable for genetic modification, leading to the generation of more 
efficient and reliable models for biomedical research. In addition, the possibility to 
directly inject Cas9 RNPs into fertilized zygotes can speed-up the process of gene 
modification in animals, bypassing the necessity of generating transgenic embryonic 
stem cells lines, shortening the time required to obtain a transgenic mouse or rat from 
a year to several weeks227,228,240,241. In a similar way, Cas9-based genome engineering 
has found application also in plants, both in species used as research models and in 
crop plants like rice, wheat, sorghum, tobacco, sweet orange and liverwort242, where in 
some instances high editing efficiencies have been observed, combined with the stable 
transmission of the alterations to the next generations243. Of note, the regulatory 
implications of such modifications are still not completely clear and will have to be 
Figure 11. Single guide RNAs. (a) Schematics of the single guide RNA (sgRNA) engineered by the addition of a 
tetraloop between the crRNA and the tracrRNA. The stem-loop structure that characterizes the sgRNA is indicated 
in the scheme. (b) Cas9 in complex with a single guide RNA and the target DNA. (a) adapted from Nishimasu et al., 
Cell, 2014. 
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addressed in the next years244. 
An immediate extension of the CRISPR/Cas9 technology is the high-throughput 
screening of genomic functions. The simple principle on which Cas9 retargeting is 
based allows the bioinformatics design and the preparation of chemically synthesized 
oligonucleotides libraries targeting hundreds of thousands specific sequences in the 
genome. These sgRNAs libraries are generally delivered as pools into cells using 
lentiviral or retroviral vectors, ensuring that each individual cell receives only one single 
sgRNA. Cultures can then be both positively or negatively selected for a specific 
phenotype and the connected sgRNAs are then identified by deep-sequencing and 
bioinformatics analysis245-248. Of note, a study reported the in vivo screen for genes 
involved in metastases formation and late-stage primary tumour development using 
cells manipulated ex vivo with whole genome sgRNA libraries249. Further 
implementations of this technology, allowed by the efficiency of the lentiviral delivery 
system, are the application of CRISPR screens to primary cells250, to obtain insights on 
physiologically relevant biological systems, or the design of multiplex screens in which 
more than one gene is targeted at time251. Different studies have compared the 
performance of CRISPR screens with that of classic RNAi approaches concluding that 
RGNs outperformed previous experimental designs, with less variation in the results 
and fewer off-target effects, and suggesting that  the combination of  the data obtained 
from the two approaches could increase the overall performance252,253. 
Beyond its employment as a targeted nuclease, Cas9 has been modified in several ways 
to bring different biological functions to specific sites of the genome (for a summary 
see Fig. 12). The knowledge of the precise configuration of its two catalytic sites allowed 
the generation of catalytically inactive Cas9 mutants (dCas9, containing the mutations 
D10A and H840A)189 that are able to bind the target DNA but cannot induce any DSB, 
becoming RNA-guided DNA-binding proteins. By fusing transcriptional repressors to 
dCas9, such as the Kruppel-associated box (KRAB) domain, the downregulation of the 
expression of protein-coding genes, as well as non-coding sequences including miRNAs 
and large intergenic non-coding RNA (lincRNAs), has been obtained in mammalian 
cells254-257. On the other hand, fusions with multiple copies of the VP16 transcriptional 
activator domain (VP64 or VP128) induced only mild upregulations of endogenous 
genes254,258,259. For this reason, different strategies have been devised to increase the 
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efficiency of the activation process, observing a clear dependence on the genomic 
context of the gene260. Examples are the use of epitope arrays fused to dCas9 to allow 
the binding of several intracellular antibodies fused to a transactivator domain261, the 
introduction of multiple MS2 hairpins in the sgRNA sequence to allow the recruitment 
of transcriptional activators through their fusion with the MS2-binding protein262 or the 
engineering of stronger tripartite transcriptional activators composed of VP64, the 
activation domain of p65 and the Epstein-Barr virus R transactivator263. In addition, the 
design of more complex scaffold RNA (scRNAs) by introducing different hairpins into 
sgRNA in order to recruit endogenous regulators of transcription has been 
proposed264.  
 
 
 
Starting from similar concepts, dCas9-mediated epigenome engineering has been 
attempted by generating different fusions of dCas9 with epigenetic-modifying 
enzymes. An example is represented by the generation of a chimera with the catalytic 
core domain of the human histone-acetyltransferase p300 that is able to upregulate 
gene expression through acetylation of lysine 27 of histone H3 when bound to 
Figure 12. Biotechnological applications of Cas9. Several applications have been designed for Cas9, both as a 
targeted nuclease for genome engineering and as a programmable DNA binding domain to direct the desired 
biological function to specific genomic regions. Adapted from Wang&Qi, Trends Cell Biol., 2016. 
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proximal or distal enhancers265. Other tested chimeric molecules include fusions with 
lysine demethylase 1266 and different DNA methyltransferases169,267. However, more in 
depth studies are needed to expand the epigenetic editing toolkit, to assess its 
complete orthogonality with endogenous mechanisms and to understand the fate of 
the modifications introduced, even though a recent investigation analysed the 
outcome of epigenome editing after long term culture169. 
Given its ability to target specific sequences, dCas9 has been employed to directly 
observe the organization and the dynamics of genomic sites of interest in cells. The 
first proof-of-principle study exploited a dCas9-eGFP fusion to track non repetitive and 
repetitive genomic loci such as telomeres268,269. Building on this idea, by using different 
Cas9 orthologues tagged with alternative fluorescent proteins, the simultaneous 
tracking of different repetitive loci has been achieved270. A direct improvement of the 
latter system uses an array of epitopes (SunTag) fused to dCas9 that recruits multiple 
copies of a fluorescently tagged intrabody in order to amplify the signal produced by a 
single non-repetitive genomic locus261. The development of Cas9-mediated 
fluorescence in situ hybridization (CASFISH) allows the visualization of both repetitive 
and non-repetitive loci in fixed cells and primary tissue sections using fluorescently 
labelled in vitro assembled dCas9 RNPs271. This method represents a fast and 
convenient way to label endogenous loci without the need to denature DNA, thus 
preserving the original nuclear architecture and the spatial relationships between 
different genomic sequences and avoiding the artefacts typical of standard FISH 
techniques. dCas9 has additionally been used to image endogenous RNA molecules in 
living cells by using a sgRNA targeting a specific RNA combined with a stabilized 
PAMmer oligonucleotide that base-pairs with the same target and contains the PAM 
sequence necessary for dCas9 binding. This method allowed to track RNA export from 
the nucleus and the accumulation of specific mRNAs into stress granules following 
oxidative stress272. 
A recently reported unconventional application for Cas9 involves the editing of single 
bases within specific sequences without the induction of DSBs273,274. These base editors 
are constituted by the fusion of a catalytically inactive Cas9 to a specific cytidine 
deaminase enzyme, that uses the single stranded DNA generated by Cas9 binding as a 
substrate for deamination, targeting different cytidine residues within the protospacer 
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sequence, according to the length of the linker between the two fusion partners. This 
base editing system can be improved by using a Cas9 nickase that, by introducing of a 
nick into the non-edited strand, enhances editing activity through the re-synthesis of 
the non-edited strand using the modified one as a template, thus incorporating the 
newly added mutation. Furthermore, the fusion to the base editor of a protein inhibitor 
of uracil DNA glycosilase (UDG) is able to boost editing efficiencies, blocking the 
engagement of the base-excision repair pathway273,274. This approach can be used for 
the correction of pathogenic single base mutations without the risk of inducing DSB or 
indels and with a superior efficiency with respect to HDR-based protocols. 
 
Limitations in the CRISPR/Cas9 technology 
	
In the past years a plethora of new applications and techniques exploiting S. pyogenes 
Cas9 has been developed and even though this CRISPR nuclease has proven a flexible 
and powerful tool to modify the genome or study its functions, some drawbacks still 
remain. One issue is connected to the relatively big size of the Cas9 protein (~1400 
amino acids, ~4,3 kilobases) that limits its delivery with some conventional vector 
systems, such as AAV vectors, that are commonly used in gene therapy approaches, 
but can ferry into the cell inserts up to 4,5 kilobases. Even though AAV-mediated Cas9 
delivery in a single vector is technically feasible275, this leaves little room for flexibility 
in vector design. This explains the effort devolved by researchers into the identification 
of smaller Cas9 orthologues that could be more easily adapted to all kind of vector 
delivery systems, including AAV. Two smaller orthologues that have been isolated from 
Neisseria meningitides (NmCas9) and Streptococcus thermophilus strain LMD-9 CRISRP1 
locus (St1Cas9) were tested for their ability to edit mammalian genomes223,276,277. In 
addition, bioinformatics analyses aided the identification of an additional smaller Cas9 
orthologue from Staphylococcus aureus (SaCas9) that was efficiently delivered in vivo 
using an AAV-based vector system to perform gene editing into liver tissue219,278. An 
alternative approach is based on the reduction of SpCas9 dimension by eliminating 
non-essential portions of the protein. The deletion of the of the REC2 domain located 
in the alpha-helical lobe of SpCas9 has been reported, even though this shorter version 
of the nuclease shows reduced cleavage activity218.  
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A second issue derives from the requirement of a specific PAM sequence in proximity 
of the intended genomic target. The canonical S. pyogenes Cas9 PAM corresponds to 
the trinucleotide 5’-NGG that should theoretically allow cleavage each 16 bp into any 
genome. However, the identification of an optimal sgRNA still remains not always 
possible, in particular when it is necessary to target specific nucleotides or short 
sequences and for homology-directed repair applications where the best efficiency is 
obtained only if cleavage occurs in close proximity to the desired alteration279. For this 
reason, the identification of new nucleases with different PAM specificities to expand 
the CRISPR toolbox can significantly increase the number of targetable genomic sites, 
with the possibility to choose between different Cas proteins according to each specific 
application. Example cited previously include S. aureus Cas9, characterized by the 5’-
NNGRRN PAM sequence278, N. meningitides Cas9 that cleaves sites upstream the 5’-
NNNNGATT PAM277 or S. thermophilus CRISPR1 Cas9 that recognizes 5’-NNAGAAW276. 
An additional Cas9 orthologue isolated from the CRISPR3 locus of S. thermophilus 
(St3Cas9) that cleaves sequences nearby the 5’-NGGNG PAM has been characterized190 
and tested for its ability to cleave mammalian genomes276. An alternative approach to 
address this limitation involves the generation of novel Cas9 variants with altered PAM 
specificities through protein engineering. Using a bacterial selection-based directed 
evolution screen, two Cas9 mutants with the ability to recognize 5’-NGA or 5’-NGC PAMs 
instead of the canonical 5’-NGG trinucleotide have been isolated280. In addition, the 
structural characterization of these variants was performed to understand the basis 
for differential PAM recognition and allowed the rational design of an additional 
mutant that specifically recognises the 5’-NAAG PAM281. Similar protein engineering 
approaches have been used to broaden the targeting range of S. aureus Cas9 by 
relaxing its PAM recognition specificity to allow the cleavage of sequences followed by 
the NNNRRT PAM282. In parallel, the need to understand the PAM requirements of 
newly discovered Cas proteins propelled the development of fast and reliable methods 
to identify and visualize PAM preferences283.  
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Other recently discovered editing systems 
	
This continuous search for alternatives to SpCas9, in addition to the identification of 
several Cas9 orthologues, led to the discovery of other CRISPR-associated proteins with 
different properties. Recently, a new putative class 2 CRISPR system (type V) has been 
identified284 and structurally characterized285,286. Its signature protein, the ~1300 amino 
acid Cpf1 protein, has been characterized as an RNA-guided nuclease that recognizes 
a T-rich PAM (TTTN-3’) upstream of the target sequence and cleaves DNA in a PAM-
distal position, generating staggered ends with 2-4 nucleotides overhangs199. The latter 
characteristic could be particularly useful to introduce exogenous DNA  sequences into 
the genome via a non-HDR mechanism287. In addition, the fact that DSBs are not 
introduced in proximity of the PAM sequence might allow a “second chance” cleavage 
mechanism where Cpf1 cuts again its target, tipping the balance between NHEJ and 
HDR in some experimental settings. In contrast to Cas9, Cpf1 contains a single 
identified RuvC-like nuclease domain and a second poorly characterized nuclease 
domain that together produce DSBs into the target DNA. The additional peculiarity of 
type V systems is that Cpf1-associated CRISPR arrays do not require a tracrRNA to be 
processed to their mature form, hence Cpf1 needs to incorporate only the crRNA, 
which is 42 nucleotides long with a spacer of 23-25 nucleotides, to be programmed for 
targeting specific sequences. Further analysis of several Cpf1 orthologues isolated 
from different bacterial strains allowed the identification of two enzymes (AsCpf1 and 
LbCpf1) that exhibit robust editing activity in mammalian cells199. Furthermore, 
knockout mice have been generated by electroporation of Cpf1 RNPs into embryos288 
or by co-injection of Cpf1 mRNA and crRNA into fertilized eggs289. 
Another recently discovered member of Class 2 CRISPR systems is C2c2, that belongs 
to type VI systems and lacks homology with any other known DNA nuclease, but 
contains two Higher Eukaryotes and Prokaryotes Nucleotide-binding (HEPN) domains, 
generally associated with RNAse activity290. Further characterization determined that 
C2c2 is indeed an RNAase guided by a single crRNA composed of a 28 nucleotides 
spacer and a constant portion of the same length. No PAM is required for recognition 
and cleavage but the nucleotide located immediately downstream the target sequence, 
named Protospacer Flanking Site (PFS), must be different from G.  C2c2 cleaves ssRNA 
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multiple times in a secondary structure-dependent manner and once activated is able 
to cleave unspecifically unrelated RNA molecules. It has been shown that C2c2 can 
downregulate mRNAs in bacteria, albeit causing appreciable growth restriction 
connected to promiscuous RNA cleavage. This effect could be exploited to induce 
growth arrest and programmed cell death in specific cells expressing a target RNA. 
Other biotechnological applications involving an enzymatically inactive form of C2c2 
include RNA labelling and RNA targeting with specific effector modules, RNA re-
localization to specific cellular sub-compartments or pull-down experiments to capture 
specific transcripts and their partners290. 
Taking into consideration the continuous search for new methods to edit genomes, 
much excitement followed the discovery of a completely independent class of guided 
nucleases. A recent study291 reported the editing of mammalian genomes using the 
Argonaute protein from Natronobacterium gregoryi (NgAgo). This is a DNA-guided 
nuclease that uses gDNAs of 24 nucleotides to generate sequence-specific DSBs 
without the need of a PAM sequence and with minimal off-target activity. Much debate 
followed the disclosure of these results, as many of the laboratories that tried to 
reproduce the data did not succeed in the attempt292. 
 
Safety issues and off-target activity 
	
An important question connected to the use of programmable nucleases is whether 
their cleavage activity is limited to the intended site or if additional genomic loci are 
targeted unspecifically by the nuclease with the consequent induction of NHEJ-
mediated indel mutations or gross chromosomal rearrangements, such as deletions, 
inversions or translocations, if multiple sites are targeted simultaneously293. 
Considering the not-so-far perspective of using designer nucleases for therapeutic 
applications, answering this question and addressing the related issue becomes 
essential since unwanted alterations could lead to unfavourable clinical outcomes. An 
interesting example in this respect comes from a therapeutic approach to treat HIV-1 
infections by ZFN-mediated knockdown of the CCR5 viral co-receptor that is currently 
in a phase II clinical trial67. Studies have shown that this ZFN cleaves also a highly 
homologous site in the CCR2 gene, possibly leading to chromosomal aberrations60,294, 
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and little is known on the effects that such off-target activity could have in patients. The 
same issues are also true for biomedical and basic research, where result 
interpretation requires an optimal knowledge of the experimental conditions and the 
eventual presence of confounding variables. It must be noted, however, that in the last 
case it is possible to devise different experimental strategies to control for nuclease 
off-target effects, similarly to what has been done in the past when using RNA 
interference protocols. The issue connected to off-target activity is common for all 
targeted nucleases and has been investigated in detail both for ZFNs295 and TALENs296. 
More recently, the discovery and application to genome editing of RGNs required 
further efforts to analyse the specificity patterns of these nucleases. The results of such 
studies will be presented more in detail in the next paragraphs. 
Different groups reported the possibility that mismatches in the sgRNA-DNA pairing 
can be tolerated by Cas9, producing cleavages in sites that are only somewhat similar 
to the desired target (see Fig. 13 for an example)189,223,297-299. More extensive studies on 
mismatch tolerance by SpCas9 confirmed that, in general, sequences containing 
mismatches in PAM-distal positions are targeted to a greater extent than sites with 
more PAM-proximal mismatches, but questioned the existence of a proper “seed 
region” where perfect match is always necessary to allow cleavage. Instead, a 
sequence-dependent and mismatch-dependent model has been proposed, with a 
clear relationship between number of mismatches and their relative positioning within 
Figure 13. Cas9 off-target effects. GUIDE-seq analysis of genome-wide off-target sites for a conventional (EMX site 
1) and a repetitive (VEGFA site 2) target. The position of off-target sites on chromosomes is indicated with red bars 
while the on-target is marked in green. Adapted from Tsai et al., Nat. Biotechnol., 2014. 
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the guide sequence and SpCas9 cleavage efficiency300,301. Another study used an in vitro 
selection protocol and purified SpCas9 RNPs to isolate from a randomized library 
sequences that are cleaved by selected sgRNAs. The subsequent analysis of the hits, 
some of which were further validated in mammalian cells, revealed a general trend for 
increased tolerance for mismatches in PAM-distal positions that is anyway dependent 
on the number of mismatches. Several exceptions to this general rule were observed 
and the working model in which only a so-called 10-12 nucleotide “seed sequence” is 
essential to specify the target sequence189,223 was refuted, stressing the importance of 
the pairing of all the 20 nucleotides of the spacer sequence to direct the nuclease. In 
addition, off-target sites identified with the in vitro screen and present in the human 
genome were tested for cleavage by expressing SpCas9 and the corresponding sgRNA 
in mammalian cells. Of all the tested loci only a minority was significantly modified302, 
suggesting that other factors in addition to the actual target sequence, such as the 
accessibility of the genomic locus or the presence of epigenetic modifications, may 
determine the range of the off-target sites of a particular guide RNA. Other studies 
reported that RGNs can also cleave off-target sites where few extra or missing 
nucleotides are present, producing DNA or RNA bulges, respectively, to accommodate 
base-paring of the remaining spacer portion303. In addition, genome-wide studies304,305 
failed to identify a simple rule governing the relationship between the level of 
homology with the on-target sequence or the identity of the mismatched nucleotides 
and the level of cleavage of each off-target. These data clearly imply that the prediction 
of the specificity profile of different sgRNAs is neither simple nor straightforward. To 
aid the identification of putative off-target sites, that could be later experimentally 
tested, several software has been developed and is available online. These tools are 
generally based on the analysis of the sequence homology with the on-target site and 
take into account the number, position and nature of the mismatches to rank each off-
target site. 
Importantly, different studies identified a significant correlation between the amount 
of nuclease present in the cell or in vitro and the level of unspecific cleavages: increased 
amounts of SpCas9 were able to target sequences more dissimilar to the specific 
one300-302. Similarly, the duration of nuclease exposure is another factor that can 
influence its off-target activity. The utilization of conventional plasmid transfection and 
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integrating viral vectors can lead to sustained expression of SpCas9 with the 
consequent induction of unwanted cleavages in a time-dependent manner, even 
though no particular cell toxicity has been observed so far306. Using whole genome 
sequencing at high coverage, two groups were able to identify only rare off-target 
mutations in human embryonic stem cells (hESC) and human induced pluripotent stem 
cells (iPS) clones307,308, in contrast to what has been observed by others in established 
cell line models. This discrepancy could be due to the different experimental system 
used and to the fact that only clonal populations have been analysed in the stem cells 
models.  
Several methods have been developed for the detection of both on-target and off-
target modifications induced by guided nucleases. Sanger sequencing of DNA from 
individual clones is the most straightforward approach to measure the editing 
efficiency of known genomic loci (whether on- or off-target sites), but this method is 
suitable only for small sample sizes, it is expensive and time-consuming. High 
throughput sequencing is a direct evolution of the latter approach that allows the 
accurate measurement of indel frequencies of hundreds of on- and off-target sites in 
parallel, reaching a sensitivity that ranges from 0,001% to 1%, depending on the 
sequencing platform used. Other methods employ mismatch-sensitive nucleases such 
as the T7 endonuclease I (T7E1) or the CEL-I enzyme (Surveyor endonuclease). These 
enzymes recognize and cleave DNA heteroduplexes obtained by re-hybridization of 
amplicons relative to the locus of interest deriving from a population of edited cells. 
Since each sequence will either be wild-type or contain a variety of different mutations, 
upon annealing heteroduplexes will be formed. Agarose gel separation of the digestion 
products allows the estimation of the indel frequency at the tested locus, with a 
sensitivity around 1% and the possibility to detect even rarer events under optimal 
conditions293. In general, T7E1 is preferred to perform this assay since it is reported to 
be more sensitive to indel mutations than the CEL-I nuclease, while both enzymes can 
detect point mutations309. An alternative approach that has been recently developed is 
based on the bioinformatics analysis of Sanger sequencing chromatograms of 
amplicons relative to a target locus obtained from a population of edited cells310. The 
Tracking of Indels by DEcomposition (TIDE) algorithm extracts and quantifies the 
information on all the indels present in a specific cell population from the capillary read 
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of the sequencing reaction, allowing a fast and cheap evaluation of the targeting 
efficiency with a sensitivity down to 1-2%.  
All the previously presented methods require the precise knowledge of the location of 
RGN-generated indels. This is not always the case, in particular if we consider that some 
off-target sites could differ from their corresponding on-target by several nucleotides. 
A ChIP-Seq approach using dCas9 has been used to profile the DNA binding sites of the 
endonuclease in mouse embryonic stem cells and HEK293T cells revealing binding to 
thousands of sites that shared strong similarities with the on-target sites in the PAM-
proximal region. However, when a selection of the identified sites was tested for 
cleavage with catalytically active SpCas9, the majority was found unmodified311,312, 
indicating that DNA binding and cleavage are often uncoupled. Similarly, in vitro 
approaches using randomized oligonucleotide libraries can be used to characterize 
sites bound135 or cleaved302 by Cas9, however, also in this case limitations connected 
to the uncoupling between binding and cleavage, to the absence of most of the 
screened sites from the reference genome and to the impossibility to examine off-
target sites that pair with the guide RNA through the formation of DNA- or RNA-bulges 
must be taken into consideration. 
Recently, different methods have been developed to characterize the genome-wide in 
vivo profile of Cas9 cleavage sites (for a summary see Fig. 14). The use of Integrase 
Defective Lentiviral Vectors (IDLVs) capture has been introduced to track the formation 
of DSBs induced by ZFNs 313 and Cas9304. IDLV capture is based on the NHEJ-mediated 
integration of IDLVs at sites targeted by the nuclease, tagging these transient events 
that can be later identified through linear amplification mediated-PCR (LAM-PCR) and 
adapter ligation. Since the efficiency of IDLV integration is much lower than the 
mutation frequency at each particular site, the sensitivity of this method may not allow 
to identify all the bona fide off-target sites, even though increased detection can be 
obtained by upscaling the IDLV input dosage304. The overall sensitivity of this assay has 
been calculated to fall between 0,5% and 1%304. A direct improvement of this technique 
is the Genome-wide, Unbiased Identification of DSBs Enabled by Sequencing (GUIDE-
Seq) where the integrase-defective lentiviral vector is substituted by a blunt-ended 
double-stranded phosphorothioate oligodeoxynucleotide that is captured at on- and 
off-target sites with higher efficiency to allow their isolation by PCR and high-
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throughput sequencing, with a sensitivity down to 0,1% (see Figs. 13 and 14)305. The 
majority of the sites identified for each tested sgRNAs was further validated by targeted 
deep-sequencing, demonstrating that the captured sequences corresponded to bona 
fide off-targets305. High-throughput genomic translocation sequencing (HTGTS) and its 
improved version LAM-HTGTS exploit the translocations induced by RGN-generated 
DSBs at on- and off-target sites to detect unspecific cleavage events. HTGTS uses the 
on-target site as a “bait” to catch “prey” sequences that correspond to off-target cuts, 
that are then amplified by LAM-PCR and sequenced314,315. Another approach captures 
DSBs induced after nuclease expression in fixed and permeabilized cells278,316. Breaks 
Labelling, Enrichment on Streptavidin and next-generation Sequencing (BLESS) relies 
on the ligation of biotinylated oligonucleotides to DSBs after cell fixation to allow the 
identification of captured loci after DNA fragmentation through deep sequencing. 
Since this method identifies only the DSBs present at the time of fixation, it is probable 
that many off-target sites are missed, resulting in poor sensitivity, with the additional 
risk of incurring in artefacts due to the fixation procedure itself. It must be noted that, 
since they identify in vivo generated DSBs, GUIDE-Seq, HTGTS and BLESS, will also 
capture naturally occurring nuclease-independent DSBs. These hits, together with PCR 
artefacts generated during library production, constitute false-positive signals that 
must be discarded during the analysis of the sequencing data by filtering for sequences 
that are homologous to the on-target site. It has been calculated that up to 95% of 
captured sites are discarded during these filtering steps293. A last method to profile off-
target activity relies on the in vitro digestion of cell-free genomic DNA. Digested genome 
sequencing (Digenome-seq) uses in vitro Cas9-digested genomic DNA to identify off-
target cleavages by whole genome sequencing317. Since digested fragments should 
present the same 5’-end given that no end-repair takes place, it is possible to look for 
straight alignments of sequence reads into the genome to identify cleaved sites, 
reaching a sensitivity below 0,1%, similar to the detection limit of targeted deep 
sequencing. Interestingly, the authors succeeded in validating by targeted deep-
sequencing only a small group of captured sites317. 
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Even though it is not well known to what extent Cas9 cleavages are limited by 
chromatin organization, some studies investigated the effects of nucleosomal 
positioning on editing efficiency318,319 so it is possible to speculate that the set of off-
target sites identified by in vivo capture will vary between cell lines, given the different 
chromatin organization and accessibility in each cell type. Digenome-seq, on the other 
hand, uses naked DNA as a substrate and for this reason is not sensitive to this kind of 
variations. In addition, GUIDE-Seq and HTGTS are dependent on NHEJ-mediated repair 
of nuclease-induced lesions that can introduce large insertions or deletions, making 
more difficult to pinpoint off-target sites293  
A comprehensive comparison between HTGTS, GUIDE-Seq, Digenome-seq and BLESS 
has not been published yet. Only a single sgRNA has been profiled with the first three 
Figure 14. Genome-wide detection of Cas9 off-target activity. Schematic representation of the different 
unbiased methods that have been developed to investigate the genome-wide profile of Cas9 off-target activity. 
Adapted from Yee, FEBS J., 2016. 
Introduction - Methods to reduce Cas9 off-target activity 
	 42 
methods showing that each technique was able to detect a different group of potential 
off-target sites indicating that no single approach is comprehensive. A small set of 
common loci, which had been previously validated, were identified by all three 
techniques317.  
Of note, these unbiased genome-wide detection technologies could be also applied 
with minimal modifications to the study of ZFNs and TALENs off-target activity.  
 
Methods to reduce Cas9 off-target activity 
	
The possibility that off-target genomic cuts may be generated during targeted 
nuclease-mediated genome editing represents the main technical limit for the 
development of therapeutic strategies to treat patients. Different approaches have 
been proposed to reduce unwanted mutations, demonstrating that a major need in 
the field is the generation of genome editing systems with no off-target activity. 
Interestingly, the application of unbiased methods to detect the genome-wide off-
targets of the newly discovered type V Cpf1 RGN revealed that it has an intrinsic higher 
fidelity than SpCas9. In particular, GUIDE-Seq analysis of 20 different crRNAs was 
unable to detect any genomic off-target for more than half of the tested sites320 and 
similar results were obtained using the Digenome-seq method321. These data suggest 
that, in perspective, the discovery and the application of new CRISPR nucleases with 
reduced off-target activity, such as Cpf1, could be a promising way to move towards an 
error-free genome editing toolbox.  
As a starting point, when using all classes of targeted nucleases, a careful choice of the 
target sequences may help reducing off-target cleavages. For RGNs, the design of guide 
RNAs that differ from any other site in the genome by several nucleotides (at least 2-3) 
is an important way to reduce unspecific cuts. Indeed, genome-wide studies have 
demonstrated that it is possible to find gRNAs with no detectable off-target activity305. 
A wide range of off-target prediction tools, many of them working on different 
genomes, has been developed by different labs and is available online: Cas-OFFinder 
from the Kim lab, CHOPCHOP from the Church lab, CRISPR Design from the Zhang lab, 
CRISPR design tool from the Broad Istitute, CRISPR/Cas9 gRNA finder from the Lin lab, 
CRISPRfinder from the Pourcel lab, ZiFiT Targeter from the Joung lab and E-CRISPR from 
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the Boutros lab. However, it must be noted that the set of predicted off-target sites on 
one hand is in general much bigger that the actual group of mistargeted loci identified 
by unbiased genome-wide methods, while on the other fails to include some of the 
sites that are captured by experimental methods305,317. In general, however, choosing 
gRNAs that minimize the number of identified off-target sites, especially the ones with 
few mismatches with target sequences, could increase the chances of reducing 
unwanted damages to the genome. 
A second approach is based on the modification of the sequence of guide RNAs. To 
optimize transcription from the RNA polymerase III U6 promoter in vivo and particularly 
for their in vitro production through T7 polymerase transcription, gRNA sequences 
should  start with a G nucleotide in the former case and a GG dinucleotide in the latter. 
The configuration of the spacer of guide RNA molecules can thus correspond to G+N20, 
G+N19 with the first G matching to the target sequence, or GG+N20, according to the 
different strategies. One study reported that the addition of two additional guanine 
nucleotides at the 5’-end of the sgRNA is able to abolish cleavage activity against the 
majority of validated off-target sites for four different guide RNAs, as measured by the 
T7E1 assay (Fig. 15a). Of note, a side-effect of this modification was a drop in on-target 
activity for two out of four tested sites298. The mechanism behind this effect is not yet 
clear and could involve guide RNA stability, concentration and structure. An additional 
explanation could be connected to an alteration of the interaction dynamics between 
the gRNA and the target DNA that leads to a decreased tolerance for mismatches, 
impairing non-specific cleavages. An additional strategy involves the truncation of 
sgRNAs (tru-gRNAs) in order to obtain a 17-18 nucleotide complementarity with the 
target sequence, instead of the classical 20 base-pairs (Fig. 15b)322. Tru-sgRNAs are 
more sensitive to mismatches if compared to standard guides, owing to their reduced 
binding energy with the target DNA, and are able to reduce off-target cleavage up to 
several thousand-folds, reaching undetectable levels for some selected sites, without 
appreciable modifications in the on-targeting activity305,322. However, it is still important 
to select tru-gRNAs with minimal homologies to the genome, since the reduction of the 
spacer length does not decrease the targeting range of the guide and possibly makes 
more difficult to avoid homologous sites containing only few mismatches with the 
intended target322. 
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The precise knowledge of the architecture of SpCas9 active sites allowed the 
generation of single mutants (D10A and H840A) capable of cleaving only one of the two 
target DNA strands, generating a nick. The use of paired nickases (Fig. 15c) has been 
shown to reduce off-target activity by different groups: instead of a single RGN, two 
Cas9 nucleases are directed to opposite DNA strands by two separate sgRNA, allowing 
the formation of two nicks that combined can generate indel mutations or can favour 
HDR using single stranded DNA oligonucleotides as templates298,323,324,325. Close 
proximity between the two nicks (between 4 and 100 bp) is important to obtain the 
desired effect, a concept similar to the one behind ZFNs nickases326, even though single 
Cas9 nickases can be used alone to stimulate HDR over NHEJ-mediated repair for safer 
gene modification approaches231. The fact that different groups have shown that 
monomeric Cas9 nickases are indeed able to induce DSB into the genome on their 
own224,322-324 or induce base substitution at their target site with high efficiency327 raises 
concern over the necessity of having two separate gRNAs to target a single locus: even 
though the unspecific cleavages relative to one guide could be reduced, other new off-
target sites could be generated by the second gRNA231. In addition, the experimental 
design involving Cas9 nickases is not straightforward as the identification of correctly 
spaced and efficient pairs of guides is not always trivial. The generation of 
programmable nickases has been reported also TALE-based platforms328. 
A strategy which is closely connected to the latter and further reduces off-target effects 
employs pairs of catalytically inactive Cas9 molecules fused through an appropriate 
linker to the FokI nuclease327,329, in direct parallel with the strategy adopted with ZFNs 
and TALENs (Fig. 15d). In this particular setting, dCas9 acts as a DNA binding domain 
to bring in close proximity two FokI monomers to promote cleavage. Two specifically-
oriented gRNAs separated by 15-25 bases are necessary to target each locus and the 
average reported cleavage efficiency is similar to that of paired Cas9 nickases, but 
lower that wild-type SpCas9. Importantly, since FokI monomers are not catalytically 
competent, mutagenic activity deriving form single dCas9-FokI fusions is avoided, 
contrary to previous approaches, while the strict topological requirements for gRNA 
positioning makes very unlikely the dimerization of FokI at off-target sites327,329. This 
approach has been combined with tru-gRNA to further minimize the undesirable 
mutagenic effects of dCas9-FokI monomers 330.  
Introduction - Methods to reduce Cas9 off-target activity 
	 45 
 
 
 
The generation of chimeras between SpCas9 and programmable DNA binding domains 
(pDBDs) has been proposed as an alternative way to increase targeting specificity331. In 
particular, the mutagenesis of key residues involved in PAM recognition to attenuate 
SpCas9 DNA binding affinity and broaden its PAM requirements allowed the 
generation of variants that were dependent on the attached pDBD for efficient 
function. The study suggests that the presence of the pDBD is able to increase the local 
concentration of Cas9, bypassing the kinetic barrier to R-loop formation that follows 
PAM recognition. Whole genome analyses to detect unspecific cleavages, combined 
with targeted deep sequencing of validated genomic off-targets, demonstrated that a 
Figure 15. Methods to reduce Cas9 off-target activity. Different methods have been developed to reduce the 
risk of Cas9 off-target activity: (a) the addition of a 5’-GG dinucleotide to sgRNAs or the use of truncated guides (tru-
gRNAs) (b); the employment of paired Cas9 nickases in which one of the two Cas9 catalytic domains has been 
inactivated (c); the generation of catalytically inactive dCas9 proteins dependent from a FokI nuclease domain for 
target cleavage (d). Adapted from Bortesi&Fischer, Biotechnol. Adv., 2015. 
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R1335K Cas9 variant fused to zinc finger proteins targeting a sequence proximal to the 
on-target locus was characterized by a significant increase in specificity331. 
Other important factors influencing the number of off-target modifications are the 
amount and persistence of SpCas9 expression in target cells: high concentrations of 
the nuclease are reported to increase off-site cleavage, whereas lowering the amount 
of SpCas9 increases specificity300-302. Transient SpCas9 expression is indeed sufficient 
to permanently modify the target genomic locus with decreased off-target activity as 
demonstrated by the enhanced specificity obtained through direct delivery of 
recombinant SpCas9-sgRNA complexes into target cells through electroporation332, 
lipofection333 or cell penetrating peptides334. Cas9-sgRNA RNP complexes induce 
mutations at the target site immediately after delivery and are quickly degraded by the 
cells afterwards, reducing the chances of off-target cleavages. In addition, it has been 
suggested that RNP delivery could be more efficient and less stressful in non-
transformed cell types such as primary cells and pluripotent stem cells with the 
additional advantage of removing completely the possibility of unwanted integration 
into the genome of foreign nucleic acids coding for components of the genome editing 
platform293. Of note, the delivery through RNPs to reduce unwanted cleavages has 
been applied to other CRISPR nucleases, such as Cpf1288,321. Similar approaches based 
on the delivery of mRNAs or proteins have been employed with ZFNs111,335,336 and 
TALENs151,337,338 in order to tightly control their intracellular levels and reduce off-target 
activity.    
Transcriptional regulation of Cas9 expression offers an additional layer to control the 
amount and the duration of nuclease persistence into the cell339,340. Alternatively, 
different studies have shown that it is possible to modulate Cas9 activity directly into 
the cell341. Following the publication of detailed structural data on Cas9 that allowed 
the identification of two relatively independent protein lobes, different strategies have 
been developed to regulate the forced assembly of split variants of Cas9 in cells by 
using small molecule-regulated inteins342, rapamycin-mediated interaction219,343 or 
exploiting photoinducible dimerizing protein domains344. The additional advantage of 
using split-Cas9 systems is the reduced size of its components that allows the 
packaging in low capacity viral vectors, such as AAV-based vectors345. An alternative 
photoactivatable Cas9 system relies on the incorporation of an unnatural photocaged 
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lysine into Cas9 to inactivate its catalytic sites. Irradiation with ultraviolet light allows 
the tight control of Cas9 activity, enabling the editing of the desired locus, albeit with 
lower efficiencies if compared to the wild-type protein346. An additional hurdle 
connected with this system is the necessity to modify cells to express an engineered 
tRNA sythetase to incorporate the desired unnatural amino acid into the nuclease.   
A different approach to address the specificity issue involves the modification of Cas9 
amino acid sequence to isolate variants with increased discriminative power. During a 
screen for SpCas9 variants with altered PAM specificities, the D1335E mutation has 
been isolated for its ability to confer increased selectivity for the canonical NGG PAM 
as well as for its increased targeting specificity as determined by testing against a panel 
of 25 previously validated off-target sites relative to three different sgRNAs and using 
genome-wide profiling with the GUIDE-seq method280. Recently, two groups have 
reported the structure-guided rational engineering of SpCas9 variants characterized by 
a lower propensity to cleave off-target sites347,348. The first study postulates that since 
Cas9 nuclease activity is stimulated by the separation of the two target DNA strands, 
by reducing its helicase activity target unwinding will be more dependent on gRNA:DNA 
pairing and mismatches between the sgRNA and the target sequence would be less 
tolerated, resulting in lower cleavage activity at off-target sites. The analysis of the 
crystal structure of SpCas9 in complex with guide RNA and the target DNA allowed the 
identification of a positively charged groove located between the HNH, RuvC and PI 
domains, likely to be involved in stabilizing the unwind target DNA. Variants containing 
alanine-substitutions of different charged residues within this groove were tested for 
their ability to reduce off-target activity. After a combinatorial screening two triple 
mutants (eSpCas9 v1.0 and v1.1 characterized by the substitutions K810A, R1003A, 
R1060A and K848A, R1003A, R1060A, respectively) were characterized by lower 
unspecific activity both at selected sites and according to unbiased genome-wide 
analyses348. A second study focused on the reduction of the unspecific interactions 
between Cas9 and the target DNA in order to eliminate the energy excess that 
characterizes the complex and allows the cleavage of mismatched sites, as previously 
suggested322. Structural studies have identified different residues making contacts with 
the phosphate backbone of the target DNA strands and their mutation into alanines 
allowed the generation of a high-fidelity Cas9 variant (SpCas9-HF1, containing the 
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mutations N497A, R661A, Q695A, Q926A) with significantly reduced genome-wide 
unspecific activity, even though some off-targets relative to repetitive and conventional 
loci were still cleaved by SpCas9-HF1. Alternative variants have been generated by 
introducing additional mutations to SpCas9-HF1 further decreasing off-targeting 
activity, even though a parallel decrease in on-target cleavage efficiency has been 
observed347. 
Altogether these efforts clearly demonstrate that a major need in the field is the 
generation of genome editing systems with no off-target activity. 
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Identification of high-fidelity Cas9 variants using a yeast-based 
screening 
 
Rationale of the experiments 
 
The number of biotechnological applications involving Cas9 has seen a huge increase 
in the past years, driven by the flexibility and the efficacy of this new genome editing 
tool. Cas9 has been applied with success in a variety of organisms, demonstrating the 
robustness that characterizes a game-changer technology. Importantly, both basic 
research and therapeutic-oriented studies, aside from efficacy, require specificity 
during editing procedures. However, several groups have shown that Cas9 cleavages 
into the genome are not always directed to the intended sites and unwanted lesions 
can be introduced in loci sharing different levels of similarity with the selected target. 
In addition, the prediction of such unwanted activity is difficult and often unreliable 
due to the absence of simple rules governing the phenomenon. Similarly, the 
assessment of the damages produced by nuclease expression is not always simple, 
and the results obtained with different techniques are often not in accordance. Hence, 
the development of methods to enhance the specificity of the CRISPR toolkit could 
represent a valid approach to eliminate the off-target issue at its roots. 
Different strategies have been proposed to reduce the introduction of unwanted 
genomic mutations such as the tight control of SpCas9 intracellular levels, the 
introduction of engineered gRNAs characterized by shorter protospacers with less 
complementarity to the target sequence (tru-gRNAs), the fusion of SpCas9 to specific 
DNA-binding domains to direct its binding or the exploitation of paired SpCas9 nickases 
and paired catalytically inactive dCas9 fused to the FokI endonuclease domain. 
However, none of these approaches completely solves the issue due to drawbacks 
intrinsic to each technology, such as an increasing complexity that often leads to loss 
of cleavage efficiency and ease of use, coupled to incomplete off-target control. 
Recently, two groups have reported the structure-guided rational engineering of 
SpCas9 variants characterized by a lower propensity to cleave off-target sites.  
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The fact that SpCas9 can cut sequences that are slightly different from the intended 
target indicates that binding and cleavage are only partially dependent on the sgRNA-
DNA pairing due to the extensive and unspecific contacts established between SpCas9 
and the DNA phosphate backbone that are appreciably lowering the stringency of the 
target recognition step, as suggested by previous studies. Differently to previous 
reports, we wanted to identify amino acid substitutions leading to an error-free SpCas9 
in an unbiased fashion through a random mutagenesis process in order to screen a 
wider mutational space, if compared to rational protein engineering approaches, and 
increase the likelihood of identifying better performing SpCas9 variants. 
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Methods 
 
Plasmids and constructs. The plasmid p415-GalL-Cas9-CYC1t, designed by George 
Church’s Lab, was used to express Cas9 in yeast (Addgene #43804)349. The Cas9 CDS 
was originally codon-optimized for applications in human cells224,349 and its expression 
is driven by the galactose inducible GalL promoter. The p415 plasmid contains the LEU2 
gene as a yeast selectable marker and the CEN6/ARSH4 centromeric sequence that 
allows its propagation at low copy number inside yeast cells. To allow the precise 
removal of the Rec1-II domain by restriction digest, synonymous mutations were 
generated through PCR to introduce two restriction sites, NcoI and NheI, upstream and 
downstream of the Rec1-II domain, respectively (for primers, see Appendix Table 1). 
The expression cassette for the sgRNA was obtained from the p426-SNR52p-
gRNA.CAN1.Y-SUP4t plasmid (Addgene #43803)349. In order to swap the original spacer 
sequence with the desired target, an assembly-PCR based strategy was adopted. The 
5’ portion of the sgRNA expression cassette was PCR-amplified using the T3 forward 
primer (annealing before the SNR52 promoter) and a reverse primer annealing 
immediately upstream of the spacer sequence and containing a 5’ overhang 
corresponding to the desired on-target sequence (see Appendix Table 1). The same 
was done for the 3’ fragment of the sgRNA, using the primer T7 reverse primer and a 
forward primer annealing immediately after the spacer sequence and containing a 5’ 
overhang antiparallel to one previously mentioned. The assembly reaction to obtain 
the gRNA cassette was prepared by mixing both PCR amplicons and performing a 
single step of denaturation, annealing and extension, followed by an exponential 
amplification using only the T3 and T7 external primers. The resulting fragment was 
then gel purified and blunt-end cloned into pRS316, a low copy number centromeric 
plasmid carrying an URA3 yeast selectable marker, pre-digested with SacII/XhoI and 
blunted, generating the pRS316-SNR52p-gRNA.ON-SUP4t plasmid. We decided to swap 
the sgRNA plasmid backbone since we discovered that p426-based plasmids, due to 
their dependence on a 2µ origin of replication that requires specific cellular machinery 
to be replicated, were not sufficiently stable in the yeast strains used during the 
experiments. If not correctly replicated, random segregation between progeny cells 
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during mitosis could dilute away the plasmids. On the other hand, pRS316 centromeric 
plasmids are always correctly segregated during mitosis.  
For the expression of SpCas9 in mammalian cells we employed a pX330-U6-
Chimeric_BB-CBh-hSpCas9 (Addgene # 42230)223 derived plasmid, where the sgRNA 
coding cassette has been removed, pX-Cas9. The SpCas9 coding sequence has been 
human codon optimized and its expression is regulated by a CBh promoter. In addition, 
two nuclear localization signals (NLS) have been added to the N- and C-terminus of 
SpCas9 to allow nuclear import and a triple FLAG is positioned at the N-terminal end 
of the protein to facilitate detection. The plasmids coding for improved Cas9 variants 
were obtained by sequential site directed mutagenesis starting from the pX-Cas9 
plasmid. For the expression of previously published enhanced SpCas9 mutants the 
VP12 (Addgene #72247)347 and the eSpCas9(1.1)  (Addgene #71814)348 plasmids were 
used. Desired spacer sequences were cloned as annealed oligonucleotides with 
appropriate overhangs into a double BbsI site located upstream the guide RNA 
constant portion in a pUC19 plasmid containing a U6 promoter-driven expression 
cassette. The same pUC19 plasmid containing an optimized guide RNA constant 
region268 was used for the preparation of optimized sgRNAs.  For the experiments 
involving lentiviral vectors, the lentiCRISPRv1 transfer vector (Addgene #49535)223 was 
employed together with the pCMV-delta8.91 packaging vector and pMD2.G, coding for 
the vesicular stomatitis virus glycoprotein (VSVG), to produce viral particles. The 
lentiCRISPRv1 transfer vector contains an expression cassette for a codon-humanized 
version of a N-terminally FLAG-tagged SpCas9 fused through a 2A-peptide to the 
puromycin coding sequence to allow selection of transduced cells.  A U6-driven 
expression cassette transcribes the sgRNA. Annealed oligos corresponding to the 
desired spacers were cloned into the guide RNA using a double BsmBI site. The 
lentiCRISPRv1-based vectors coding for enhanced SpCas9 variants were generated by 
swapping part of the SpCas9 coding sequence with a PCR fragment corresponding to 
the region of the CDS containing the mutations (for primers, see Appendix Table 1). A 
complete list of the guide RNA target sites is available in the Appendix. 
Yeast culture. The yLFM-ICORE yeast strain350,351 was used to generate the reporter 
yeast strains used in this study. Synthetic minimal media (SD) were employed in all 
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yeast experiments (yeast nitrogen base without amino acids 6.7 g/L, L-isoleucine 600 
mg/L, L-valine 150 mg/L, L-adenine 200 mg/L, L-arginine 20 mg/L, L-histidine 10 mg/L, 
L-leucine 100 mg/L, L-lysine 90 mg/L, L-methionine 20 mg/L, L-phenylalanine 50 mg/L, 
L-threonine 200 g/L, L-tryptophan 20 mg/L, L-uracil 20 mg/L, L-glutamic acid 100 mg/L, 
L-aspartic acid 200 g/L, L-serine 400 mg/L, D-(+)-glucose 20 g/L). Single amino acids 
were omitted according to the experimental setup, when selective medium was 
required. For the induction of Cas9 expression, 20 g/L D-(+)-galactose and 10 g/L D-(+)-
raffinose were used instead of dextrose. Specific medium for ADE2 mutants colour 
screening was prepared using low adenine concentrations (5 mg/L). When non-
selective medium was required, YPDA rich medium was employed (yeast extract 10 g/L, 
peptone 20 g/L, D-(+)-Glucose 20 g/L, L-adenine 200 mg/L). All solutions were prepared 
using ddH2O, filter-sterilized and stored at 4°C. Solid media were prepared by autoclave 
sterilization, adding 20 g/L of agar to the solution. All chemicals to prepare yeast media 
were obtained from Sigma-Aldrich.  
Yeast transformation. The day prior to transformation, approximately 1 mm3 of the 
desired yeast strain was inoculated in 5 mL of rich medium or selective synthetic 
medium and grew overnight at 30°C while shaking at 200 rpm. The next day 3-5 mL of 
the culture were inoculated in a total volume of 30 mL of the same medium and grew 
at 30°C shaking at 200 rpm for further 2-4 hours. Cells were then harvested by 
centrifugation at 2000xg for 2’, washed in 30mL of ddH2O, centrifuged again at 2000xg 
for 2’ and resuspended in 10 mL of LiAc/TE 1X (lithium acetate 0,1 M and Tris 10 mM 
EDTA 1 mM, pH 7.5). The solution was centrifuged again at 2000xg for 2’ and 
resuspended in a proper volume of LiAc/TE 1X (100 mg of yeast pellet in 500 μL). The 
transformation mix contained 500 ng of plasmid DNA, 5 μl of carrier salmon sperm 
DNA (approx. 1μg) previously sheared by sonication and boiled at 100°C for 10’, 50 μL 
of resuspended yeast culture and 300 μL of polyethylene glycol (PEG) 500 g/L with a 
molecular weight of ~36,500 (Sigma-Aldrich) diluted in LiAc/TE 1X. After vortexing, the 
transformation mix was placed for 30’ at 30°C and then heat-shocked using a dry bath 
for 30’ at 42°C. Cells were then centrifuged at 3000xg for 3’, resuspended in 5 mL of the 
appropriate SD selective medium or directly plated on selective SD agarose plates and 
incubated at 30°C. For spontaneous reversion frequency evaluation, after 
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transformation with p415-GalL-Cas9-CYC1t cells were grown in selective medium for 
24 hours. The concentration of cells was then evaluated by measuring the OD600 and 
1000 cells were plated on selective plates depleted of leucine (SDl) or 106 cells were 
spread on plates further depleted of adenine (SDla) of tryptophan (SDlt), to evaluate 
the number of revertants for each locus. 
Yeast colony PCR. Colony PCRs were performed by resuspending approximately 1 
mm3 of yeast colony in 49μL of ddH2O. 1 μL of lyticase (10000 U/mL, Sigma-Aldrich) was 
added to digest the cell wall and the suspension was then incubated at 30°C for 30’. 
The cells were pelleted, the supernatant was removed and the dry pellet was boiled for 
10’ at 100°C. The pellet was then resuspended in 50 μL of ddH2O and 5 μL were used 
as a template in the PCR reaction, using the Phusion High-Fidelity DNA Polymerase 
(Thermo Scientific).  
Recovery of plasmid DNA from yeast. In order to isolate the mutant Cas9 plasmids 
from yeast, single colonies were grown overnight at 30°C shaking at 200 rpm in 5 mL 
of SD medium without leucine (SDl), to select for the presence of the p415-GalL-Cas9-
CYC1t plasmid, while relaxing the selection on the guide RNA-expressing plasmid to 
induce its dilution and loss. The next day cells were harvested by centrifugation for 5’ 
at 5000xg and resuspended in 250 μl of buffer A1 (Nucleospin Plasmid, Macherey-
Nagel) containing 0.1mg/ml of RNase A. Cells were then mechanically lysed by adding 
100 μL of acid-washed glass beads (Sigma-Aldrich) and by vortexing continuously for 
5’. Plasmid DNA was then recovered from the supernatant using standard miniprep 
silica columns, following the manufacturer’s instructions. DNA was eluted in 30 μL of 
10 mM TrisHCl pH 8.5. The eluted DNA was treated with NcoI and NheI that can digest 
only the sgRNA-expressing vector, in order to avoid contaminations since these 
plasmids are also selectable through an ampicillin resistance. After digestion, 10 μL of 
the mix were transformed using chemically competent E. coli. The plasmids recovered 
were then digested to double check their identity and then Sanger sequenced to 
identify the mutations introduced in the Rec1-II domain.  
Assembly of modified TRP1 and ADE2 genomic cassettes. The DNA cassettes used 
to engineer the ADE2 (ADE2-Off1, ADE2-Off2, ADE2-Off3 and ADE2-Off4) and TRP1 
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(TRP1-On) genomic loci were built using a similar strategy. Two different colony PCRs 
were performed to amplify the two halves of each wild-type locus separately. The first 
one employed a forward primer upstream of the gene CDS and a reverse overhang 
primer containing the on- or off1-4-target sequence followed by the KpnI or BamHI 
restriction sites, respectively (see Appendix Table 2). All reverse primers contained a 
stop codon before the on/off-target sequence to ensure truncation of the protein. The 
second half of the cassette was assembled using a reverse primer which anneals 
downstream the ADE2 and TRP1 coding sequences and a forward primer which 
anneals 100 bp before the reverse primer used to build the first half of the cassette. In 
this way, when the two parts were joined together, the final construct contained a 
100bp long homology region upstream and downstream of the on-/off-target 
sequences. In addition, these forward primers contained the same restriction site 
present in the reverse primer of the corresponding first half of the cassette. The TRP1 
and ADE2 fragments were assembled by ligating the two halves digested with KpnI or 
BamHI (New England BioLabs), accordingly. The products were separated on an 
agarose gel to remove homoligation-derived fragments. The final cassette was 
enriched by PCR using the most external primers and directly transformed in yeast.  
Generation of yeast reporter strains.The delitto perfetto approach enables the 
genetic targeting of specific loci with the practicality of a general selection system 
through the exploitation of the homology directed repair mechanism that is 
particularly efficient in yeast352. The first step consists in the insertion of a COunter 
selectable REporter I-SceI cassette (CORE-I-SceI) in the specific locus of interest. The 
cassette contains a recognition site for I- SceI, as well as the coding sequence for the 
endonuclease itself under the control of the galactose-inducible GAL1 promoter, the 
resistance gene kanMX4 (G418) and the counterselectable marker URA3 gene from 
Kluyveromyces lactis (KlURA3). The CORE-I-SceI cassette was amplified with primers 
containing specific overhangs for the ADE2 and TRP1 loci (see Appendix Table 2). Each 
locus was edited sequentially, following the same procedure, starting from the ADE2 
locus. 500 ng of locus-specific CORE-I-SceI cassette was transformed in yeast and cells 
were plated on YPDA plates and incubated at 30°C overnight. The next day, colonies 
were replica-plated on YPDA media containing 200 μg/mL of G418 (Invivogen). 
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Resistant colonies were screened for successful cassette insertion into the desired 
locus by colony PCR using primers annealing to the genomic sequences flanking the 
integration site and to the cassette. The CORE-I-SceI cassette integrated within the 
targeted locus was then swapped with the final edited sequence (TRP1-On, ADE2-Off1, 
ADE2-Off2, ADE2-Off3 and ADE2-Off4), generating a total of four different yeast strains 
characterized by the same on-target sequence and four different off-targets. The 
appropriate intermediate yeast strain containing the target CORE-I-SceI cassette was 
inoculated overnight in 5mL of YPDA. The next day, before transformation, the 
inoculum was resuspended in 30mL of synthetic medium containing galactose and 
raffinose instead of dextrose (SRG). This step is essential to induce the transcription of 
the I-SceI endonuclease which cuts its target site located within the CORE cassette. 
DSBs increase the normal frequency of HR-driven repair events, favouring cassette-
swap with the desired new sequence. After 4 hours incubation in SRG medium, yeast 
was transformed with 500ng of the HR template containing the desired sequence 
following the standard transformation protocol. Transformants were then plated on 
SD containing 60 mg/L of uracil and 1 g/l of 5-fluoroorotic acid (5-FOA) (Toronto 
Research Chemicals). 5-FOA, in the presence of orotidine 5'-phosphate decarboxylase 
(encoded by KlURA3), is converted in fluorouracil which is a potent thymidylate 
synthase inhibitor. 5-FOA-resistan colonies were then replica-plated on YPDA and YPDA 
supplemented with G418, to further select for the loss of the CORE cassette. By 
comparing the two replica plates it is possible to select G418-sensitive FOA-resistant 
colonies that correspond to positive clones. Colony PCRs, performed using genomic 
primers that anneal upstream and downstream of the entire genomic locus, were 
analysed by Sanger sequencing to confirm the sequence of the edited locus. The newly 
generated yeast strains containing the modified TRP1 and ADE2 loci were called 
yACMO-off1, yACMO-off2, yACMO-off3 and yACMO-off4, characterized by a selected 
on-target sequence in the TRP1 locus and four different off-target sequences in the 
ADE2 locus, each containing a single mismatch with respect to the on-target sequence 
in a position that is more PAM-proximal for off1 and more PAM-distal for off4 (see 
Appendix Table 3).  
Yeast screening for SpCas9 mutants. The mutants’ library was generated by error 
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prone PCR (epPCR) using the GeneMorph II kit (Agilent). Following the manufacturer's 
instructions, the initial amount of template DNA (p415-GalL-Cas9-CYC1t) and the 
number of cycles were set to obtain an average of 5 mutations per kilobase. 50 bp-long 
primers were selected to anneal 150 bp upstream and downstream of the REC1-II 
coding sequence (see Appendix Table 4). The PCR library was directly assembled in vivo 
by co-transformation of the mutagenized amplicon pool with the p415-GalL-Cas9-
CYC1t plasmid, previously digested with NcoI and NheI to remove the REC1-II domain, 
with an insert/plasmid ratio of 3:1. The two 150 bp homology regions at both ends of 
the amplicons were used by yeast to repair the digested plasmid by homologous 
recombination, thus incorporating the mutagenized portion. Clones containing 
mutations in these 150bp flanking regions were probably negatively selected during 
this in vivo assembly step due to loss of complete homology. Nonetheless, these 
mutations lied outside our region of interest (the REC1-II domain). The mutagenic 
library was screened concomitantly to its assembly by co-transformation of the 
fragments in the yACMO-off4 yeast strain stably expressing a sgRNA matching the on-
target sequence located in the TRP1 locus. After transformation, the culture was grown 
overnight in SD medium lacking uracil and leucine (SDlu, for selecting cells carrying 
both the sgRNA- and Cas9-expressing plasmids) to allow recovery and correct 
recombination. The next day, Cas9 expression was induced by growing the culture in 
galactose-containing medium (SRGlu) for 5 hours prior to plating on several selective 
plates lacking tryptophan and containing low concentrations of adenine (SDluta5), to 
discriminate colonies according to the editing status of the TRP1 and ADE2 loci. After 
48 hours, TRP1+/ADE2- (red) colonies were streaked on selective plate with low adenine 
and no tryptophan containing galactose and raffinose (SRGluta5) to keep Cas9 
expression constitutively induced and force the generation of off-target clevages. After 
further 48 hours of incubation, Cas9-expressing plasmids were extracted from the red-
most streaks, corresponding to colonies in which Cas9 cleaved only the on-target site, 
and the mutations were characterized by Sanger sequencing. 
Yeast colony colour analysis and quantification. All plates images were acquired 
with a Canon EOS 1100D (1/60, f/9.0 and ISO 800) and analysed with OpenCFU353. For 
all images an inverted threshold (value = 2) was used with a radius between 8 and 50 
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pixels. Discrimination between white and red colonies was obtained by computing the 
average signal in the RGB channels and setting a manual threshold that accurately 
discriminates between red and white colonies in each experiment.  
Mammalian cells and transfections. 293T/17 cells were obtained from the American 
Type Culture Collection (ATCC) and were cultured in Dulbecco's modified Eagle's 
medium (DMEM; Life Technologies) supplemented with 10% fetal calf serum (FCS; Life 
Technologies) and antibiotics (PenStrep, Life Technologies). 293multiGFP cells were 
generated by stable transfection with pEGFP-IRES-Puromycin and selected with 1 μg/ml 
of puromycin. 293blastEGFP were obtained by low MOI infection of HEK293T cells with 
the EGFP-expressing lentiviral vector pAIB-GFP followed by clonal selection with 5 
μg/ml of blasticidin. For transfection, 1×105  293multiGFP or 293T cells/well were 
seeded in 24-well plates and transfected the next day using TransIT-LT1 (Mirus Bio) 
according to manufacturer’s protocol with 400-750 ng of Cas9-expressing plasmids and 
200-250 ng of sgRNA-expressing plasmids. For transient transfection experiments 
involving EGFP expression, 100 ng of the pEGFP-N1 plasmid were used. To determine 
the level of EGFP downregulation by Cas9 after transfection into 293multiGFP, cells 
were collected 7 days post-transfection and were analysed by flow cytometry using a 
FACSCanto (BD Biosciences). 
Lentiviral vector production and transductions. Lentiviral particles were produced 
by seeding 4x106 293T cells into a 10 cm dish. The day after, the plates were transfected 
with 10 μg of each lentiCRISPR-based223 transfer vector together with 6.5 μg of pCMV-
deltaR8.91 packaging vector and 3.5 μg of pMD2.G using the polyethylenimine (PEI) 
method. After an overnight incubation, the medium was replaced with fresh complete 
DMEM and 48 hours later the supernatant containing the viral particles was collected, 
spun down at 500xg for 5 minutes and filtered through a 0.45 μm PES filter. 
Quantification of the vector titers was performed using the SG-PERT method354. Vectors 
stocks were conserved at -80°C for future use. 
For transductions, 105 293blastGFP cells were seeded in a 24-well plate and the next 
day were transduced with 0,4 Reverse Transcriptase Units (RTU)/well of each vector by 
centrifuging at 1600xg 16°C for 2 hours. After an overnight incubation, the viral 
supernatant was removed and the cells were kept in culture for a total of 48 hours 
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before adding 0,5 μg/ml puromycin selection that was maintained throughout the 
experiment. To determine the level of EGFP downregulation by Cas9 after infection, 
293blastGFP cells were collected at the indicated time-points after transduction and 
were analysed by flow cytometry using a FACSCanto (BD Biosciences). 
Detection of Cas9-induced genomic mutations. Genomic DNA was obtained at 7 
days post-transfection, using the QuickExtract DNA extraction solution (Epicentre). PCR 
reactions to amplify genomic loci were performed using the Phusion High-Fidelity DNA 
polymerase (Thermo Fisher). Samples were amplified using the oligos listed in 
Appendix Table 10. Purified PCR products were analysed by sequencing and applying 
the TIDE tool310. To quantify the CCR2-CCR5 chromosomal deletion, a semi-quantitative 
PCR approach was set-up using primers flanking the CCR5 on-target site and the CCR2 
off-target locus (Appendix Table 10). The number of PCR cycles was modulated in order 
not to reach the amplification plateau. Quantifications were obtained by performing 
densitometric analyses using the ImageJ software and exploiting the FANCF genomic 
locus as an internal normalizer.  
Western blots. Cells were lysed in NEHN buffer (20 mM HEPES pH 7.5, 300 mM NaCl, 
0.5% NP40, NaCl, 1 mM EDTA, 20% glycerol supplemented with 1% of protease inhibitor 
cocktail (Pierce)). Cell extracts were separated by SDS-PAGE using the PageRuler Plus 
Protein Standards as the standard molecular mass markers (Thermo Fisher Scientific). 
After electrophoresis, samples were transferred to 0.22 μm PVDF membranes (GE 
Healthcare). The membranes were incubated with mouse anti-FLAG (Sigma) for 
detecting SpCas9 and the different high-fidelity variants, with mouse anti-α-tubulin 
(Sigma) for a loading control and with the appropriate HRP conjugated goat anti-mouse 
(KPL) secondary antibodies for ECL detection. Images were acquired using the UVItec 
Alliance detection system. 
Targeted deep-sequencing. Selected off-target sites280 for the VEGFA3 and EMX1 
genomic loci, together with their relative on-target, were amplified using the Phusion 
high-fidelity polymerase (Thermo Scientific) or the EuroTaq polymerase (Euroclone) 
from 293T genomic DNA extracted 7 days after transfection with wild-type SpCas9 or 
evoCas9 together with sgRNAs targeting the EMX1 and the VEGFA3 loci, or a pUC empty 
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vector. Off-target amplicons were pooled in near-equimolar concentrations before 
purification and indexing. Libraries were indexed by PCR using Nextera indexes 
(Illumina), quantified with the Qubit dsDNA High Sensitivity Assay kit (Invitrogen), 
pooled according to the number of targets and sequenced on an Illumina Miseq system 
using an Illumina Miseq Reagent kit V3 - 150 cycles (150bp single read). The complete 
primer list used to generate the amplicons is reported in Appendix Table 6.  
A reference genome was built using Picard (http://broadinstitute.github.io/picard) and 
samtools355 from DNA sequences of the considered on-/off-target regions. Raw 
sequencing data (FASTQ files) were mapped against the created reference genome 
using BWA-MEM356 with standard parameters and resulting alignment files were sorted 
using samtools. Only reads with mapping quality above or equal to 30 were retained. 
Presence of indels in each read for each considered region was determined by 
searching indels of size 1bp directly adjacent to the predicted cleavage site or indels of 
size >=2bp overlapping flanking regions of size 5bp around the predicted cleavage site.  
GUIDE-seq. We used GUIDE-seq to determine the genome-wide spectrum of the off-
target sites relative to the VEGFA site 2 repetitive locus. 2x105 293T cells were 
transfected with 750 ng of a Cas9 expressing plasmid, together with 250 ng of sgRNA-
coding plasmid or an empty pUC19 plasmid, 10 pmol of the bait dsODN containing 
phosphorothioate bonds at both ends (designed according to the original GUIDE-seq 
protocol305) and 50 ng of a pEGFP-IRES-Puro plasmid, expressing both EGFP and the 
puromycin resistance gene. The day after transfection cells were detached and 
selected with 2 µg/ml of puromycin for 48 hours to eliminate non transfected cells. 
Cells were then collected and genomic DNA was extracted using the DNeasy Blood and 
Tissue kit (Qiagen) following the manufacturer’s instructions and sheared to an average 
length of 500bp with the Bioruptor Pico sonication device (Diagenode). Library 
preparations were performed with the original adapters and primers according to 
previous work305. Libraries were quantified with the Qubit dsDNA High Sensitivity Assay 
kit (Invitrogen) and sequenced with the MiSeq sequencing system (Illumina) using an 
Illumina Miseq Reagent kit V2 - 300 cycles (2x150bp paired-end). 
Raw sequencing data (FASTQ files) were analyzed using the GUIDE-seq computational 
pipeline357. After demultiplexing, putative PCR duplicates were consolidated into single 
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reads. Consolidated reads were mapped to the human reference genome GrCh37 
using BWA-MEM356; reads with mapping quality lower than 50 were filtered out. Upon 
the identification of the genomic regions integrating double-stranded 
oligodeoxynucleotide (dsODNs) in aligned data, off-target sites were retained if at most 
eight mismatches against the target were present and if absent in the background 
controls. Visualization of aligned off-target sites is available as a color-coded sequence 
grid. 
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Results 
 
Design of a reporter yeast strain for the detection of Cas9 activity 
We decided to use Saccaromyces cerevisiae as an experimental model to develop a 
directed evolution screen to isolate high-specificity SpCas9 variants. The advantage of 
using a yeast-based assay platform resides on one side in the similarities that yeast 
shares with bacteria, such as a fast doubling rate, the possibility to isolate single clones 
with ease and the availability of fast and reliable transformation protocols; on the other 
hand, yeast DNA organization and metabolism is similar to the one of higher eukaryotic 
cells and is often used as a model to study nuclear biology, while this aspect is 
completely missed in prokaryotes. This is particularly relevant in consideration of the 
prospective application of the identified variants in human cells, since it makes more 
likely that the observed behaviour will be conserved also in mammalian systems. We 
first designed a strategy to generate auxotrophic reporter yeast strains for 
simultaneously measuring Cas9 on- versus off-target activity by modifying the TRP1 
(chromosome IV) and ADE2 (chromosome XV) genomic loci. By using the delitto perfetto 
approach, we substituted the wild-type coding sequences of the two genes with 
reporter cassettes in which each CDS was split in two halves by the insertion of a 
specific target sequence that was matched by a guide RNA of interest (on-target) in the 
case of TRP1 locus, while different sequences containing a single mismatch each in 
positions spanning the whole length of the target, from more PAM-proximal to more 
PAM-distal nucleotides, were located in the ADE2 locus (ADE2off1-off4, see Appendix 
Table 3). A 100 bp duplication was added on both sides of the target sequence and a 
stop codon was positioned immediately upstream, in between the two homology 
regions, to ensure premature interruption of translation (Fig. 16a). We designed the 
on- and off-target sequences on the EGFP coding sequence, a widely used and 
standardized experimental model that allowed us to validate the functionality of the 
chosen target sites in a reciprocal experiment performed in mammalian cells by using 
a fluorescence-disruption assay. Co-transfection of 293T cells with pEGFP-N1 together 
with SpCas9 and the sgRNA-on induced a robust downregulation of EGFP fluorescence. 
When a sgRNA matching the off1 sequence (sgRNA-off1) was used instead, we still 
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observed a clear drop in EGFP intracellular levels (Fig. 16b). Notably, the mutation 
characterizing the sgRNA-off1 is located immediately before the PAM (+1 nucleotide), 
inside the seed sequence, further demonstrating that the general rule of perfect 
complementarity between the sgRNA and its target in the first 8-12 PAM-proximal 
nucleotides is not always respected.  
 
 
 
We thus generated four different reporter yeast strains that were named yACMO-
off1/off4, depending on the off-target sequence characterizing the ADE2 locus. The 
Figure 16. Design of an in vivo yeast assay to quantify SpCas9 on- and off-target activity. (a) Generation of 
yeast reporter strains. The TRP1 and ADE2 loci were modified by the insertion of a reporter cassette containing an 
on-target site (TRP1) or different off-target sequences (ADE2, sequences are reported in the orange box). The 
presence of homology regions (HR) on both sides of the target allows efficient repair by single strand annealing 
upon cleavage by Cas9. Using appropriate selective plates, it is possible to follow the editing status of the two loci. 
The survival of a colony will indicate TRP1 on-target cleavage, while the colour of the colony allows to assess the 
cleavage of the ADE2 off-target. (b) SpCas9 has off-target activity. Fluorescence microscope (bottom) and relative 
bright fields (top) images of 293T cells transfected with EGFP and SpCas9 together with a control sgRNA, a guide 
perfectly matching EGFP CDS (sgRNA-on) or an off-target sgRNA containing a single mismatch immediately before 
the PAM sequence (sgRNA-off1). The on and off1 spacers are identical to the ones engineered into the reporter 
yeast strains. (c) Assay readout. After transformation with SpCas9 and sgRNA coding plasmids cells are plated on 
selective plates to measure the total number of transformants and on reporter plates with no tryptophan and low 
adenine to screen for Cas9 editing activity. By comparing the total number of colonies on the two plates the on-
target efficiency can be estimated, while by calculating the percentage of white and red colonies on reporter plates 
a measure of the specificity can be obtained. 
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knockout of the TRP1 and ADE2 genes by reporter cassette insertion produces defects 
in the tryptophan and adenine metabolic pathways, suppressing growth in the absence 
of tryptophan, and leading to the accumulation in the cell vacuole of an intermediate 
product of adenine biosynthesis generated by the block at the level of the ADE2 gene 
product when cells are grown at low concentrations of adenine, thus conferring a 
characteristic red pigmentation to the colonies on agar plates. Following the formation 
of double strand breaks induced by Cas9, each locus can be efficiently repaired by 
yeast cells using the single strand annealing repair pathway thanks to the presence of 
the two flanking homology regions, obtaining a reversion to prototrophy for the two 
nutrients. Thus, a screening based on auxotrophies selection can be used to evaluate 
Cas9 cleavage activity at the two genomic loci, measuring simultaneously both on-
targeting and off-targeting events. The successful editing at each of the two loci can be 
visualized using appropriate reporter plates, which are depleted of tryptophan and 
contain only low concentrations of adenine (SDluta5, Fig. 16c). After transformation 
with plasmids for the expression of SpCas9 and the guide RNA, cells are plated in equal 
numbers on appropriate selective media, to measure the total number of 
transformants, and on SDluta5 plates, to discriminate colonies according to the editing 
status of the off-target locus. The assay readout consists in a two-step process: the first 
is to compare the number of colonies obtained on SDluta5 reporter plates and on plates 
selecting only for the total number of transformants (SDlu plates), lacking uracil and 
leucine for the auxotrophic selection of the uptake of the sgRNA- and Cas9-expressing 
plasmids. This allows the evaluation of the on-target cleavage efficiency. The second 
step consists in counting the number of red colonies (TRP1+/ADE2-), corresponding to 
on-target cleavages, and white colonies (TRP1+/ADE2+), in which also the off-target 
locus has been edited, on the reporter plates for the evaluation of the on- versus off-
target activity (Fig. 16c).  
Before proceeding, we evaluated the rate of spontaneous reversion for the ADE2 and 
TRP1 loci of the different yACMO strains that, if too high, could have introduced a 
confounding variable in the readout of our assay. Reversion of the TRP1 locus can in 
fact lead to the isolation of false positive clones, while spontaneous recombination of 
the ADE2 gene can generate false negative colonies. To approximate the experimental 
conditions used during our assay, we transformed each of the four strains separately 
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with a plasmid encoding for SpCas9; after 24 hours incubation in selective medium, 
cells were spread on selective plates to measure the total number of transformants 
and a 1000-fold more cells were plated on selective plates depleted of tryptophan or 
adenine, to count the number of revertants for each locus. By comparing the number 
of colonies obtained in the different selective conditions it was possible to estimate a 
mean reversion frequency of approximately 1-1,5x10-5 for both the TRP1 and ADE2 loci.  
 
Validation of the yACMO reporter strain 
We validated the functionality of the reporter assay by testing our four reporter strains 
(yACMO-off1/off4) in combination with wild-type SpCas9. To maximize the overall 
efficiency, prior to the challenge with SpCas9, each of the strains was stably 
transformed with a plasmid coding for the sgRNA-on, perfectly matching the on-target 
sequence in the TRP1 locus. The four strains were then transformed with a plasmid for 
the expression of wild-type SpCas9 controlled by a galactose-inducible promoter that, 
after a 4 hour recovery incubation, was induced overnight in galactose-containing 
Figure 17. Validation of the yACMO strain using wild-type SpCas9. 
(a) Representative plates obtained after transformation of wt SpCas9 
into the yACMO-off1/off4 reporter strains stably expressing an sgRNA 
matching the on-target sequence in the TRP1 locus. Plates on the left 
select for the total transformants, while images on the right correspond 
to reporter plates. Cas9 expression was induced overnight prior to 
plating. (b) Quantification of the mean percentage of red (on-target) 
and white (off-target) colonies obtained on reporter plates after 
transformation with wild-type SpCas9. Error bars represent s.e.m. for 
n=3. 
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media prior to plating on SDlu and reporter SDluta5 plates. In these experimental 
conditions we consistently reached 100% on-target cleavage (compare left and right 
panels in Fig. 17a), while the off-target activity, measured as the percentage of white 
colonies (TRP1+/ADE2+) on the reporter plates, increased in accordance with the 
distance of the mismatched base from the PAM sequence, as expected. For the last two 
off-targets (off3 and off4), SpCas9 was completely unable to discriminate between the 
matching and the two mismatched sequences (Figs. 17a and 17b). Considering these 
results, we decided to screen for SpCas9 variants using the yACMO-off4 strain, 
containing the strongest off-target sequence, in order to obtain mutants with a marked 
increase in fidelity.  
 
Yeast-based screening for high-specificity SpCas9 variants 
Starting from the assumption that SpCas9 establishes unspecific interactions with the 
target DNA backbone and that these bonds participate in the stabilization of 
mismatched gRNA:DNA heteroduplexes, allowing the cleavage of off-target sites, we 
decided to randomly mutagenize specific Cas9 domains to identify amino acids 
Figure 18. Selection of a target domain for random library generation. (a) Schematics of SpCas9 domains. The 
Rec1-II domain is part of the alpha helical recognition lobe. BH: bridge helix. (b) Hybrid surface/ribbon structure 
(PDB ID 4UN3) of SpCas9 in complex with a sgRNA and the target DNA. The Rec1-II domain is highlighted in blue, 
while the rest of the structure is coloured in grey.  
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substitutions that reduce such unspecific interactions. Differently from published 
studies347,348, we believed that an unbiased approach could have led to the isolation of 
non-trivial amino acid substitution increasing the likelihood to obtain a SpCas9 variant 
with higher fidelity. To find a suitable target for random mutagenesis, we analysed 
available structural data to identify which domain could be more involved in the 
formation of such kind of interactions. We excluded from our analysis the nuclease 
lobe of Cas9, since it contains the two catalytic sites that must be preserved to maintain 
cleavage activity. The recognition lobe, containing the Rec1, Rec2 and the bridge helix 
domains, has been reported to make the several contacts with the gRNA:DNA duplex. 
In addition, the recognition lobe as a whole is one of the least conserved regions across 
all the three Cas9 families belonging to type II CRISPR systems, indicating a high degree 
of sequence plasticity. The bridge helix, on the contrary, is one of the most conserved 
regions among different Cas9 orthologues, suggesting that its sequence is particularly 
important for nuclease function.  The Rec1-Rec2 region spans more than 600 amino 
acids, a dimension not suitable for random mutagenesis, but the majority of interacting 
residues are located in the last portion of the Rec1-II domain, approximately between 
residues 400 and 700 (Fig. 18).  
A library of REC1-II variants, generated by error-prone PCR to contain approximately 4-
5 mutations per molecule, was directly assembled in the yACMO-off4 reporter yeast 
strain exploiting homologous recombination between the mutagenized REC1-II 
fragments, containing appropriate homology arms, and a plasmid expressing a 
galactose-inducible SpCas9 in which the same region had been previously removed. 
After co-transformation and an overnight recovery incubation in SDlu medium to allow 
the repair of Cas9-encoding plasmids by homologous recombination and the selection 
of transformed cells, cultures were induced for 5 hours with galactose to allow SpCas9 
expression and cells were plated on several SDluta5 reporter plates. We shortened the 
induction time, with respect to previous experiments, to obtain variants that 
maintained high on-target activity since we observed that wild-type SpCas9 can fully 
cleave the on-target sequence in this restricted time span (data not shown). Two days 
later we obtained multiple colonies and streaked the red ones on new reporter plates 
containing galactose instead of dextrose to reactivate SpCas9 expression and to keep 
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it constantly switched on to exacerbate any off-target effect. After 48 hours, plasmids 
were recovered from the red-most streaks and after amplification in bacteria were 
Sanger-sequenced to identify the mutations introduced in the REC1-II domain. After a 
Figure 19. Yeast screen for high-specificity SpCas9 
variants. (a) Schematic representation of the yeast 
screening workflow. (b) Evaluation of the on-target activity 
and the specificity of SpCas9 variants obtained from the 
yeast screening through re-challenging with the yACMO-off4 
reporter strain. Cas9 expression was induced for 5 h prior to 
plating. The dashed line indicates an on-target activity which 
is at least 80% the one of wild-type Cas9. Specificity is 
defined as the fraction of red colonies obtained on reporter 
plates.  (c) Evaluation of the specificity of the C13 variant. 
C13 was transformed in the yACMO-off1/off4 reporter 
strains expressing an on-target sgRNA and the percentage 
of red (on-target) and white (off-target) colonies was 
evaluated after 24h of Cas9 expression. Error bars represent 
s.e.m. for n=3. 
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single round of selection, we identified several amino acidic substitutions, some of 
which were present more than once in the mutants’ pool, in combination with different 
groups of mutations. Of note, it is likely that mutants containing the same set of 
variations represent clones deriving from the same original cell that replicated during 
the recovery incubation. However, given the diversity of substitutions obtained, this 
phenomenon did not affect the results of our screening. We then performed a re-
challenging experiment in the yACMO-off4 strain with each isolated variant in order to 
measure more precisely its cleavage activity, discard those that did not efficiently cut 
their target compared to wild-type SpCas9 and rank the remaining ones according to 
the latter parameter and their ability to discriminate off-target sites (Fig. 19b). An 
outline of the experimental workflow is schematized in Fig. 19a. To further validate the 
results of the screening, we evaluated more in detail the specificity of one of the 
obtained variants (C13 variant) by challenging all four yACMO reporter strains. After 24 
hours of Cas9 expression, the quantification of white and red colonies on reporter 
plates showed significantly reduced off-target activity when compared to wild-type 
SpCas9 (compare Fig. 19c and Fig. 17b).  
	
Optimization of high-fidelity SpCas9 variants in mammalian cells 
We selected a pool of substitutions belonging to best performing variants isolated from 
the yeast screen according both to on-target cleavage efficiency and reduction of 
unspecific activity. We then reasoned that their hierarchical combination would have 
allowed to obtain a significant increase in fidelity with respect to the identified mutants, 
since it could be expected that some of the mutations in each randomly generated 
variant may have been neutral or detrimental.  
Using a reporter cell line stably expressing EGFP (293multiGFP), we tested the on-target 
activity (sgGFPon) of double mutants (DM) by measuring the loss of fluorescence 
induced by frameshift mutations into the EGFP coding sequence. In parallel, we 
evaluated their ability to avoid the cleavage of the same site after the introduction into 
the sgRNAs of one or two mismatched bases in PAM-distal positions (position 18 for 
sgGFP18 and positions 18-19 for sgGFP1819). Wild-type SpCas9 was not able to 
discriminate these two surrogate off-target sequences, as confirmed by an equal 
cleavage efficiency when guided by both matched and mismatched sgRNAs  that 
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produced the same reduction in the percentage of EGFP+ cells (Figs. 20a and 20b). After 
a first round of selection we combined the top performing substitutions into triple 
mutants (TM) and repeated the challenging of the EGFP reporter cell line (Fig. 20a). We 
then performed a last round of selection after generating a quadruple mutant by 
combining the best substitutions of the previous round (Variant A). In addition, we 
tested another sgRNA containing two mismatches in a more PAM-proximal region 
(positions 13 and 14, sgGFP1314) to verify that the observed increase in fidelity of our 
variant was conserved for mutations spanning the whole spacer sequence. Variant A 
induced little or no loss of EGFP fluorescence for all mismatched guide RNAs, a result 
that was particularly striking for the sgRNA containing a single substitution in position 
18 from the PAM (sgGFP18). On the other hand, this strong increase in specificity 
produced a small albeit measurable decrease in on-target activity (~20% loss, Fig. 20b). 
In order to address this issue, we generated by rational design two alternative 
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derivatives of Variant A (Variant B and Variant C) and we tested their characteristics 
using the same EGFP knockout assay. As expected, we observed a complete restoration 
of on-target cleavage efficiency coupled to a small increase in off-target activity (Fig. 
20b).  
Side-by-side comparison of our quadruple mutants (Variant A-B-C) with previously 
published high-fidelity variants347,348 using our EGFP reporter cell line revealed a 
marked increase in fidelity, which was particularly evident using the sgRNA containing 
a single mismatch in position 18. For this particular surrogate off-target, we measured 
approximately a 17 to 4-fold absolute reduction in unspecific cleavage when comparing 
Variant A-B-C with SpCas9-HF1, which in our hands was already discriminating 
mismatched sites much better than eSpCas9(1.1) (Fig. 20b). This observation was 
further confirmed by calculating the on-/off-target ratios of the different SpCas9 
variants calculated for the two strongest surrogate off-targets (sgGFP1819 and 
sgGFP18) (compare dotted lines in Fig. 20b).  
We next assessed more in detail the on-target activity of Variant A and Variant B by 
targeting different regions of the EGFP coding sequence (a complete list of the target 
sites is reported in Appendix Table 5) using the 293multiGFP reporter cell line and 
measuring the loss of fluorescence. We did not analyse Variant C any further since it 
behaved similarly to Variant B. In accordance with previous results (Figs. 20a and 20b), 
we observed wild-type levels of activity for Variant B, while Variant A was slightly 
underperforming at some of the sites, with a significant drop in activity for one of the 
tested loci (Figs. 21a and 21b). To rule out the possibility that the different cleavage 
behaviour measured towards on- and off-target sites was due to an alteration of the 
intracellular levels of our SpCas9 variants, we analysed by western blot the lysates of 
293T cells transfected with equal amounts of wild-type SpCas9, Variant A and Variant 
Figure 20 (on previous page). Selection of optimized SpCas9 variants in mammalian cells. (a) Hierarchical 
combination of mutations obtained from the yeast screening. 293 cells stably expressing EGFP were transfected 
with single (SM), double (DM) and triple (TM) mutants generated by the hierarchical combination of mutations 
obtained from the best performing yeast-isolated variants together with an on-target sgRNA (sgGFPon) or each of 
the mismatched guides. Loss of EGFP fluorescence was measured by FACS analysis at 7 days post-transfection. (b) 
Side-by-side comparison of the best generated variants with previously published mutants. The 293-EGFP knockout 
assay was used to assess the specificity of the top isolated variants (Variant A-B-C) and to compare their 
performance with previously published high-fidelity mutants. Loss of EGFP fluorescence was measured by FACS 
analysis at 7 days post transfection. sgGFP1314 contains mismatches in position 13&14 from the PAM; sgGFP1819 
contains mismatches in positions 18&19; sgGFP18 contains a single mismatch in position 18. Dotted lines indicate 
on/off target ratios calculated for the indicated on/off couples. Dashed lines indicate the background loss of EGFP 
fluorescence. Error bars represent s.e.m. for n³2. 
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B, together with the two previously published high-fidelity variants eSpCas9(1.1)348 and 
SpCas9-HF1347. This experiment did not show any major difference in the expression 
levels of the analysed Cas9 (Fig. 21c). Given these results, we decided to further 
characterize Variant B, which we named evoCas9 (evolved Cas9), that retained near 
wild-type levels of activity and reduced drastically the cleavage of non-matching 
sequences in our EGFP-disruption cellular model.  
 
 
Characterization of sgRNA requirements of evoCas9 
Since previous reports347 highlighted the incompatibility of a combination between 
truncated sgRNAs322 and high-fidelity SpCas9 variants as a way to further increase their 
specificity, we decided to test if evoCas9 was able to target different regions of the EGFP 
Figure 21. evoCas9 on-target activity against EGFP. (a) evoCas9 activity against EGFP loci. 293 cells stably 
expressing EGFP were transfected with wt SpCas9, evoCas9 or Variant A together with sgRNA targeting different 
regions of the EGFP coding sequence. Loss of EGFP fluorescence was measured by FACS analysis at 7 days post 
transfection.  Dashed lines indicate the background loss of EGFP fluorescence. Error bars represent s.e.m. for n³2. 
(b) Ratio of on-target activity of evoCas9 and Variant A to wild-type SpCas9 calculated on EGFP loci. The median and 
interquartile range are shown. A level of on-target activity above 70% of the wt protein is indicated in green. (c) 
evoCas9 intracellular expression. Representative western blot of lysates from 293T cells transfected with wt SpCas9, 
evoCas9 or the other high-fidelity variants. Tubulin was used as a loading control. SpCas9 is detected using an anti-
FLAG antibody. 
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coding sequence using sgRNAs with a length spanning from 17 to 19 nucleotides by co-
transfection in the 293multiGFP reporter cell line. As expected, evoCas9 was unable to 
cleave the two shorter targets and retained only marginal activity with the 19 nt sgRNA, 
while wild-type SpCas9 was characterized by high activity with all the tested sgRNAs 
(Fig. 22a). This result is in accordance with the increased dependency of our high-
specificity SpCas9 variant on the pairing between the sgRNA and the target DNA 
sequence and suggests that in some cases even a 19 nucleotide pairing between the 
guide RNA and the target could not be enough to ensure cleavage. We then 
investigated if the common practice of adding a mismatched G nucleotide at the 
beginning of sgRNAs to favour transcription from the human U6 polymerase III 
promoter could be applied to evoCas9 without losing nuclease activity, since previous 
studies reported such effect347. We thus tested in parallel two sgRNAs targeting the 
EGFP coding sequence differing only for the presence/absence of a 5’-G and observed 
that the presence of the additional G in an otherwise matching spacer produced a drop 
in evoCas9-mediated cleavage, leaving wild-type SpCas9 activity unaffected (Fig. 22b). 
We next generated a set of sgRNAs targeting a single EGFP locus containing 19 to 23 
matching nucleotides with an added guanine at the beginning of the spacer sequence 
and tested their efficacy in our EGFP-knockout model. While wild-type SpCas9 retained 
robust activity with all the tested guides, even though longer spacers were less efficient 
in promoting cleavage, evoCas9 was unable to target the EGFP CDS with any of the 
selected sgRNAs (Fig. 22c). This result was further confirmed by measuring the editing 
of two genomic loci which were targeted using sgRNAs containing an additional G at 
their 5’-end (Fig. 22d). In addition, an sgRNA containing a 22 bp spacer completely 
matching the target sequence and starting with a matched 5’-G, was able to induce the 
cleavage of its target only when coupled with wild-type Cas9, but not with evoCas9 (Fig. 
22c). Notably, the addition of a single mismatch in position 20 of the guide RNA (sgRNA 
site25(19+G)) completely abrogates evoCas9 cleavage. Taking into account the current 
working model that assumes that mismatches located in more PAM-distal positions of 
the spacer sequence are more easily tolerated by Cas9, this result represents an 
unexpected discrepancy with previous data (see Fig. 20b) showing that a mismatch in 
position 18 of the guide cannot be completely discriminated by evoCas9. This, together 
with the complete loss of activity observed with spacer sequences longer than 20 bp 
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and containing or not mismatched 5’-Gs, indicates that evoCas9 does not tolerate 
alterations of the RNA:DNA heteroduplex in PAM-distal positions that are structurally 
located at the end of the cavity that harbours the duplex itself. In addition, other groups 
have reported that the inclusion of two extra guanines at the 5’-terminus of sgRNAs 
increases   targeting   specificity298.   This   effect,   which   is still   without   a  biological  
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explanation,  in our  opinion could be connected to the behaviour we observed with 
our mutant. Given the impossibility to exploit the common strategy to add an extra G 
at the 5’-end of the sgRNA when using our high-specificity SpCas9 variant, we next 
Figure 22 (continued). sgRNA requirements for evoCas9 activity. The EGFP knockout assay was performed using 
wt SpCas9 and evoCas9 together with different truncated sgRNAs (17-19 nt) (a), an sgRNA containing a mismatched 
5’-G nucleotide (site 20+G) or with the same sgRNA without a 5’-G (site 20) (b) and with sgRNAs spanning a length of 
19-23 nt and containing a mismatched 5’-G or fully annealing with the target sequence (site 25+2, 22 nt spacer) (c). 
(d) Indel analysis at two genomic loci targeted using wt SpCas9 and evoCas9 guided by sgRNAs containing a 5’ 
mismatched G. (e) EGFP knockout assay with wt SpCas9 and evoCas9 using sgRNAs with fully matching spacers 
starting with nucleotides other than G or with their counterparts containing a mismatched 5’-G. (f) evoCas9 activity 
and specificity using optimized sgRNAs. evoCas9 together with wt SpCas9 and previously published variants were 
tested using the EGFP disruption assay with optimized versions of the sgRNA presented in Fig. 20 to assess the 
effect on on-target activity and specificity. Above the graphs further information on the target sequences and the 
spacers is reported. In (a) underlined nucleotides represent the actual spacer sequence used. Bold Gs indicate non-
matching 5’ guanines. Lowercase nucleotides represent the bases immediately preceding the target site at each 
locus. For all the experiments loss of EGFP fluorescence was measured by FACS analysis at 7 days post transfection. 
For endogenous loci indel analysis cells were collected 7 days post-transfection. Dashed lines indicate the 
background loss of EGFP fluorescence. Error bars represent s.e.m. for n³2. 
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explored the feasibility of expressing sgRNAs starting with a nucleotide other than G 
using the human U6 polymerase III promoter. We designed a set of guide RNAs 
targeting selected EGFP loci with 20 bp spacers starting with C, T and A and a 
corresponding set in which the same guides were modified by the addition of a 5’ 
mismatched G. When tested in combination with wild-type SpCas9 and evoCas9 using 
our EGFP-knockout cellular model, we measured robust editing for all the selected 
guides (both with and without the extra 5’-G) in the presence of wild-type SpCas9, while, 
on the other hand, evoCas9 was unable to cleave its targets when guided by 5’-G-
containing spacers, as expected. Nonetheless, when the 5’ extra G was removed, we 
were able to obtain a partial restoration of the targeting activity for two out of three 
tested guides (Fig. 22e). Overall, these data indicate the it may be possible to evaluate 
on a case-by-case basis the employment of spacer sequences not starting with a 
guanine, even without its addition at the beginning of the transcript. Lastly, since the 
introduction of mutations may have altered SpCas9 contacts with the sgRNA, we tested 
whether evoCas9, together with eSpCas9(1.1) and SpCas9-HF1, was still able to bind an 
optimized version of the sgRNA268, which was structurally modified to increase its 
transcription and interaction with SpCas9 to obtain a more efficient target cleavage. 
We generated the optimized versions of sgGFPon and its previously employed 
surrogate off-targets and we tested their behaviour in our EGFP-disruption model. In 
accordance with the data obtained with non-optimized sgRNAs, we observed a 
complete absence of discrimination between matched and mismatched spacers by 
wild-type SpCas9, while the mutated variants could prevent unspecific cleavages, albeit 
to different extents, similarly to what previously observed (compare Fig. 22f with Fig. 
20b). In particular, this side-by-side comparison confirmed that our high-specificity 
mutant, evoCas9, was able to better discriminate non-matching spacers, especially 
when containing a single mismatch in a more PAM-distal position (sgGFP18-OPT, Fig. 
22f). In addition, we probably did not observe a further increase in on-target cleavage 
since our reporter assay had already reached a plateau, likely determined by the 
transfection efficiency relative to the cell line used (Fig. 22f). Altogether, these data 
indicate that structurally modified sgRNAs can be employed in combination with newly 
generated high-specificity variants without encountering any major negative effect on 
their enhanced target discrimination capability.  
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evoCas9 activity towards endogenous loci 
We next wanted to further validate our findings using endogenous loci. We thus 
selected a group of previously tested genomic target sites in order to compare the 
cleavage activity of evoCas9 with the one of wild-type SpCas9 at each locus. In addition, 
we introduced in the comparison also SpCas9-HF1, as a further benchmark. After 
transfection in 293T cells of each SpCas9 variant together with sgRNAs targeting the 
different loci, we analysed indel formation by using the Tracking of Indels by 
Decomposition (TIDE) software package on Sanger-sequenced amplicons relative to 
each target site. For the majority of the loci, we did not observe any major difference 
in targeting efficiency between wild-type SpCas9 and evoCas9, with the latter being in 
general slightly less active with an overall mean activity which is 80% of that of the wild-
type protein (Fig. 23a and Fig. 23b). Compared to the other loci, evoCas9 showed very 
poor cleavage efficiency towards the ZSCAN2 locus (Fig. 23a). As regards the SpCas9-
HF1 variant, we measured generally lower cleavage efficiency, with a global mean 
activity which is 60% if compared to the wild-type (Fig. 23a and Fig. 23b). This is not in 
accordance with previously published observations347 and we hypothesize that this 
discrepancy could be due to the different experimental system used. Nevertheless, 
since all the experiments have been run in parallel, we believe to have conducted a fair 
comparison between the two high-fidelity variants. These data demonstrate that 
Figure 23. evoCas9 activity on endogenous loci. (a) wt SpCas9, evoCas9 and SpCas9-HF1 activities towards 
endogenous loci were compared by transfecting 293T cells and by measuring indel formation at 7 days post-
transfection using the TIDE tool. (b) Ratio of on-target activity of evoCas9 and SpCas9-HF1 to wild-type SpCas9 
calculated on endogenous loci. The median and interquartile range are shown. A level of on-target activity above 
70% of the wt protein is indicated in green. Error bars represent s.e.m. for n=2. 
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evoCas9 retains near-wild type levels of on-target activity against a panel of 
endogenous loci, outcompeting the previously reported SpCas9-HF1 variant. 
 
Evaluation of evoCas9 off-target activity 
Together with the activity towards on-target sites, we measured evoCas9 specificity by 
verifying the editing rate at two previously validated off-target sites relative to the 
FANCF site 2 and CCR5 sp11 loci. In particular, the FANCF site 2-related off-target was 
one of the few non-repetitive sites that SpCas9-HF1 was unable to discriminate347, while 
the selected CCR5 sp11 off-target site falls in the highly homologous CCR2 gene, a 
target that is considered relevant for therapeutic purposes. After transient transfection 
in 293T cells, we measured indel formation at these two off-target loci using TIDE 
revealing a significant decrease of cleavage in cells expressing evoCas9 when 
compared to wild-type SpCas9-transfected cells (Figs. 24a). In addition, the calculation 
of the on-/off-target ratios for wild-type SpCas9, evoCas9 and SpCas9-HF1 confirmed 
that our variant was able to outperform its competitors at these two loci (Fig. 24b). The 
concerted cleavage of the CCR5 sp11 locus and its off-target in the CCR2 gene can lead 
to a chromosomal deletion of approximately 15 kilobases (schematized in Fig. 24c). We 
measured the frequency of this chromosomal rearrangement by semi-quantitative 
PCR in cells transfected with wild-type SpCas9, evoCas9 or SpCas9-HF1 together with 
the sgRNA targeting the CCR5 locus. While the translocation event was particularly 
evident in cells edited by wild-type SpCas9, we observed a strong reduction in the 
amount of deletion to barely detectable levels both in presence of SpCas9-HF1 and 
evoCas9. Densitometric analyses further revealed that deletion produced by evoCas9 
was almost two-fold less with respect to the one generated by the former variant (Fig. 
24d). 
Figure 24 (next page). Side-by-side comparison of evoCas9 and SpCas9-HF1 specificity. (a) Off-target activity of 
evoCas9 on selected loci. 293T cells were transfected with wt SpCas9, evoCas9 or SpCas9-HF1 together with sgRNAs 
targeting the FANCF site 2 or the CCR5 sp11 locus. Indel formation at two previously validated off-target sites was 
evaluated at 7 days post transfection using the TIDE tool. The sequences of the on- and off-target sites for each 
locus are reported below the corresponding graphs. (b) On/off ratios calculated from the mean indel percentages 
obtained in (a). (d) Schematic representation of the CCR5 locus and its off-target site in the highly homologous CCR2 
gene. Simultaneous cleavage of the two sites generates a chromosomal deletion of approximately 16 kb. (e) Semi-
quantitative PCR was performed on genomic DNA of 293T cells transfected with wt SpCas9, evoCas9 or SpCas9-HF1 
and the CCR5 guide RNA to assess the amount of chromosomal deletion generated in each condition. The FANCF 
locus was used as an internal normalizer. The amount of deletion was quantified using densitometry with ImageJ. 
Error bars represent s.e.m. for n=2. 
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We then investigated the ability of evoCas9 to avoid unwanted genomic cleavages by 
performing targeted deep sequencing on a selected set of off-target sites relative to 
the VEGFA site 3 and EMX1-K genomic loci. All the chosen sites were previously shown 
to be edited together with the on-target locus280. The advantage of amplicon-seq lies in 
the possibility to simultaneously measure several targets with high coverage in order 
to detect even low abundant editing events. Analysis of sequencing data demonstrated 
that, while retaining high on-target activity on both genomic loci, evoCas9 was able to 
reduce at background levels the cleavage of the majority of the tested off-target sites 
(Figs. 25a and 25b). The first VEGFA site 3 off-target site (VEGFA3-OT1) was the only 
locus where we measured editing levels above the background for evoCas9 (Fig. 25b). 
It must be considered, however, that the same locus is edited almost as the on-target 
site by wild-type SpCas9 and that the previously reported SpCas9-HF1 variant was 
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unable to completely suppress the unspecific cleavage of this sequence due to its 
highly repetitive nature347. For four VEGFA site 3 off-target sites (VEGFA3-OT1, -OT4, -
OT5, -OT7) we measured significantly higher background editing rates (Fig. 25b): we 
believe that this could be explained by some peculiar characteristics of the local 
chromatin that is more fragile and thus prone to accumulate mutations.  
Altogether these data indicate that evoCas9 significantly decreases unwanted genomic 
cleavages to undetectable levels for the majority of tested off-target sites. In addition, 
Figure 25. Validation of evoCas9 
specificity by targeted deep-
sequencing. Targeted deep-seq of 
previously validated off-target sites 
relative to the EMX1 site 1 locus (a) and 
the VEGFA site 3 locus (b) was 
performed on genomic DNA of 293T 
cells expressing either wt Spcas9 or 
evoCas9 together with each specific 
sgRNA. Cells not expressing Cas9 were 
sequenced to determine background 
indel levels. Genomic DNA from three 
biological replicates was mixed before 
library preparation. 
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side-by-side comparisons with the previously published SpCas9-HF1 variant 
demonstrated an increased ability to discriminate mismatched sites.  
Genome-wide specificity of evoCas9 
We decided to extend our analysis of evoCas9 off-target activity at a genome-wide level 
by using the previously reported GUIDE-seq technique305. This approach is based on 
the integration of a 34 bp oligonucleotide tag into sites which have been cut by Cas9 in 
order to allow their capture for library preparation and next-generation sequencing. In 
this way, it is possible to identify in an unbiased fashion a collection of novel genomic 
sites associated with a particular guide RNA that are unspecifically targeted by Cas9. 
We performed a GUIDE-seq analysis of the off-target sites relative to a guide RNA 
targeting the VEGFA site 2 locus, which is highly repetitive, and has been shown to 
generate numerous unwanted cleavages into the cellular genome. Additionally, past 
reports347 indicated that some of the detected off-targets were still cleaved by the high-
fidelity SpCas9-HF1 variant. We thus generated GUIDE-seq libraries from genomic DNA 
of 293T cells transfected either with wild-type SpCas9 or evoCas9, together with the 
VEGFA site 2 sgRNA and the bait double stranded oligonucleotide. Sequencing data 
were analysed using a publicly available software pipeline357 revealing for wild-type 
SpCas9 600 different off-target sites characterized by 7 or less mismatches with the on-
target sequence (Figs. 26a and 26b). Of note, approximately 100 of these off-target 
sequences were edited more efficiently that the on-target site, according to the number 
of reads obtained by GUIDE-seq analysis that have been reported to be a good proxy 
of the actual cleavage activity at each specific site305 (Fig. 26a). When the same analysis 
was performed on evoCas9 samples, a total of only 10 sites were detected, the majority 
of which shared high similarity with the on-target sequence and were characterized by 
less than five mismatches with the VEGFA site 2 locus (Fig. 26a). We detected only one 
off-target that was cleaved efficiently (more than the on-target) by evoCas9 and this 
was probably due to the particular nature of this sequence. In fact, it differed by only 
two nucleotides from the intended target and contained two uninterrupted stretches 
of cytosines at the level of each mismatch (Fig. 26a), maybe allowing the formation of 
bulge sites to accommodate the non-matching nucleotides.  
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Overall our GUIDE-seq analysis demonstrated that evoCas9 retains very high-specificity 
at the genome-wide level even when tested using a repetitive target sequence 
characterized by multiple off-targets into the cellular genome.    
 
Specificity of an evo-dCas9-based transcriptional activator 
An alternative application for Cas9, independent from its nuclease activity, is the 
generation of RNA-guided transcriptional activators by fusing a catalytically inactive 
Figure 26. Genome-wide specificity of evoCas9. (a) 
GUIDE-seq analysis of the off-target sites relative to the 
VEGFA site 2 locus performed for both wt SpCas9 and 
evoCas9 in 293T cells. (b) Total number of detected off-
target sites for wt SpCas9 and evoCas9. Genomic DNA 
from three biological replicates was mixed before 
library preparation. Black square denotes on-target site. 
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version of Cas9 (dCas9) to various protein domains that stimulate transcription. We 
built a VP64-based transcriptional activator using a catalytically inactive mutant of 
evoCas9 (evo-dCas9) and tested it side-by-side with a wild-type dCas9-VP64 activator 
using a reporter system based on an inducible EGFP expression vector normally 
regulated by a Tet trans-activator through its binding to an array of Tet operators in 
the context of a minimal CMV promoter. We substituted the Tet trans-activator with 
the Cas9-based transcriptional activator guided by an RNA targeting the repeated Tet 
operator sequences (Fig. 27a). We designed two different on-target sgRNAs differing 
only for the presence or the absence of an extra 5’-G nucleotide, plus three additional 
mismatched guides based on the same on-target sequence, bearing either one or two 
mutations in different positions along the spacer sequence, without an added guanine 
at the beginning of the transcript. We observed lower absolute levels of EGFP 
fluorescence when the activation was driven by evo-dCas9-VP64 if compared to dCas9-
VP64 for both matching and mismatched guide RNAs, suggesting stronger binding to 
the target DNA by wild-type dCas9 (Fig. 27b). However, the on-target fold activation 
relative to the control sgRNA was similar for both wild-type dCas9 and evo-dCas9, due 
to the lower background activation observed in the presence of our high-specificity 
variant, most likely due to the lower propensity of evo-Cas9 to bind DNA unspecifically 
(Fig. 27c). Interestingly, we did not observe any difference in EGFP transcriptional 
activation when comparing samples transfected with evo-dCas9-VP64 together with 
the on-target TetO-on guide RNA or the on-target guide with the added extra 5’-G (Fig. 
27b). This, combined with previous data showing a consistent loss of editing activity 
when using sgRNA containing an additional starting G (Fig. 22a-d), suggests that 
evoCas9 is indeed able to bind target sites using sgRNAs characterized by a 
mismatched extra 5’-guanine, but is then unable to cut the bound DNA.  Accordingly, 
when we compared the EGFP fold-activation obtained using mismatched guides, the 
increased specificity observed using evo-dCas9-VP64 was modest when compared with 
dCas9-VP64, further reinforcing the idea that evoCas9 binds to mismatched targets, 
even though less efficiently, but is then unable to complete the cleavage reaction (Fig. 
27c). Overall, these results indicate that evoCas9 can be exploited to build a 
transcriptional regulator characterized by lower background activation, albeit less 
absolute potency, and slightly increased fidelity.  
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Long-term specificity of evoCas9 
Since the permanent expression of Cas9 into cells has been associated with increased 
off-target activity, an important issue that had to be addressed was the long-term 
behaviour of evoCas9 into cells. We therefore generated lentiviral particles to obtain 
the stable expression of wild-type SpCas9, evoCas9 or SpCas9-HF1 together with an 
sgRNA of interest. We decided to exploit a cellular EGFP-knockout model similar to the 
one previously employed in this study, together with the same set of sgRNAs directed 
towards the EGFP coding sequence, either perfectly matching the target locus or 
containing one or more mismatches in different positions of the spacer sequence, thus 
acting as surrogate off-targets. We transduced the reporter cell line with equal 
amounts of the different lentiviral vectors and kept the cultures under antibiotic 
Figure 27. evo-dCas9 transcriptional activation. (a) 
Schematic representation of the Tet Responsive 
Element (TRE)-EGFP based transcriptional activator 
reporter. Upon binding of dCas9-VP64 to TetO repeats 
EGFP expression is activated. (b) EGFP activation was 
measured in 293T cells transfected with dCas9 or evo-
dCas9 based transcriptional activators together with 
matching sgRNAs (both with or without a 5’ mismatched 
G) or mismatched guides. TetO-off6 contains a 
mismatch in position 6 from the PAM, TetO-off1314 
contains two mismatches in positions 13-14 and TetO-
off1819 contains two mismatches in positions 18-19. (c) 
Fold activation of EGFP expression with respect to the 
non-targeting control calculated from the data in (b). 
Error bars represent s.e.m. for n=2. EGFP expression 
was measured by FACS analysis at 2 days post-
transfection. 
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selection throughout the duration of the experiments to isolate the transduced 
population and avoid the eventual dilution of editing events in time due to loss of 
edited cells or reduced fitness of transduced cells. The measurement of the decrease 
of EGFP fluorescence at different time points revealed that wild-type SpCas9 cut the 
target sequence with very high efficacy regardless whether the sgRNA was perfectly 
matching or not the target site; this was observed even from the earliest time points, 
in accordance with the results obtained in transient transfection experiments (see Fig. 
28a and Fig. 20a-b). On the contrary, both evoCas9 and SpCas9-HF1 did not cleave 
EGFP efficiently using the sgGFP1314 and sgGFP1819 sgRNAs, both containing double 
mismatches (Fig. 28b-c). Of note, while loss of fluorescence was at background levels 
for evoCas9 samples at all time points, a measurable number of EGFP-negative cells 
that remained constant over time was present in the cultures transduced with SpCas9-
HF1-expressing vectors (Fig. 28c). In addition, the two Cas9 variants significantly 
differed when tested with the strongest surrogate off-target, sgGFP18, containing a 
single mismatch in a PAM-distal position. While SpCas9-HF1 cleaved the locus with 
similar efficiency with both the matching and mismatched sgRNA, evoCas9 showed a 
differential activity with the two tested guides. The curves representing the percentage 
of non-fluorescent cells reported for evoCas9-transduced cultures revealed that the 
loss of fluorescent cells increased in time and reached less than half the level of the 
on-target knockout at 40 days post-transduction (Figs. 28b-c). Interestingly, we 
observed a progressive reduction in the number of EGFP negative cells in cultures 
treated with SpCas9-HF1 (see samples sgGFPon and sgGFP18 in Fig. 28). This effect 
could be connected to Cas9-induced cellular toxicity with the consequential death of 
highly transduced cells, which would more likely belong to the EGFP-negative 
population. These data suggest that, even though it is conceivable that not all off-target 
sites could avoided by our high-specificity Cas9 variant, a carefully selected guide RNAs 
combined with evoCas9 may allow long-term expression of the nuclease without any 
unwanted cleavage occurring in the cellular genome. 
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Figure 28. Long-term specificity of evoCas9. Stable expression of wt SpCas9 (a), evoCas9 (b) and SpCas9-HF1 (c) 
was obtained through lentiviral transduction of a 293T cell line stably expressing EGFP. Each lentiviral vector was 
also expressing an on-target sgRNA or the different mismatched guides presented in Fig. 20. EGFP knockout was 
evaluated by FACS analysis at the time points indicated in the graphs. Cell were kept under puromycin selection for 
the whole duration of the experiments. Error bars represent s.e.m. for n=2. 
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Hit-and-go Cas9 delivered through a lentiviral based self-limiting 
circuit 
 
Rationale of the experiments  
	
An important factor influencing the number of off-target modifications induced by 
Cas9 is the amount and persistence of its expression in target cells: high concentrations 
of the nuclease have been reported to increase off-site cleavage, whereas lowering the 
amounts of SpCas9 increases specificity300-302,342. Transient SpCas9 expression is indeed 
sufficient to permanently modify the target genomic locus with decreased off-target 
activity as demonstrated by the enhanced specificity obtained through direct delivery 
of recombinant SpCas9-sgRNA complexes into target cells332-334 or by using a SpCas9 
variant activated by inteins, whose expression can be modulated using a small 
molecule ligand342. It is likely that any Cas9 protein present after the target locus has 
been edited has a substantial probability to modify additional unwanted sites. Even 
though direct delivery of SpCas9-sgRNA ribonucleoprotein complexes may decrease 
off-target effects, it is highly inefficient and unsuitable for in vivo approaches. On the 
other hand, although viral vectors are optimal delivery tools, they generate stable 
expression of the transferred factors which is not necessarily beneficial for 
CRISPR/Cas9 applications. We thus combined the strong points of these two 
technologies by generating a Self-Limiting Cas9 for Enhanced Safety (SLiCES) 
deliverable through a lentiviral vector. This circuitry, once deployed into target cells, 
generates a transient Cas9 expression-peak that allows modification of the intended 
genomic locus, while simultaneously neutralizing Cas9 expression itself, thereby 
protecting the host cell from long-term nuclease-mediated off-target editing.   
 
SLiCES - Methods 
	 88 
Methods 
 
Plasmids and oligonucleotides. The 3XFLAG-tagged S. pyogenes Cas9 was expressed 
from the pX-Cas9 plasmid, which was obtained by removal of an NdeI fragment 
including the sgRNA expression cassette from pX330-U6-Chimeric_BB-CBh-hSpCas9 
(Addgene #42230)223. The sgRNAs were transcribed from a U6 promoter driven 
cassette, derived from px330 and cloned into pUC19. sgRNA oligos were cloned using 
a double BbsI site inserted before the sgRNA constant portion following a previously 
published cloning strategy223. For the preparation of optimized sgRNAs the same 
design strategy was adopted, swapping the constant portion of the guide RNA with its 
optimized counterpart268. The human codon optimized coding sequence of S. 
thermophilus CRISPR 1 Cas9 used for generating a plasmids expressing a FLAG-tagged 
St1Cas9 was obtained from pMSP1673280 (Addgene #65769) through Addgene,  
together with a plasmid to express the S. thermophilus gRNA (pBPK2301280, Addgene 
#65778). S. thermophilus spacer oligos were cloned into pBPK2301 using BsmBI and 
sgRNAs were transcribed from a U6 promoter. The list of sgRNAs target sites employed 
in this study is available in the Appendix. pcDNA5-FRT-TO-EGFP plasmid was obtained 
by subcloning EGFP from pEGFP-N1 into pcDNA5-FRT-TO (Invitrogen). pcDNA5-FRT-TO-
EGFP-Y66S was obtained by site directed mutagenesis of pcDNA5-FRT-TO-EGFP to 
insert the Y66S mutation in the EGFP coding sequence. A sgRNA resistant, non-
fluorescent truncated EGFP fragment (1-T203K-stop), obtained by site directed 
mutagenesis of the pcDNA5-FRT-TO-EGFP plasmid, was amplified by PCR and inserted 
in place of the EGFP in the pcDNA5-FRT-TO-EGFP plasmid, yielding the donor plasmid 
pcDNA5-FRT-TO-rEGFP(1-T203K-stop).  
The SV5-EGFP-based NHEJ reporters employed in this study (Rep. SV5, NHEJ-REP.W and 
NHEJ-Rep.M) were generated by cloning into the NheI/BspEI sites of the reporter 
plasmid dsDNA oligos corresponding to the complete target sequence (including PAM) 
recognized by a sgRNA of interest. The target is inserted between the SV5 tag and EGFP 
coding sequences, with the EGFP sequence positioned out of frame with respect to the 
starting ATG codon of the SV5 tag open reading frame (ORF). A stop codon is inserted 
in the SV5 frame, immediately after the target sequence. The target sequences cloned 
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in the reporter are listed in Appendix Table 8-9. The pcDNA3 MHC-I-roTag plasmid is 
described in358.  
All the spacer sequences employed in the study are listed in Appendix Table 8 and 
Table 10. 
 
Cell culture and transfections. 293T/17 cells were obtained from ATCC. 293TR cells, 
constitutively expressing the Tet repressor (TetR), were generated by lentiviral 
transduction of parental 293T/17 cells using the pLenti-CMV-TetR-Blast vector 
(Addgene # 17492)359 and were pool selected with 5 µg/ml of blasticidin (Life 
Technologies). Similarly, 293T-SpCas9 cells, stably expressing SpCas9, were obtained 
by lentiviral transduction with the lentiCas9-Blast vector (a gift from Feng Zhang, 
Addgene # 52962)360 at MOI of 1 and were pool-selected using 5 µg/ml of blasticidin. 
293multiEGFP cells were generated by stable transfection of pEGFP-IRES-Puromicin 
and selected with 1 µg/ml of puromicin. 293-iEGFP and 293-iY66S cells (Flp-In T-REx 
system; Life Technologies) were generated by Flp-mediated recombination using the 
pcDNA5-FRT-TO-EGFP or the pcDNA5-FRT-TO-EGFP-Y66S as donor plasmids, 
respectively, in cells carrying a single genomic FRT site and stably expressing the 
tetracycline repressor (293 T-Rex Flp-In, cultured in selective medium containing 15 
μg/ml blasticidin and 100 μg/ml zeocin, Life Technologies). Briefly, the parental 
commercial cell line (293 T-Rex Flp-In) was co-transfected with each of the two donor 
plasmids together with a plasmid coding for the Flp recombinase (pOG44) in a ratio 1:9 
to allow site specific integration of the desired sequence. Antibiotic selection was 
relaxed for two days to promote recombination before switching to a new antibiotic 
cocktail (15 μg/ml blasticidin and 100 μg/ml hygromycin, Life Technologies) that selects 
the correct integration event and allowed the generation of the clonal lines 293-iEGFP 
and 293-iY66S, which were cultured in the same selective medium. Specific integration 
in 293-iEGFP and 293-iY66S clones was verified by checking for the loss of zeocin 
resistance. All cell lines were cultured in DMEM supplemented with 10% FBS, 2mM L-
Gln, 10 U/ml penicillin, and 10 μg/ml streptomycin and the appropriate antibiotics 
indicated above. 
293T, 293-iEGFP or 293-iY66S cells were transfected in 12 or 24 multi wells with 250-
500 ng of Cas9-expressing plasmid and 250-500 ng of the desired sgRNA-expressing 
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plasmid using TransIT-LT1 (Mirus Bio), according to manufacturer’s instructions. Cells 
were collected 2-4 days after transfection or as indicated. 
In 293-iEGFP and 293-iY66S cells the expression of EGFP was induced by treatment with 
100 ng/ml doxycycline (Cayman Chemical) for 20 h before fluorescence measurement. 
 
lentiSLiCES vectors. lentiSLiCES was prepared from the lentiCRISPRv1223 transfer 
vector by substituting the EFS-SpCas9-2A-Puro cassette with a SpCas9(intron)-IRES-
Blasticidin fragment together with a CMV-TetO promoter. The intron introduced in 
SpCas9 derives from the mouse immunoglobulin heavy chain precursor V-region 
intron (GenBank ID: M12880.1) and is necessary to avoid leaky Cas9 expression during 
plasmid amplification in bacteria that would lead to plasmid digestion due to the 
concomitant presence of the self-targeting sgRNA. An EMCV-IRES regulating the 
translation of a blasticidin resistance gene was cloned downstream of SpCas9 to allow 
the antibiotic selection of transduced cells, even after the generation of frameshift 
mutations in the Cas9 coding sequence following Cas9 self-cleavage of the integrated 
vector. The sgCtr-opt or the sgCas9-a-opt were assembled with an H1-TetO promoter 
within a pUC19 plasmid, PCR amplified and then cloned into a unique EcoRI site in 
lentiCRISPRv1 and selected for the desired head-to-tail orientation. The spacer 
sequences targeting the chosen locus were cloned into the lentiCRISPRv1 sgRNA 
cassette using the two BsmBI sites, following standard procedures245. All the primers 
employed for cloning are listed in Appendix Table 7. 
 
Lentiviral vector production. Lentiviral particles were obtained by using 293T or 
293TR cells, for lentiCRISPR or lentiSLiCES production, respectively. Lentiviral vector 
production and collection has been described in the Methods section of the first part 
of the results. After collection, lentiSLiCES viral vectors were concentrated using 
polyethylene glycol (PEG) 6000 (Sigma). Briefly, a 40% PEG 6000 solution in water was 
mixed in a 1:3 ratio with the vector-containing supernatant and incubated for 3 hours 
to overnight at 4°C. Subsequently, the mix was spun down for 45 minutes at 2000xg in 
a refrigerated centrifuge. The pellets were then resuspended in a suitable volume of 
DMEM complete medium. lentiCRISPR vectors were used unconcentrated. The titer of 
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the lentiviral vectors (reverse transcriptase units, RTU) was measured using the 
product enhanced reverse transcriptase (PERT) assay354. 
 
Infections and EGFP fluorescence detection. One day before transduction 105 293T, 
293-iEGFP or 293-multiEGFP cells were seeded in a 24-well plate. For lentiSLiCES 
vectors, cells were transduced by centrifuging 2 RTU/well for 2 hours at 1600xg at 16°C, 
leaving the vectors incubating with the cultures overnight. Starting from 24 hours post 
transduction onwards the cultures were selected with 5 µg/ml of blasticidin, where 
needed. For lentiCRISPR vectors, 0.5 RTU/well were used following the same 
transduction protocol and cells were selected with 0.5 µg/ml of puromycin. 
When targeting genomic EGFP sequences, cells were collected and analysed using a 
FACSCanto flow cytometer (BD Biosciences) to quantify the percentage of EGFP loss or 
induction (gene substitution experiments). 
 
Western blots. The protocol for the preparation of cell lysates and western blots has 
been reported in the Methods section of the first part of the results. The membranes 
were incubated with mouse anti-FLAG (Sigma) for detecting SpCas9 and St1Cas9, 
mouse anti-α-tubulin (Sigma), rabbit anti-GFP (Santa Cruz Biotechnology), mouse anti-
roTag mAb358 and with the appropriate HRP conjugated goat anti-mouse (KPL) or goat 
anti-rabbit (Santa Cruz Biotechnology) secondary antibodies for ECL detection.  
 
Detection of Cas9-induced genomic mutations. Genomic DNA was isolated at 72h 
post-transfection or as indicated for transduction experiments, using the DNeasy 
Blood & Tissue kit (Qiagen). PCR reactions to amplify genomic loci were performed 
using the Phusion High-Fidelity DNA polymerase (Thermo Scientific). Samples were 
amplified using the oligos listed in the Appendix Table 10. Purified PCR products were 
analysed either by sequencing and applying the TIDE tool310 or by T7 Endonuclease 1 
(T7E1) assay (New England BioLabs). In the latter case PCR amplicons were denatured 
and re-hybridized before digestion with T7E1 for 30 min at 37°C. The digested material 
was then separated using standard agarose gel electrophoresis and quantified using 
the ImageJ software. Indel formation was calculated according to the following 
equation: % gene modification = 100 x (1 – (1- fraction cleaved)1/2). 
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GUIDE-seq experiments. GUIDE-seq was performed as previously described with few 
modifications305. Briefly, 293T cells stably expressing SpCas9 (293T-SpCas9) were 
transfected with 250ng of sgRNA-encoding plasmid and 10pmol of annealed GUIDE-
seq oligonucleotides (dsODNs) using Lipofectamine 3000 transfection reagent 
(Invitrogen). Four days post transfection genomic DNA was extracted using the DNeasy 
Blood and Tissue kit (Qiagen). Library preparation and data analysis have been 
described in detail in the Methods section of the first part of the Results. 
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Results 
 
Effects of long-term Cas9 expression on editing activity  
We first wanted to evaluate the impact on off-target activity produced by long term 
expression of SpCas9 into cells. To obtain stable Cas9 expression, we transduced the 
293-iEGFP cell line, carrying a single chromosomal copy of EGFP, with a lentiviral vector 
expressing SpCas9 together with sgRNAs that can fully (sgGFP-W, for its ability to target 
the wild-type sequence) or partially (sgGFP-M or sgGFP-MM, for the presence of a single 
or a double mismatch in the spacer sequence, respectively; see Appendix Table 8) 
anneal to the same EGFP target. The tolerance of SpCas9 for single (sgGFP-M) or double 
(sgGFP-MM) mismatches in cleaving EGFP allows for the quantification of the nuclease 
specificity. While the percentage of EGFP negative cells obtained with the on-target 
sgRNA quickly reached a plateau at 10 days post-infection, the two mismatched sgRNAs 
generated unspecific EGFP knockout which accumulated over time (Fig. 29a). The 
delivery of the recently developed more specific eSpCas9(1.1) variant348 guided by the 
same sgRNAs only partially reverses the time dependent accumulation of off-target 
cleavages (Fig. 29b). The slight increase in EGFP-negative cells over time in the control 
samples is most likely caused by the progressive loss of functionality of the Tet-mediated 
inducible expression circuit, which is probably due to cellular stress. Consistently, the 
analysis of the on/off ratios calculated from the editing of two genomic loci (ZSCAN and 
VEGFA) and their related off-target sites after long-term Cas9 expression indicated a 
progressive decrease over time, thus confirming increased off-target cleavages (Fig. 
29c). These results clearly show that the delivery of SpCas9 through a conventional 
lentiviral system correlates with increased off-target activity and this is particularly 
evident over time due to prolonged SpCas9 expression.  
Figure 29 (next page). Long term expression of Cas9 correlates with the accumulation of off-target cleavages. 
(a) Time course curves of the percentages of 293-iEGFP non-fluorescent cells obtained after transduction with a 
lentiviral vector (lentiCRISPR) expressing SpCas9 together with either a perfectly matching sgRNA (sgGFP-W) or two 
different sgRNAs containing one or two mismatches with the target sequence (sgGFP-M and –MM, respectively). A 
vector expressing an irrelevant sgRNA was used as control (sgCtr). (b) As in (a) using a lentiviral vector expressing a 
SpCas9 variant with increased fidelity (eSpCas9(1.1)). (c) DNA modification specificity, defined as on-target/off-target 
indels frequency ratio, after long term SpCas9 expression with sgRNAs targeting the VEGFA and ZSCAN endogenous 
loci. Percent modification of previously validated off-target sites was quantified by TIDE analysis after one week and 
21 days post-transduction. For all the experiments, cells were selected with puromycin in order to eliminate non-
transduced cells. In panels (a-c) data presented as mean ± s.e.m. for n=2 independent experiments.  
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Design of a Self-Limiting Cas9 circuitry for Enhanced Safety (SLiCES) 
To generate a transient SpCas9 activity peak in target cells in order to allow the 
modification of the intended target with the parallel switch-off of nuclease expression, 
we developed a Self-Limiting Cas9 circuitry for Enhanced Safety and specificity (SLiCES) 
(schematized in Fig. 30a). Cas9 was expressed in target cells together with two different 
sgRNAs: one guide molecule targets Cas9 activity towards a genomic locus of interest; 
in parallel, the second sgRNA allows the recognition of the Cas9 coding sequence itself, 
introducing indel mutations and thereby shutting down nuclease expression. The 
presence of a second sgRNA could in principle increase the likelihood of introducing a 
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higher number of unwanted cleavages into the cellular genome. However, given the 
artificial nature of the nucleotidic sequence encoding Cas9, derived from the human 
codon optimization of a prokaryotic gene, no highly homologous sequences were 
expected to occur in the host genome. This allowed to easily select guide RNAs with 
minimal off-target sites into the human genome and particularly into genes, according 
to available online prediction tools. The self-limiting SpCas9 circuitry was set up by 
selecting three different sgRNAs targeting different regions of the SpCas9 coding 
sequence (sgCas-a, -b and -c). The potential off-target sites generated by sgCas-a, -b 
and –c were evaluated in 293T cells stably expressing SpCas9 through GUIDE-seq 
analysis, a genome-wide unbiased approach.  Both sgCas-a and –c did not generate 
detectable off-target while retaining the ability to efficiently cleave the on-target site. 
On the other hand, sgCas-b produced only 6 off-target sites (Fig. 30b).	
When co-expressed with SpCas9, all three guide molecules were shown to efficiently 
downregulate SpCas9 levels (Fig. 30c and 30d, upper panels). Co-transfection in EGFP 
expressing cells of any of the three self-targeting sgRNAs (sgCas-a, -b or –c) together 
with SpCas9 and a sgRNA that fully base pairs with the EGFP target sequence (sgGFP-
W) reduced intracellular EGFP to levels (4-10% of residual protein) similar to those 
detected in cells co-transfected with the same sgGFP-W and a control sgRNA (sgCtr), 
where no downregulation of SpCas9 was induced (Fig. 30c). These results 
demonstrated that the DNA editing activity is not impaired when SpCas9 is inactivated 
through the SLiCES circuit. A similar experiment performed using a sgRNA targeting 
EGFP with a single mismatch within the seed region at the last nucleotide before the 
PAM sequence (sgGFP-M) showed non-specific EGFP downregulation, with almost 60% 
decrease of EGFP intracellular levels, in accordance with the long-term experiments 
presented in the previous section. This effect was less pronounced (~25-40% reduction) 
in cells where SpCas9 expression was downregulated through the self-limiting Cas9 
circuit (sgCas-a, -b). Of note, the sgCas-c guide RNA was not able to reduce unspecific 
EGFP knockout, even though intracellular Cas9 levels were indeed diminished (Fig. 
30c). The different levels of non-specific EGFP downregulation closely reflected the 
ability of individual sgRNAs to decrease SpCas9 intracellular levels: sgCas-a, which 
generated the lowest non-specific EGFP downregulation (73% residual EGFP, Fig. 30c), 
showed the highest SpCas9  disruption  activity (Fig. 30c, upper panel).  Similar results  
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were obtained with a reciprocal experiment where cells were transiently transfected 
with a mutated EGFP target characterized by a single nucleotide substitution (EGFP-
Y66S) that fully matched the sgGFP-M sequence and conversely differed from sgGFP-
W by a single nucleotide immediately adjacent to the PAM sequence (Fig. 30d). In both 
experimental setups the introduction of SLiCES induced a 2 to 4-fold improvement in 
target specificity, as defined by the ratio between SpCas9 editing in cells targeted by 
the perfectly matched sgRNA over the mismatched sgRNA (Figs. 30c-d, lower panel). 
This result was also confirmed in 293-iEGFP cells stably expressing a single copy of the 
EGFP gene, where we obtained a 4 to 5-fold improvement of the on-/off-ratio as 
measured both by flow cytometry to quantify the number of EGFP-negative cells and 
by T7 endonuclease I assay to assess indel formation at the genomic EGFP target locus 
(Figs. 30e-g).  
Previous reports268,361 have demonstrated that it is possible to modulate SpCas9 
cleavage activity against its targets by altering the structure of the constant portion of 
the guide RNA molecule. To test whether the optimization of the guide RNAs may 
Figure 30 (on previous page). The SLiCES circuit. (a) Scheme of the SLiCES circuit. SpCas9 is expressed together 
with sgRNAs directed to its own open reading frame (ORF) for self-limiting activity and to a selected target sequence. 
(b) GUIDE-seq analysis performed in 293T cells stably expressing SpCas9 and transfected with sgCas-a, -b and –c 
individually. Genomic DNAs obtained from three independent experiments were pooled prior to library preparation. 
(*) The on-target site was not detected in sgCas-b samples since this guide targets the 3xFLAG tag fused to SpCas9 
which was absent from SpCas9 expressed in 293T-Cas9 cells.  (c) Regulation of SpCas9 and EGFP target gene 
expression by the SLiCES circuit. Western blot analysis of 293T cells co-transfected with plasmids expressing EGFP, 
SpCas9 and sgRNAs fully (sgGFP-W) or partially matching (sgGFP-M) the EGFP coding sequence in combination with 
three sgRNAs targeting the SpCas9 ORF (sgCas-a, -b, -c) or a control sgRNA (sgCtr), as indicated. (d) Western blot of 
cells co-transfected with plasmids expressing EGFP-Y66S, SpCas9, sgRNAs perfectly matching (sgGFP-M) or containing 
one mismatch (sgGFP-W) with the EGFP-Y66S target sequence together with sgRNAs specific for the SpCas9 ORF 
(sgCas-a, - b, -c) or a control sgRNA (sgCtr), as indicated. For (c) and (d): Lower graph reports the ratio of the 
percentages of decreased EGFP or EGFP-Y66S levels obtained using on-target sgRNAs over the percentages obtained 
with the off-target sgRNAs in the presence of sgCas-a, -b, -c, as indicated. Lane (-) corresponds to a reference sample 
containing the non-targeting sgCtr only; transfection efficiency was normalized using roTag tagged MHC-Ia 
expression plasmid (Transf-ctr); SpCas9 was detected using an anti-FLAG antibody. (e) Percentage of non-fluorescent 
293-iEGFP cells obtained after expression of different self-limiting SpCas9 circuits. Cells were transfected with sgRNAs 
perfectly matching (sgGFP-W) or containing one mismatch (sgGFP-M) with the EGFP ORF together with three sgRNAs 
targeting the SpCas9 ORF (sgCas-a, -b, -c) or a control sgRNA (sgCtr), as indicated. The dashed line represents the 
average background of EGFP negative cells. (f) On/off ratios were calculated from the percentage of EGFP negative 
cells obtained in (b) with sgGFP-W (on-target) relative to sgGFP-M (off-target) in combination with different SLiCES 
circuits (sgCas-a, -b or -c) or a non-targeting (sgCtr) sgRNA, as indicated in the graph. (g) Representative T7 
Endonuclease assay from cells expressing different SLiCES circuits. The on/off specificity ratio was calculated by 
measuring indels formation in the EGFP gene in the presence of sgGFP-W or sgGFP-M together with a control sgRNA 
or the three sgRNAs targeting the SpCas9 ORF (sgCas-a, -b, -c). Lane (-) corresponds to a reference sample containing 
the non-targeting sgCtr only. (*) Indicates the expected band obtained by T7 endonuclease activity. Error bars in (e) 
and (f) represent s.e.m. for n=2 independent experiments. 
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further improve the on-target specificity, we generated alternative SLiCES circuits 
where the sgRNAs were structurally modified to increase their transcription and their 
interaction with SpCas9, according to previous studies268. The optimization of the 
SpCas9-targeting sgCas-a guide RNA (sgCas-a-opt), which enhances the efficiency of 
nuclease removal as demonstrated by western blot analysis (Fig. 31d), produced a 9-
fold improvement in cleavage specificity when tested in a stable EGFP-expressing cell 
Figure 31 (on previous page). Effect of sgRNAs optimization on SLiCES circuit. (a) Percentage of non-fluorescent 
293-iEGFP cells obtained after transfection of SpCas9 with sgRNAs targeting EGFP (sgGFP-W or sgGFP-W-opt, if 
optimized) or containing a single mismatch (sgGFP-M or sgGFP-M-opt, if optimized) together with the sgCas-a. The 
optimized version of the SLiCES sgRNA (sgCas-a-opt) was tested with both standard and optimized sgRNAs targeting 
EGFP, as indicated. (b) On/off ratios were obtained from the percentage of EGFP negative cells after targeting a single 
chromosomal EGFP gene copy (293-iEGFP cells) with sgGFP-W or sgGFP-W-opt (on-target) relative to sgGFP-M or 
sgGFP-M-opt (off-target) in combination with the self-targeting sgCas-a, its optimized variant, or a non-targeting 
(sgCtr) sgRNA, as indicated in the graph. (c) Percentage of non-fluorescent 293-iEGFP cells obtained after transfection 
of SpCas9 with sgRNAs targeting EGFP (sgGFP-W) or containing a single mismatch (sgGFP-M) together with the sgCas-
c or sgCas-c-opt, if optimized. (d) Western blot analysis of 293T cells co-transfected with SpCas9 and sgCas9-a or 
sgCas-a-opt and sgCas9-c or sgCas-c-opt. SpCas9 was detected using an anti-FLAG antibody. Transfection efficiency 
was normalized using roTag tagged MHC-Ia expression plasmid (Transf-ctr). Error bars represent s.e.m. for n=2 
independent experiments.  
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line, further ameliorating the effect observed with conventional guides (Figs. 31a-b). 
Consistently, the optimization of the least active self-inactivating sgRNA (sgCas-c-opt) 
resulted in reduced off-target activity paralleled by a further decrease in SpCas9 
intracellular levels (Figs. 31c-d). Conversely, the optimization of the sgRNA towards the 
intended target site (sgGFP-W-opt and sgGFP-M-opt) did not increase the specificity in 
combination either with sgCas9-a or sgCas9-a-opt and, on the contrary, produced a 
reduction in the on-/off-target ratio when compared to the standard SLiCES circuit 
(Figs. 31a-b). Presumably, the enhanced downregulation of EGFP driven by the sgGFP-
W-opt correlated also with increased off-target cleavages induced by the sgGFP-M-opt 
sgRNA that could not be counteracted by a sufficiently rapid SpCas9 downregulation 
mediated by both the standard and the optimized versions of the self-limiting sgCas-a 
sgRNA (Figs. 31a-b). In conclusion, the SLiCES circuitry produced the highest on-target 
specificity when composed of an optimized self-limiting sgRNA (sgCas-a-opt), efficiently 
downregulating SpCas9, in combination with a non-optimized sgRNA targeting the site 
of interest (sgGFP-W/M).  
 
Effect of SLiCES on gene editing by homologous recombination 
We next evaluated the effect of the application of SLiCES on the specificity of gene 
targeting obtained by homologous recombination. This is particularly relevant in 
situations where the sequence that has to be edited shares homologies with other 
regions of the genome, for example when only one of the two heterozygous alleles of 
a gene needs to be modified. In addition, the removal of Cas9 soon after the cleavage 
of the target site lowers the possibility of the introduction of further indel mutations 
after homologous recombination with the donor template has occurred, in all the 
instances where the donor sequence cannot be modified to avoid re-editing by Cas9. 
To this aim, we used as an experimental model cells carrying a single chromosomal 
copy of a non-fluorescent EGFP, containing a single nucleotide substitution that impairs 
fluorophore maturation (Y66S). In these cells, 293-iY66S, the recovery of EGFP 
fluorescence following the substitution of the mutated gene with a wild-type allele was 
used to measure SpCas9-mediated homology-directed repair in the presence of a co-
transfected donor plasmid carrying a non-fluorescent fragment of wild-type EGFP. We 
used the sgGFP-M (fully matching to the EGFP Y66S mutant sequence) or the sgGFP-W 
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(containing a single mismatch with the target) sgRNAs to introduce DSBs at the target 
locus. Compared to the conventional SpCas9 approach (sgCtr), the target specificity for 
EGFP homology-directed repair was improved by 4-fold when using the SLiCES circuitry 
driven by the sgCas-a self-targeting guide, as measured by the on/off ratio calculated 
on the percentage of EGFP positive cells obtained after successful gene editing (Figs. 
32a-b). As previously observed, the sgCas-b and sgCas-c sgRNAs were unable to 
increase significantly the discrimination between the matching and the mismatched 
EGFP-targeting guide. Additionally, further improvement (7,5-fold) was obtained with 
the optimized version of sgCas-a (sgCas-a-opt) (Figs. 32a-b), in accordance with 
previous EGFP knockout experiments. 
Altogether, given its superior ability to modulate SpCas9 off-target activity, we decided 
to exploit the sgCas-a-opt self-targeting sgRNAs for further implementations of the 
SLiCES circuit. Nevertheless, the other self-limiting guides, as well as other specifically 
tailored sgRNAs, could be still employed to obtain different circuit behaviours by 
changing the kinetics of SpCas9 downregulation into cells.  
 
Figure 32. Specificity of homology-directed repair mediated by SLiCES. (a) Percentage of fluorescent 293-iY66S 
cells obtained after transfection with a donor DNA plasmid (carrying a non-fluorescent fragment of wt-EGFP), SpCas9 
together with sgRNAs matching (sgGFP-M) or containing one mismatch with the EGFP-Y66S target sequence (sgGFP-
W) and the three sgRNAs targeting the SpCas9 ORF (sgCas-a, -b, -c or sgCas-a-opt) or a control sgRNA (sgCtr), as 
indicated. Homology-directed repair in the absence of sgGFP-M or sgGFP-W was about 0.01%. (b) Target specificity 
of SpCas9 activity expressed as on/off ratios using different self-limiting circuits applied to a gene substitution model. 
On/off ratios were obtained from the percentage of EGFP positive cells generated by SpCas9 homology-directed 
repair of the EGFP-Y66S mutation with the sgGFP-M (on-target) relative to the sgGFP-W (off-target) sgRNAs in 
combination with a DNA donor plasmid (carrying wild-type EGFP sequence) in 293-iY66S cells containing a single 
mutated EGFP gene copy. Error bars represent s.e.m. for n=2 independent experiments.  
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Adaptation of SLiCES to other RNA-guided nucleases 
To demonstrate that the SLiCES methodology is readily transferrable to other RNA-
guided nucleases, this self-limiting approach was adapted to a Cas9 orthologue 
deriving from Streptococcus thermophilus CRISPR1 locus (St1Cas9). We selected three 
self-targeting sgRNAs (sgCas-St1-1, -2 and -3) and verified that they were able to induce 
St1Cas9 downregulation (Fig. 33b) when co-expressed with St1Cas9. To test their effect 
on St1Cas9 specificity we developed a reporter plasmid that allows to easily detect 
cleavage events by measuring NHEJ-dependent expression of EGFP. This NHEJ-reporter 
contains a target sequence recognized by the sgRNA of interest inserted between an 
SV5 tag and the EGFP coding sequences, with the EGFP ORF positioned out of frame 
with respect to the starting ATG codon of the SV5 tag ORF. A stop codon has been 
added to the SV5 frame, immediately after the target sequence, to stop its translation. 
After Cas9-mediated cleavage of the target sequence and repair by NHEJ, indel 
mutations are inserted randomly at the breakpoint, inducing the shift of the EGFP ORF 
in the same frame of the SV5 tag ORF, allowing its detection either directly by 
fluorescence measurements of by western blot through the SV5-tag. If no editing 
occurs, the reporter plasmid expresses only an SV5 peptide of few kDa. A schematic 
representation of the NHEJ reporter is presented in Fig. 33a. We generated alternative 
versions of the NHEJ-reporter containing two target sequences differing for a single 
nucleotide (NHEJ-Rep.W and NHEJ-Rep.M). We next co-transfected 293T cells with 
St1Cas9, an sgRNA perfectly matching the NHEJ-Rep-W together with each self-
targeting sgRNA or a control guide and the NHEJ-Rep.W or the NHEJ-Rep.M reporters. 
Reporter activation was then measured by western blot revealing efficient on-target 
cleavage (activation of the NHEJ-Rep.W) when St1Cas9 was expressed with both sgCas-
St1-1 and sgCas-St1-2 sgRNAs, while less activity was detected in the presence of the 
sgCas-St1-3 self-targeting guide RNA (Fig. 33b). When off-target activity was assessed 
by quantifying NHEJ-Rep.M activation, we observed increased discrimination of the off-
target site in the presence of the SLiCES circuit driven by sgCas-St1-1, while no relevant 
effect was obtained with the other two self-targeting guide RNAs, as demonstrated by 
the on/off ratios calculated from the densitometric analysis of western blot images 
(Figs. 33b-c). These data indicate that the SLiCES technology can be easily adapted to 
other RNA-guided nucleases without major modification to circuit design, provided 
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that a self-targeting guide RNA with the desired characteristics can be identified. 
 
	
 
SLiCES specificity towards endogenous genomic loci 
Next, the target specificity of SpCas9 and of the most effective version of the SLiCES 
circuit (driven by sgCas-a-opt) were comparatively analysed. After transfection of the 
SLiCES components into 293T cells, four genomic sites (VEGFA site 3, ZSCAN2 and two 
targets in the EMX1 locus, EMX1-K and EMX1-R) and two previously validated off target 
sites347 for each sgRNA were analysed by Tracking of Indels by DEcomposition (TIDE)310 
Figure 33. Activity of SLiCES with Streptococcus thermophilus CRISPR1/Cas9. (a) Schematic representation of the 
SV5-GFP-based NHEJ reporter. (b) Evaluation of St1Cas9 activity expressed through the SLiCES system. Western blot 
of 293T cells transfected with St1Cas9, the NHEJ reporter carrying either a target sequence that fully base pairs with 
the sgRep-SV5 (NHEJ-Rep.W) or including one mismatch (NHEJ-Rep.M), the sgRNA sgRep-SV5 and three different 
St1Cas9 targeting sgRNAs (sgCas- St1, -2, -3). St1Cas9 mediated cleavages are detected by frameshift of the EGFP ORF 
and SV5-EGFP expression by the NHEJ reporter. Lane (sgCtr) corresponds to a sample transfected with a non-self-
targeting sgRNAs; lane (-) corresponds to a sample transfected with a non-targeting sgRNA. St1Cas9 was detected 
using an anti-FLAG antibody. Western blot is representative of n=2 independent experiments. (c) Modulation of 
St1Cas9 expression by self-limiting circuits increases on target specificity. On/off target ratios calculated from levels 
of SV5-EGFP expression obtained from cells transfected with NHEJ- Rep.W or NHEJ-Rep.M together with sgRep-SV5 in 
combination with St1Cas9 targeting sgRNAs (sgCas-St1, -2, -3) or a non-self-targeting sgRNAs sgCtr, as in (b).  Error 
bars represent s.e.m. for n=2 independent experiments.  
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revealing that the SLiCES approach increased cleavage specificity by approximately 1.5-
2.5 fold, as measured by the fold improvement in the on/off ratio, without significantly 
diminishing on-target cleavage efficiency (Figs. 34a-d). These results, in accordance 
with previous data obtained on both transient and stable EGFP experimental models, 
demonstrated the efficiency of SLiCES in reducing SpCas9 off-target activity.  
 
	
	
Adaptation of SLiCES to lentiviral delivery 
Lentiviral vectors are optimal tools for the delivery of transgenes by enabling the 
transduction of difficult-to-transfect cell lines and primary cells as well as for their in 
vivo applicability. The self-limiting SpCas9/sgRNA circuitry regulated by the best 
selected self-limiting sgRNA (sgCas-a-opt) was thus transferred to a lentiviral system to 
Figure 34. Activity of SLiCES on endogenous loci. Indels formation induced by the SLiCES circuit (sgCas-a-opt) 
targeting the VEGFA site 3, ZSCAN2, EMX1 loci and their respective validated off-target sites. Fold increase (F.I.) of the 
on/off ratio with the sgCas-a-opt relative to the sgCtr is reported below the graphs for each off-target. Percent 
modification was quantified by TIDE analysis. Error bars represent s.e.m. for n=2 independent experiments.  
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generate lentiSLiCES (Figs. 35a-b). Two technical expedients had to be adopted in order 
to implement an all-in-one lentiviral system to deliver SLiCES. First of all, to avoid the 
leaky expression of SpCas9, and the consequent degradation of DNA during plasmid 
preparation in bacteria, an intron was introduced into the SpCas9 open reading frame 
to form an expression cassette divided in two exons (exon 1 and 2, schematized in Fig. 
35a). As splicing does not occur in bacteria, the transcripts produced are translated as 
a catalytically inactive SpCas9 fragment. Second, to circumvent the self-cleavage 
activity during lentiviral vector production, Tetracycline inducible (TetO) promoters 
were introduced to regulate both SpCas9 and the self-targeting sgRNA expression. The 
TetO promoter is negatively regulated by a specific repressor, TetR, which is expressed 
in producing cells and, in the absence of doxycycline, inhibits transcription through its 
binding to tetracycline operator sequences located within the SpCas9 and sgRNA 
promoter regions (schematized in Fig. 35b).  
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To verify the efficacy of this failsafe mechanism, we analysed producer cell lysates 
during vector production. Even in the absence of doxycycline, we detected low levels 
of Cas9 expression likely connected to the translation of spliced viral genomes, 
generated by LTR-driven unrepressed transcription (Fig. 35c). Notably, no reduction in 
SpCas9 intracellular levels was observed in the presence of the sgCas-a-opt self-
targeting sgRNA, indicating that the additional repression of the self-targeting guide 
promoter was effectively blocking SpCas9 self-editing (Fig. 35c). On the other hand, the 
drop of SpCas9 intracellular levels in producing cells observed with the activation of 
the self-limiting circuitry by the addition of doxycycline to the culture medium 
demonstrates the strict requirement of the repressible promoters at viral production 
steps in order to obtain un-altered lentiSLiCES particles (Fig. 35c).  
	
Characterization of lentiSLiCES specificity 
To evaluate the on/off target activity of lentiSLiCES, we followed the percentage of EGFP 
negative 293-multiEGFP cells at different time points after transduction with self-
limiting lentiviral vectors either carrying the specific sgRNA sgGFP-W (lentiSLiCES-W) or 
the mismatched sgGFP-M (lentiSLiCES-M). We then compared these measurements 
with the effect obtained with corresponding non-self-limiting lentiviral vectors 
expressing the same sgRNAs directed towards EGFP (lentiCtr-W or –M). Both lentiCtr-
W and lentiSLICES-W showed similarly stable on-target activity at all the time points 
within a 3 weeks period (Fig. 36a). Conversely, the percentage of EGFP cells 
unspecifically targeted by the sgGFP-M increased in time with the lentiCtr delivery 
system; this effect was not observed when the same was sgRNA delivered through 
lentiSLiCES throughout the 3 weeks period (Fig. 36a). Therefore, lentiSLiCES generated 
no off-target accumulation in time (compare day 7 and day 21, Fig. 36a). Consistently, 
Figure 35 (on previous page). lentiSLiCES. (a) Graphical representation of lentiSLiCES viral vector. (b) Steps 
required for the production of the lentiSLiCES viral vectors. SpCas9 expression is prevented in bacterial cells to allow 
plasmid amplification through the introduction of a mammalian intron within the SpCas9 open reading frame. 
Production of lentiSLiCES viral particles is obtained in cells stably expressing the Tetracycline Repressor (TetR) to 
prevent SpCas9 and sgCas self-limiting sgRNA expression driven by Tet repressible promoters. In target cells the 
absence of the TetR allows the expression of the lentiSLiCES circuit leading to target genome editing and 
simultaneous SpCas9 downregulation. (c) lentiSLiCES circuit behaviour in viral vector packaging cells. Western blot 
analysis of 293TR cells transfected with EGFP and self-limiting or non- self-limiting transfer vectors carrying sgGFP-W 
(lentiSLiCES-W or lentiCtr-W, respectively), or with lentiSLiCES carrying a non-targeting sgRNA (lentiSLiCES-Ctr). 
Cultures were treated as indicated with doxycycline to upregulate expression of SpCas9 and of the self-targeting 
sgCas-a-opt. SpCas9 was detected using an anti-FLAG antibody. Western blot is representative of n=2 independent 
experiments. 
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at the end-point we observed the largest difference between the ratios of the EGFP 
negative cells obtained with the sgGFP-W over the sgGFP-M delivered either through 
the lentiSLICES (on/off ratio ~5) or the lentiCtr systems (on/off ratio ~2) (Fig. 36b).  
We then evaluated the effect of lentiSLiCES on the editing of the VEGFA site 3 and 
ZSCAN2 genomic loci and related off-target sites. In agreement with previous results 
on the EGFP locus, the target specificity of lentiSLiCES towards these endogenous 
sequences showed significant improvement as compared to the non-self-limiting 
lentiCtr (approximately 2-4 fold increase when considering the on/off-ratios) (Fig. 36c-
d). Of note, we also observed a reduction in the cleavage efficiency of the on-target 
sites that was more pronounced for the ZSCAN2 locus and was most likely connected 
with the transient nature of SpCas9 expression induced by the self-limiting circuit (Fig. 
36c). These data suggest that the decreased expression of SpCas9 obtained through 
the SLiCES circuit improves editing specificity. Indeed, at early time points (2 days post-
transduction) the SpCas9 protein was already much less present in cells treated with 
the lentiSLiCES than in cells treated with the non-self-limiting lentiviral control (lentiCtr) 
(Fig. 36e). Notably, in lentiCtr treated cells the levels of SpCas9 remained stable and 
higher than in lentiSLiCES transduced cells, where no nuclease could be detected at 
any later time point. To functionally assess the level of SpCas9 activity delivered 
through lentiSLiCES, the NHEJ reporter plasmid (NHEJ-Rep.W) expressing an SV5 tag 
fused with EGFP (SV5-EGFP) upon targeted nuclease activity (schematized in Fig. 33a) 
was transfected in cells transduced with lentiSLiCES or lentiCtr non self-limiting vectors 
both expressing a guide RNA that was able to recognize the target sequence inserted 
in the reporter. Activation of the reporter thus correlates with the residual SpCas9 
activity. The NHEJ-Rep.W revealed that SpCas9 delivered through the lentiCtr was active 
at all time points following transduction, as expected, while the activity of SpCas9 
carried by the lentiSLiCES was detected 2 days after transduction, but could not be 
observed at later time points (30 days), indicating correct disruption of the SpCas9 
coding sequence by the self-targeting sgRNA (Fig. 36f).  
Altogether these data demonstrate the efficient adaptation of the SLiCES circuit to an 
all-in-one lentiviral vehicle that after transduction efficiently edits the intended locus 
while reducing off-target cleavages and promoting a parallel switch-off mechanism, 
leaving no long-term trace of SpCas9 activity in transduced cells.  
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Figure 36. Genome editing with lentiSLiCES vectors. (a) EGFP knock-down by lentiSLiCES vectors. Time course 
curves of the percentages of EGFP negative 293-multiEGFP cells, following transduction with lentiviral vector carrying 
self-targeting (lentiSLiCES) or non-self-targeting (lentiCtr) sgRNAs in combination with either sgGFP-W (on-target) or 
sgGFP-M (off-target) sgRNAs, as indicated in the graph. Error bars represent s.e.m. for n=2 independent experiments. 
(b) Target specificity of SpCas9 delivered through the lentiSLiCES. On/off ratios were calculated from the percentages 
of EGFP negative cells reported in (a). Below the graphs is reported the fold increase (F.I.) of specificity calculated 
from the on/off ratios at each time point. Error bars represent s.e.m. for n=2 independent experiments. (c-d) Indel 
formation induced by lentiSLiCES vectors at the ZSCAN and VEGFA loci and at their validated off-target sites. Percent 
modification was quantified by TIDE analysis on genomic DNA collected 20 days post-transduction and selection with 
blasticidin. Values indicate the on/off ratios calculated from indels obtained with each off target. Error bars represent 
s.e.m. for n=2 independent experiments. (e) Expression levels of SpCas9 at the indicated time points after 
transduction with lentiSLiCES or with lentiCtr. SpCas9 was detected using an anti-FLAG antibody. Western blot is 
representative of n=2 independent experiments.  (f) SpCas9 activity was monitored by SV5-EGFP protein levels 
produced by the NHEJ-reporter plasmid transfected in 293-multiEGFP cells one day before or 28 days after 
transduction with lentiSLICES targeting EGFP (lentiSLiCES-W) or with a lentiSLiCES control vector (lentiSLiCES-Ctr). 
Cas9 activity was detected at 2 days or 30 days post-transduction, as indicated. The activity of the non-self-limiting 
lentiCtr-W vector targeting EGFP was monitored at the same time points for comparison. Western blot is 
representative of n=2 independent experiments.  
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Discussion 
 
The limitations of SpCas9-based genome editing clearly emerge from our data showing 
that long term nuclease expression delivered through lentiviral systems as well as the 
short-term transient expression of Cas9 may result in the generation and the 
accumulation of unwanted cleavages in cellular genomes. This issue is particularly 
relevant to the field and has been widely reported in literature305,331,341,347,348,362,363, 
raising concerns on the prospective therapeutic application of Cas9 into patients. Of 
note, in some instances, this detrimental effect could not be completely overcome even 
with the recently developed, more specific, SpCas9 variants eSpCas9(1.1)348 and 
SpCas9-HF1347. This limitation is even more obvious where the choice for the sgRNA is 
constrained by the target site. A practical real-world example derives from diseases 
associated to SNPs, where the correction of the genomic site through HDR requires 
nuclease cleavage in close proximity to the target nucleotide364. Similarly, the 
correction of highly homologous genes involved in diseases (i.e. SMN, Ig and TCR 
genes) significantly limits the choice of sgRNAs or requires high levels of specificity to 
discriminate between the target site and its very similar homologous copies. Thus, 
where off-target cleavages cannot be avoided by a careful choice of the guide RNA 
sequence due to experimental limitations, Cas9-mediated editing would certainly 
benefit from those strategies that allow to increase the nuclease on-/off-target ratio.  
Several methods to reduce Cas9 off-target activity have been designed in the past years 
and a major step forward towards the solution of this issue was the development of 
high-fidelity Cas9 variants. Two groups used rational structure-guided protein 
engineering to design mutants with increased specificity347,348, however we believe that 
the unbiased screening approach we employed in the present study allows the 
identification of non-trivial substitutions leading to a further increase in specificity, as 
demonstrated by the isolation of evoCas9, as well as other alternative variants we did 
not characterize in detail yet. In addition, once built, our yeast platform can be easily 
adapted with minimal modifications to screen for improved variants of other RNA-
guided nucleases as well as for the identification of additional mutations reducing off-
target activity in other SpCas9 domains.  
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When compared side-by-side with eSpCas9(1.1) and SpCas9-HF1 using an EGFP 
knockout reporter assay, evoCas9 demonstrated superior performance in off-target 
discrimination, with the ability to almost completely avoid the cleavage of a sequence 
containing a single mismatch in a very PAM-distal position, a feature completely absent 
from previously published mutants. Accordingly, when the same assay was repeated 
prolonging evoCas9 expression by lentiviral transduction, the differences with the wild-
type protein and SpCas9-HF1 were even more pronounced, although the control of the 
same PAM-distal mismatched target was only partial. Similarly, when we tested 
evoCas9 off-target activity against endogenous loci we could detect cleavage only for 
sites differing from the intended target by one nucleotide (FANCF site 2 and CCR5) or 
relative to highly repetitive target sequences (VEGFA site 2 and site 3). Overall, these 
results indicate that careful sgRNA selection, when possible, is crucial to avoid residual 
levels of unspecific cleavage and the exploitation of widely available online sgRNA 
design tools can help in predicting possible obvious matches in the target genome. 
Importantly, in our experimental conditions evoCas9 was generally characterized by a 
further 2 to 4-fold reduction in off-target activity if compared to SpCas9-HF1 (Fig. 20 
and Fig. 24), that already reduced unwanted cleavages to background levels for many, 
but not all, of the tested sites347. In particular, GUIDE-seq analysis of the VEGFA site 2 
locus off-target sites captured only 10 sites for evoCas9, while identifying around 600 
loci for the wild-type nuclease: previously published results reported ~20 sites for 
SpCas9-HF1 together with only ~150 sites for wild-type Cas9347, most likely indicating 
lower sequencing depth that may have led to an underestimation of SpCas9-HF1 off-
target activity.  
The characterization of evoCas9 on-target activity revealed a partial loss of editing for 
some of the endogenous tested sites that was particularly pronounced for the ZSCAN2 
locus. This effect could indicate a trade-off between specificity and cleavage activity, 
where the reduction of the binding and cleavage of off-target sites is paralleled to a 
lesser extent by a similar effect on the on-target site, and has been observed also in 
previously published reports347. The combination of evoCas9 with optimized guide 
RNAs, which we demonstrated to be compatible with our variant, may help in reverting 
this loss of activity given their general ability to improve SpCas9 functionality361. Our 
yeast screen allowed the identification of several substitutions that may be further 
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combined to generate alternative high-fidelity variants with a different balance in the 
trade-off between specificity and activity. In addition, further screening using our yeast 
platform could lead to the identification of other mutations not yet discovered in the 
present study. Alternatively, the extension of the duration of SpCas9 expression 
through stable transduction of target cells may increase the overall editing efficiency. 
As we have demonstrated, evoCas9 is indeed able to avoid cleavage of at least some 
off-target sites even after prolonged expression into cells (Fig. 28).  
Additional investigations will be necessary to understand the mechanism behind 
evoCas9 increased specificity. Preliminary observations obtained using an evoCas9-
based transcriptional activator revealed that our variant bound DNA less efficiently 
than the wild-type protein. This suggests that the modifications introduced in evoCas9 
reduce the strength of the non-sequence specific interactions between the nuclease 
and the target DNA backbone. Binding and cleavage will be thus more dependent on 
the perfect base pairing of the spacer RNA sequence with the target DNA. Further 
biochemical characterization will clarify the kinetic details of evoCas9 interaction with 
the target DNA and of the cleavage reaction. The solution of the crystal structure of 
evoCas9 in complex with a mismatched target DNA or in silico modelling approaches 
starting from available structural data will provide important insights on the effects of 
the substitutions introduced in the variant on off-target recognition. In addition, 
valuable information could be gathered to explain the particular behaviour observed 
when evoCas9 was tested with sgRNA longer than 20 nucleotides or containing a 
mismatched guanine at the 5’-end of the spacer sequence (position 20), leading to a 
complete loss of cleavage activity.  
Finally, it is possible to speculate that a further improvement of targeting specificity 
could be obtained by the combination of evoCas9 with some of the previously 
proposed methods to reduce off-target activity, such as paired Cas9 nickases325 or RNP 
delivery. However, there is no absolute compatibility, as we demonstrated that tru-
gRNAs322 cannot be combined with evoCas9 without a significant drop in cleavage 
efficiency. 
Permanent expression of Cas9 into target cells represents an issue that in some cases 
even SpCas9 mutants with highly increased fidelity, such as evoCas9, may not be able 
to handle. Different methods, such as RNP delivery or RNA transfection, have been 
Discussion 
	 111 
proposed as a way to reduce Cas9 permanence into cells. However, these delivery 
methods are highly inefficient for in vivo treatments. Our self-limiting circuit strategy, 
lentiSLiCES, exploits the efficiency of viral based delivery and simultaneously limits the 
intracellular amount of SpCas9 post-transduction and viral integration. By limiting in 
time and abundance Cas9 expression, SLiCES avoids the accumulation of off-target 
cleavages that instead are observed with the use of conventional Cas9 delivery 
approaches. The use of integrating lentiviral vectors coupled to our self-targeting 
strategy may rise safety concerns associated with the potential introduction of 
unwanted chromosomal translocations between multiple copies of integrated vectors 
after self-editing. Nevertheless, fine tuning of the amount of vector used should limit 
the amount of integration to a single event per cell. In addition, the quick kinetics of 
Cas9 downregulation (see Fig. 36e), may suggest that self-editing of the Cas9 transgene 
occurs before integration, thus limiting the damage at the level of the cellular genomic 
DNA. Furthermore, to improve the safety of the SLiCES strategy, Integrase Defective 
Lentiviral Vectors (IDLV)365 could be used to maintain the viral-based efficiency in 
cellular delivery, while avoiding any possible issue related to lentiviral integration.  
A variety of Cas9 applications, such as the regulation of gene expression obtained by 
the combination with transcriptional activation domains262,265,323 might be significantly 
improved through their adaptation to lentiSLiCES. In fact, these approaches as well as 
the refined modulation of gene expression obtained with a genetic kill-switch 
circuit366,367 could be potentiated by a tunable self-limiting approach to restrict in time 
Cas9-mediated induction of the targeted cellular promoters. Finally, SLiCES may 
significantly improve some recently developed Cas9 genome engineering procedures 
that are susceptible to continuous nuclease activity. For instance, current techniques 
to efficiently substitute genomic sequences use Cas9 to increase the rate of homology-
directed repair; nevertheless, these techniques are often limited by the continuous re-
cleavage of the newly substituted genomic sequence by Cas9364. Even though 
modification of the exogenous donor template by introducing silent mutations in the 
targeted sequence or at the PAM level may help in avoiding re-editing by Cas9, it is not 
always an applicable strategy. This may occur where the sequence of nucleotides 
surrounding the edited base or region has a biological significance and cannot be thus 
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modified (e.g. non coding sequences, binding sites). In all these cases the nuclease 
inactivation strategy presented in this thesis work represents a valid alternative. 
Similar approaches aimed at controlling Cas9 activity have been recently developed by 
exploiting various inducible systems341. Nevertheless, the methodologies reported so 
far suffer from a number of limitations going from decreased editing activity generated 
by nuclease splitting368 or chemical modification342 to background activity344 or 
extended time of required induction343. 
lentiSLiCES offers an efficient delivery tool that after editing creates a nuclease-free 
cellular environment, greatly improving the safety margins of the CRISPR technology. 
Notably, at the systemic level, a pre-existing immunity against SpCas9 was recently 
proved in mice369 suggesting that in vivo approaches will be severely limited by the 
immune response against the nuclease; thus the transient nature of the SLiCES system 
may have a significant impact for CRISPR clinical use.  
The development of evoCas9, characterized by a highly increased fidelity, aims to 
address pressing safety issues associated with the use of Cas9 into the clinic370, in order 
to contribute to fill the gap between bench and bedside for this promising technology. 
The increased specificity of evoCas9 for the first time ever could allow the design of 
therapeutic strategies based on the editing either by NHEJ or HDR of highly 
homologous sequences, differing only for one or few bases, for example when only 
one pathogenic allele must be targeted. 
Overall, the “hit and go” nature of SLiCES and its adaptability to new emerging Cas9 
techniques, combined with the implementation of its viral delivery, allows more 
controllable genome editing procedures with limited unwanted off-target activity. On 
the other hand, the identification of evoCas9, that retains near-wild type levels of on-
target cleavage while reducing off-target activity to levels below those obtained with 
the best performing variants reported so far, represents a step towards the generation 
of a CRISPR toolbox more suitable for therapeutic applications as well as for basic 
research.  Furthermore, it is possible to envision the combination of lentiSLiCES with 
evoCas9 to obtain an all-in-one safe and error-free genome editing platform for more 
reliable in vivo approaches. 
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Contribution to the experiments 
 
All the experiments not specifically mentioned below were performed by myself. 
 
Identification of high-fidelity SpCas9 variants: 
The experiments involving the generation of the yeast reporter strains for the 
evaluation of Cas9 on- and off-target activity, the screening for the selection of high-
fidelity SpCas9 variants in yeast and their validation in the EGFP-knockout mammalian 
system were performed together with Michele Olivieri, during his Master thesis and 
some months after his graduation. 
Library preparation for GUIDE-seq off-target analysis was performed by Francesca 
Lorenzin.  
Bioinformatics analyses for the GUIDE-seq experiments were performed by Davide 
Prandi, while the analyses related to targeted deep-sequencing experiments for off-
target activity evaluation were carried out by Alessandro Romanel. 
 
Self-limiting Cas9 circuits: 
The experiments involving the transient transfection of plasmid DNA for the set up and 
the initial evaluation of SLiCES behaviour were performed by Gianluca Petris, who also 
helped to conduct the TIDE analyses to measure lentiSLiCES specificity against 
endogenous loci. 
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• High-fidelity SpCas9 variants related oligos 
 
Table 1. Primers used for plasmid cloning 
 
 Table 2. Primers used yeast reporter cassette construction  
Primer name Sequence (5’- … -3’) 
Rec1-II-NheI-F CCAGAAAGCACAAGTTGCTAGCCAGGGGGACAGTC 
Rec1-II-NheI-R GACTGTCCCCCTGGCTAGCAACTTGTGCTTTCTGG 
Rec1-II-NcoI-F CAGCGCACTTTCGACCATGGAAGCATCCCCCA 
Rec1-II-NcoI-R TGGGGGATGCTTCCATGGTCGAAAGTGCGCTG 
T3-Forward  AATTAACCCTCACTAAAGGG 
T7-Reverse  TAATACGACTCACTATAGGG 
sgRNA-Ontarget-F CTCGTGACCACCCTGACCTAGTTTTAGAGCTAGAAATAGCAA 
sgRNA-Ontarget-R  TAGGTCAGGGTGGTCACGAGGATCATTTATCTTTCACTGCG 
Apa-ZhangCas-F ACGTGGGCCCTCTGGCCAG 
Nhe-ZhangCas-R TACGCTAGCTCCCTTTTTCTTTTTTGCCTGG 
Apa-JoungCas-F ATTAGGGCCCCCTGGCCCGAGGGAAC 
Spe-JoungCas-R TAATACTAGTGACTTTCCTCTTCTTCTTGGG 
Primer name Sequence (5’- … -3’) 
TRP1-genomic-F CCAAGAGGGAGGGCATTGG 
TRP1Pt1-ON-Kpn-R 
TGCGGTACCGTAGGTCAGGGTGGTCACGAGTTAGAGGAACTCTTGG
TATTCTTGC 
TRP1Pt2-Kpn-F TTAGGTACCGTAATCAACCTAAGGAGGATGTTT 
TRP1-genomic-R TGCTTGCTTTTCAAAAGGCCTG 
ADE2-genomic-F TGCCTAGTTTCATGAAATTTTAAAGC 
ADE2Pt1-OFF1-Bam-R 
CCAGGATCCGGAGGTCAGGGTGGTCACGAGTTAGACGCAAGCATCA
ATGGTAT 
ADE2Pt1-OFF2-Bam-R 
CCAGGATCCGTAGGTAAGGGTGGTCACGAGTTAGACGCAAGCATCA
ATGGTAT 
ADE2Pt1-OFF3-Bam-R 
CCAGGATCCGTAGGTCAGGGCGGTCACGAGTTAGACGCAAGCATCA
ATGGTAT 
ADE2Pt1-OFF4-Bam-R 
CCAGGATCCGTAGGTCAGGGTGGTAACGAGTTAGACGCAAGCATCA
ATGGTAT 
ADE2Pt2-Bam-F ATTAGGATCCTGGTGTGGAAATGTTCTATTTAG 
ADE2-genomic-R GTAATCATAACAAAGCCTAAAAAATAG 
TRP1-CORE-F 
TATTGAGCACGTGAGTATACGTGATTAAGCACACAAAGGCAGCTTGG
AGTTAGGGATAACAGGGTAATTTGGATGGACGCAAAGAAGT 
TRP1-CORE-R 
TGCAGGCAAGTGCACAAACAATACTTAAATAAATACTACTCAGTAATA
ACTTCGTACGCTGCAGGTCGAC 
ADE2-CORE-F 
CCTACTATAACAATCAAGAAAAACAAGAAAATCGGACAAAACAATCA
AGTTAGGGATAACAGGGTAATTTGGATGGACGCAAAGAAGT 
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Table 3. On and off target sites used to generate the yACMO strains 
 
Table 4. Error-prone PCR primers 
 
Table 5. Spacer sequences used to prepare sgRNAs for reporter assays 
ADE2-CORE-R 
ATATCATTTTATAATTATTTGCTGTACAAGTATATCAATAAACTTATAT
ATTCGTACGCTGCAGGTCGAC 
Target name Sequence (5’- … -3’, with lowercase PAM), mismatch in bold 
TRP1-on CTCGTGACCACCCTGACCTAcgg 
ADE2-off1 CTCGTGACCACCCTGACCTCcgg 
ADE2-off2 CTCGTGACCACCCTTACCTAcgg 
ADE2-off3 CTCGTGACCGCCCTGACCTAcgg 
ADE2-off4 CTCGTTACCACCCTGACCTAcgg 
Primer name Sequence (5’- … -3’) 
epPCR-F 
GTCTAAAAATGGCTACGCCGGATACATTGACGGCGGAGCAAGCCAG
GAGG 
epPCR-R 
TCTCGGGCCATCTCGATAACGATATTCTCGGGCTTATGCCTTCCCATT
AC 
Target name Spacer sequence (5’- … -3’) 
GFPon GGGCACGGGCAGCTTGCCGG 
GFP1314 GGGCACCCGCAGCTTGCCGG 
GFP1819 GCCCACGGGCAGCTTGCCGG 
GFP18 GGCCACGGGCAGCTTGCCGG 
GFP site 2 GTCGCCCTCGAACTTCACCT 
GFP site 14 GAAGGGCATCGACTTCAAGG 
GFP site 16 GCTGAAGCACTGCACGCCGT 
GFP site 18 GACCAGGATGGGCACCACCC 
GFP site 20 GAAGTTCGAGGGCGACACCC 
GFPon-19nt GGCACGGGCAGCTTGCCGG 
GFPB-18nt GGCAAGCTGCCCGTGCCC 
GFPW-17nt GTGACCACCCTGACCTA 
GFP site 20 (+G) gGAAGTTCGAGGGCGACACCC 
GFP site 25 (+G) gCCTCGAACTTCACCTCGGCG 
GFP site 25 (19+G) gCTCGAACTTCACCTCGGCG 
GFP site 25 (+2+G) gGCCCTCGAACTTCACCTCGGCG 
GFP site 25 (+3+G) gCGCCCTCGAACTTCACCTCGGCG 
GFP site 25 (+2) GCCCTCGAACTTCACCTCGGCG 
GFP 5’-C CTCGTGACCACCCTGACCTA 
GFP 5’-C+G gCTCGTGACCACCCTGACCTA 
GFP 5’-T TTCAAGTCCGCCATGCCCGA 
GFP 5’-T+G gTTCAAGTCCGCCATGCCCGA 
GFP 5’-A ACCATCTTCTTCAAGGACGA 
GFP 5’-A+G gACCATCTTCTTCAAGGACGA 
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5’- mismatched nucleotides are indicated in lowercase. Mutations are indicated in bold. 
 
Table 6. Targeted deep-sequencing oligos  
Common forward overhang: 5’-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG-3’ 
Common reverse overhang: 5’-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG-3’ 
Mutations are indicated in bold. PAM are included in lowercase. 
 
• SLiCES circuits 
 
Table 7. Primers used for lentiSLiCES plasmid cloning 
TetO-on GTGATAGAGAACGTATGTCG 
TetO-on+G gGTGATAGAGAACGTATGTCG 
TetO-off6 GTGATAGAGAACGTCTGTCG 
TetO-off1314 GTGATACTGAACGTATGTCG 
TetO-off1819 GACATAGAGAACGTATGTCG 
Locus  Target Forward (5’-…-3’) Reverse (5’-…-3’) 
EMX1-on GAGTCCGAGCAGAAGAAGAAggg CCGGAGGACAAAGTACAAACGGC AAGCAGCACTCTGCCCTCGTG 
EMX1-ot1 GAGTTAGAGCAGAAGAAGAAagg CTTTTATACCATCTTGGGGTTACAG CTAGGAAAGATTAACAGAGAGTCTGAC 
EMX1-ot2 GAGTCTAAGCAGAAGAAGAAgag CAATGTGCTTCAACCCATCACGGC CCTCTACTTCATTGTACTCAAGGTAAG 
EMX1-ot3 AAGTCTGAGCACAAGAAGAAtgg TAGTTCTGACATTCCTCCTGAGGG CTCTGTTGTTATTTTTTGGTCAATATCTG 
EMX1-ot4 GAGTCCTAGCAGGAGAAGAAgag AAAGCCTGGAGGCTGCCAGGT ATCTAGCTGTCCTGTCTCATTGGC 
EMX1-ot5 GAGGCCGAGCAGAAGAAAGAcgg CAGGAGCCGGGTGGGAG CCTCAGCCTTCCCTCAGCCAC 
VEGFA3-on GGTGAGTGAGTGTGTGCGTGtgg CTGGGTGAATGGAGCGAGCAG GGAAGGCGGAGAGCCGGACA 
VEGFA3-ot1 AGTGAGTGAGTGTGTGTGTGggg GAAGGGGAGGGGGAAGTCACC CGTGCGTGCCGCCGTTGATC 
VEGFA3-ot2 TGTGGGTGAGTGTGTGCGTGagg TCTGTCACCACACAGTTACCACC GTAGTTGCCTGGGGATGGGGTATG 
VEGFA3-ot3 GCTGAGTGAGTGTATGCGTGtgg CACCTGGCCCATTTCTCCTTTGAGG TGGGGACAGCATGTGCAAGCCACA 
VEGFA3-ot4 GGTGAGTGAGTGTGTGTGTGagg GGACCCCTCTGACAGACTGCA CACACACCCTCACATACCCTCAC 
VEGFA3-ot5 AGAGAGTGAGTGTGTGCATGagg GGAAGAATGCAAAGGAGAAGCAAGTAC GACCTGGTGGGAGTTGATTGGATC 
VEGFA3-ot6 AGTGTGTGAGTGTGTGCGTGtgg CCTTGGGAATCTATCTTGAATAGGCCT GACACCCCACACACTCTCATGC 
VEGFA3-ot7 TGTGAGTAAGTGTGTGTGTGtgg CCTAAGCTGTATGTGAGTCCCTGA CTGTTTTGCTAAGAGATGATTAGATGGTC 
VEGFA3-ot8 GTTGAGTGAATGTGTGCGTGagg GCCCTCTCCGGAAGTGCCTTG GAAGGGTTGGTTTGGAAGGCTGTC 
VEGFA3-ot9 GGTGAGTGAGTGCGTGCGGGtgg CCACAGGAATTTGAAGTCCGTGCT CCCCACGTCCACCCATACACAC 
VEGFA3-ot10 AGCGAGTGGGTGTGTGCGTGggg GACGTCTGGGTCCCGAGCAGT GGCCGTCAGTCGGTCCCGA 
VEGFA3-ot11 TGTGAGTGAGTGTGTGCGTGtga GGAGGGTTGAACTGTGACAGAACTG TGAGTATGTGTGAGTGAGAGTGTGCA 
VEGFA3-ot12 ACTGTGTGAGTGTGTGCGTGagg GATCCTTAGGCGTGCGTGTGC CACCGGCACAGTGACACTCAC 
VEGFA3-ot13 TGTGAGTGAGTGTGTGTATGggg AGACCTTCAATGTGGATGTGCGTG CATAGAGTGTAGCAGATTTCCATAACTTC 
Primer name Sequence (5’- … -3’) 
Cas9-intron-F 
CTTTAAAGAGGACATCCAGAAAGCCCAGGTAAGGGGCTCACAGTAG
C 
Cas9-intron-R 
CGTGCAGGCTATCGCCCTGGCCGGACACCTGTGGAGAGAAAGGCAA
AG 
Xho-CMV-F ATTACTCGAGGTTGACATTGATTATTGACTAGTTA 
CMV-TO-Bam-R AATGGATCCTCTCCAGGCGATCTGACG 
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Table 8. Spacer sequences used to prepare sgRNAs  
Mismatched 5’-G are indicated in lowercase. Mutations are indicated in bold. 
 
Table 9. Target sequences for S. thermophilus NHEJ reporters  
Mutations are indicated in bold. 
 
• sgRNAs targeting genomic sites and oligos to amplify each locus 
 
Table 10. Spacer sequences for genomic targets & oligos for the amplification of genomic loci 
Mlu-EMCV-IRES-F ATTAACGCGTGTTATTTTCCACCATATTGCCG 
Blast-Mlu-R ATTAACGCGTTTAGCCCTCCCACACATAAC 
Eco-H1TOgRNA-F 
TAATGAATTCTAGTAGAATTGAGGTACCAATATTTGCATGTCGCTATG
TG 
gRNA-MfeI-R ATTCAATTGAAAAAAGCACCGACTCGGTGC 
Nhe-STOP-Mlu-1 CTAGCTGATAATGTACA 
Nhe-STOP-Mlu-2 CGCGTGTACATTATCAG 
Target name Spacer sequence (5’- … -3’) 
Cas-a gTACGCCGGCTACATTGACGG 
Cas-b GATCCTTGTAGTCTCCGTCG 
Cas-c GGCTACGCCGGCTACATTGA 
GFPW gCTCGTGACCACCCTGACCTA 
GFPM gCTCGTGACCACCCTGACCTC 
GFPMM gCTCGTCACCACCCTGACCTC 
STh1-1 GGCAGAAGGCTGACCCGGCG 
STh1-2 gGCCTACAGAAGCGAGGCCC 
STh1-3 gAGACTAACGAGGACGACGA 
RepSV5 GTCCCCTCCACCCCACAGTG 
Target name Target sequence (5’- … -3’, PAM in lowercase) 
NHEJ-Rep.W GTCCCCTCCACCCCACAGTGcaagaaa 
NHEJ-Rep.M GTCCCCTCCACCCAACAGTGcaagaaa 
Locus  Target Forward (5’-…-3’) Reverse (5’-…-3’) 
GFP gCTCGTGACCACCCTGACCTACGG ACCATGGTGAGCAAGGGCGAGGA AGCTCGTCCATGCCGAGAGTGATC 
VEGFA3 GGTGAGTGAGTGTGTGCGTGTGG GCATACGTGGGCTCCAACAGGT CCGCAATGAAGGGGAAGCTCGA 
VEGFA3-ot1 AGTGAGTGAGTGTGTGTGTGGGG CAGGCGCCTTGGGCTCCGTCA CCCCAGGATCCGCGGGTCAC 
VEGFA3-ot2 TGTGGGTGAGTGTGTGCGTGAGG AGTCAGCCCTCTGTATCCCTGGA GAGATATCTGCACCCTCATGTTCAC 
ZSCAN2 GTGCGGCAAGAGCTTCAGCCGGG GACTGTGGGCAGAGGTTCAGC TGTATACGGGACTTGACTCAGACC 
ZSCAN2-ot1 GTGTGGCAAGGGCTTCAGCCAGG CACGACTGCAGGCTCATGAGC GAAGCGCTTACCACACACATCAC 
ZSCAN2-ot2 ATGGGGAAAGAGCTTCAGCCTGG AGTCACATGCTGCCTGGATTGAC GTGGAGGAGATTTCTCTAGGAGAG 
EMX1-K GAGTCCGAGCAGAAGAAGAAGGG CTGCCATCCCCTTCTGTGAATGT GGAATCTACCACCCCAGGCTCT 
EMX1-R gGCCTCCCCAAAGCCTGGCCAGGG same as above same as above 
EMX1-K-ot1 GAGTTAGAGCAGAAGAAGAAAGG TGTGGGGAGATTTGCATCTGTGGA TTGAGACATGGGGATAGAATCATGAAC 
EMX1-K-ot2 GAGTCTAAGCAGAAGAAGAAGAG CTGCTGTTTCCTGAAGCTGCCACT CTGCCATGGAAATTCCAGAGGGAAC 
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Mismatched 5’-G are indicated in lowercase. Mutations are indicated in bold. PAM included in 
the target sequences.	
 
EMX1-R-ot1 ACCTCCCCATAGCCTGGCCAGGG TGAACGAATCAGGTCTGAGAGGATC GAGCTTCACTCCAGAGAGGCTGT 
EMX1-R-ot2 TCCTCCCCACAGCCTGGCCAGGG TGCTACTGCTGGCTGCAGAGATG GCATTCGTTTTGGGAGGCAGAGGA 
VEGFA2 GACCCCCTCCACCCCGCCTCCGG TCAGCGGACTCACCGGCCAG GCGCCGAGTCGCCACTGCGG 
FANCF2 GCTGCAGAAGGGATTCCATGAGG GCCAGGCTCTCTTGGAGTGTC AGCATAGCGCCTGGCATTAATAGG 
FANCF2-ot1 GCTGCAGAAGGGATTCCAAGAGG CCCGTGAGGTGCTGAGATTTGAAC CACATGGAGGAGGTGACGCTG 
CCR5sp11 GGTACCTATCGATTGTCAGGAGG ATGCACAGGGTGGAACAAGATGGA CTAAGCCATGTGCACAACTCTGAC 
OT-CCR2 GGTATCTATCGATTGTCAGGAGG CATTGTGGGCTCACTCTGCTGCA CTGAGATGAGCTTTCTGGAGAGTCA 
CXCR4 GGAAGCGTGATGACAAAGAGG AGAGGAGTTAGCCAAGATGTGACTTTGAAACC GGACAGGATGACAATACCAGGCAGGATAAGGCC 
